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1.1 Background and Introduction.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
There are many sources of variability in drug response that are unique to the paediatric 
population. Firstly, there are marked increases in body size as well as significant 
changes in the expression and function of drug metabolizing enzymes and transporters. 
Additionally, differences in cardiac output and blood flow influence the perfusion of 
drug eliminating organs, and differences in the acid-base balance, the concentration and 
composition of drug-binding plasma proteins and other blood components potentially 
influence plasma protein binding. Moreover, the relative size of organs vary, as well 
as body composition, with the amount of total body water and extracellular water 
decreasing with age. All these factors can alter drug exposure in paediatric patients 
[1]. Furthermore, developmental changes in drug pharmacodynamics influence the 
variability in paediatric drug response. Changes in the function and expression of 
receptors and target proteins can alter the pharmacological response to drug exposure, 
while disease states may also affect the physiological system and physiological feedback 
mechanisms, making diseases that are unique to the paediatric population or diseases 
with a different progression in children compared to adults, unique contributors to the 
variability in paediatric drug response [2]. 
Unfortunately, the sources of variability in drug exposure and response in 
children have not been studied in as much detail as they have been in adults. As a result, 
evidence-based drug dosing algorithms that account for functional differences between 
children and adults, as well as for functional differences between children of different 
ages are often lacking. Between 1995 and 2005, off-label and unlicensed paediatric drug 
prescription was high around the world with the number of paediatric patients receiving 
at least one off-label or unlicensed drug ranging between 80% to 93% in the neonatal 
intensive care units, between 36% to 100% in paediatric wards, and between 3.3% to 
56% in non-hospital settings [3], without any apparent difference between university 
hospitals and general hospitals in hospital setting [4,5]. At the same time, out of all the 
new drugs licensed by the European Medicines Evaluation Agency (EMEA) only 33% 
was licensed for use in children, 23% for infants and 9% for neonates and while attention 
to drug licensing for the paediatric population was increased, an increasing trend in drug 
licensing for the full paediatric population could not be observed during this period [6,7]. 
When evidence-based dosing information is missing, paediatric drug doses 
are often empirically extrapolated from adult doses. Consensus-based paediatric drug 
dosing guidelines are sometimes formalized in paediatric formularies after years of 
clinical experience [8,9]. To improve paediatric drug dosing, it is essential to study the 








































Scope and Intent of Investigation  |  13
in an integrated manner and to determine the relevance to and interaction with other 
factors like for instance diseases status, (concomitant) therapy, and genetics. Laws in 
the US and Europe like the Pediatric Rule (FDA – 1998), the Best Pharmaceuticals for 
Children Act (FDA – 2002), and the Paediatric Regulation (EMEA – 2007) have been 
introduced to encourage or compel pharmaceutical companies to perform paediatric 
studies for new chemical entities. However, to date laws that apply to marketed off-
patent drugs are lacking.
The objective of the research described in this thesis was to develop a novel 
model-based approach to derive drug dosing algorithms for the paediatric population, 
which account for developmental changes in drug response in this population. 
Naturally, this approach should take into account changes in drug pharmacokinetics, 
including absorption, distribution, metabolism and elimination (ADME), as well as 
drug pharmacodynamics, including effect site distribution, target activation, and signal 
transduction. However, as a first step in the research on paediatric pharmacology, the 
studies in this thesis are limited to the developmental changes in drug pharmacokinetics. 
For many drugs, the developmental differences in drug clearance are thought to be 
the major cause of age-dependent differences in dose requirements [10]. Specific focus 
is on uridine 5’-diphosphate glucuronosyltransferase (UGT) 2B7-mediated drug 
glucuronidation in neonates and young children. The UGT enzyme family is responsible 
for the glucuronidation of various endogenous en exogenous compounds in humans, 
but has been studied less extensively than the cytochrome P450 enzyme family, 
which is involved in the oxidation of the majority of the currently marketed drugs [11]. 
Inappropriate dose adjustments of UGT substrates in the paediatric population may lead 
to therapeutic failure or to overdosing, which may cause serious side-effects and even 
fatalities [12]. In this chapter an outline is presented of the various investigations that are 
described in this thesis.
Chapter 2 provides an overview of the various in vitro and in vivo methodologies to study 
the onset and development, the so-called ontogeny, of hepatic enzyme systems. Special 
emphasis is on the results obtained with these methods for UGTs. Different endpoints 
representing different parts of the physiological system that can be studied to determine 
enzyme ontogeny were identified. Since the number of components interacting with 
each part of the physiological system increases in going from mRNA transcription, 
to enzyme expression, in vitro enzyme activity, and in vivo glucuronidation clearance, 
conclusions on hepatic enzyme ontogeny may differ when different endpoints are used 
to characterize the changes in the physiological system. Additionally, different techniques 
to obtain and/or analyze data from each part of the physiological system may further 








































14  |  Chapter 1
though the ontogeny profiles of the different UGT isoenzymes may vary significantly, 
the onset and development of UGT enzyme expression and activity generally occur after 
20 weeks of gestation with a boost in expression and activity occurring in the first weeks 
of life. Since many other physiological changes also occur within this timeframe and 
since children are encountered most frequently in hospital settings during the first weeks 
to months of life, detailed information on clinical changes in drug pharmacokinetic is 
particularly relevant for the youngest patients. Therefore the focus of the research in the 
current thesis was on preterm and term neonates to children up to three years of age. 
1.2 Paediatric Morphine Glucuronidation Model for 
Individualized Dosing
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
An in vivo approach was used to study clinically relevant differences in drug disposition 
and exposure in early childhood. Traditional compartmental and non-compartmental in 
vivo approaches either require dense concentration-time information from each individual, 
obtained according to a stringent study design to ensure similar drug dosing and blood 
sampling in each individual, or they rely on imprecise measurements of steady state 
concentrations. A further drawback of traditional approaches is that they do not allow for 
the identification of the sources of variability within a population. Therefore ‘population 
modeling’, also known as non-linear mixed effect modelling, was the preferred tool for 
the studies in the current thesis. Population modeling not only allows for the analysis of 
dense, sparse, and/or unbalanced data, and for the identification and quantification of 
the sources of variability in a population, it also allows for the identification of significant 
predictors of this variability, known as covariates [13]. The information obtained on these 
covariates can subsequently be used as the basis for evidence-based dosing algorithms. 
A population modeling approach was applied in Section II to describe and quantify 
developmental changes in the glucuronidation of the selective UGT2B7 probe morphine 
[14,15] in preterm and term neonates, and children up to three years of age. The resulting 
model, including the model covariates, was used to develop a dosing algorithm for this 
population. 
In Chapter 3, sparse and unbalanced concentration-time data on morphine and 
its two major metabolites, morphine-3-glucuronide (M3G) and morphine-6-glucuronide 
(M6G), that were obtained during routine clinical practice from 248 term and preterm 
neonates to children younger than three years, were analyzed. In a comprehensive 
covariate analysis, all potential covariates were tested for significance and included in 
the model when they were sufficiently predictive of variability in morphine disposition 








































Scope and Intent of Investigation  |  15
population model that described the developmental changes in morphine clearance and 
distribution in this young population with a bodyweight-based function. To ascertain 
that the model indeed described the data without bias, the final model was validated 
internally using advanced methods like a normalized prediction distribution error 
(NPDE) analysis, after which simulations were performed to obtain an optimized, 
individualized morphine dosing algorithm that yields similar steady state concentrations 
for morphine, M3G and M6G throughout the population of preterm and term neonates 
to three-year-old children. 
Before applying the model-derived morphine dosing algorithm obtained in 
Chapter 3 in clinical practice, the predictive performance of the paediatric population 
pharmacokinetic model for morphine and its metabolites was corroborated using six 
external datasets in Chapter 4. This ascertained that the model could not only accurately 
predict morphine and metabolite concentrations in independent datasets of postoperative 
and ventilated patients with similar characteristics as the patients in the internal dataset 
used for model building in Chapter 3, but also in datasets of patients on very invasive 
extracorporeal membrane oxygenation (ECMO) treatment. The results from this study 
justified the next step in developing an evidence-based paediatric dosing algorithm for 
morphine, namely the prospective evaluation of the algorithm in a clinical trial [16]. 
Chapter 5 describes the results obtained with the prospective validation of the 
novel paediatric dosing algorithm of morphine. In a randomized controlled trial that 
compared postoperative analgesic efficacy of morphine and paracetamol in patients 
under the age of 1 year, the patients in the morphine arm were dosed according to the 
optimized and individualized paediatric dosing algorithm obtained with the population 
pharmacokinetic model developed and validated in Chapter 3 and Chapter 4. According 
to this highly non-linear dosing regimen, neonates younger than ten days received 
morphine maintenance doses that were between 25% and 50% of the traditional, linear, 
and consensus-based morphine regimen, whereas older children received up to about 
150% of this traditional dose. In this proof-of-principle study, it was assessed whether 
the proposed morphine doses based on the pharmacokinetic differences quantified in 
the population model, sufficed to obtain a satisfactory clinical response throughout the 
population, or whether further dose adjustments based on age-related differences in 
pharmacodynamics were necessary. The clinical response to morphine was assessed by 
analyzing the nurse-controlled morphine rescue medication that was administered based 
on a standardized pain-protocol using validated, age-appropriate COMFORT-behaviour 
[17] and VAS [18] scores to assess pain. Morphine and metabolite plasma concentrations 
were measured to ascertain that the concentration predictions by the population model 
were still accurate in patients dosed according to the novel algorithm, thereby confirming 









































16  |  Chapter 1
1.3 Semi-Physiological Covariate Model for Paediatric 
Glucuronidation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
It would require a tremendous amount of resources to develop and thoroughly validate 
paediatric population models for each individual drug in every population in a manner 
similar to what was described for morphine in Section II. Hence a novel approach is 
proposed in Section III, to limit the amount of resources and expedite the development 
of population pharmacokinetic models for the paediatric population. This approach is 
based on the hypothesis that paediatric covariate models for drug elimination describe 
system-specific properties rather than drug-specific properties [19] and can therefore be 
directly extrapolated from one drug to another drug that shares a common elimination 
pathway. The drug-specific parameter values in the population model of the new drug 
are on the other hand still estimated in a population analysis based on concentration-
time data of this drug. As such, this approach can be considered a semi-physiological 
hybrid between population pharmacokinetic modeling, called top-down modeling, and 
physiologically-based pharmacokinetic modeling, called bottom-up modeling.
The new semi-physiological approach for the development of paediatric 
population models is introduced in Chapter 6. In this proof-of-concept study, the paediatric 
covariate model for morphine glucuronidation that was developed and validated in 
Section II, was directly extrapolated to the glucuronidation of zidovudine, a drug which 
is also predominantly eliminated through UGT2B7-mediated glucuronidation [15,20]. The 
descriptive and predictive performance of this semi-physiological model was found to 
be similar to the descriptive and predictive performance of a reference model that was 
developed using a comprehensive covariate analysis of the zidovudine data to provide 
the best description of these data based on statistical criteria.
In Chapter 7 the physiological and physicochemical basis of the developed 
semi-physiological paediatric covariate model that quantifies the developmental 
changes in UGT2B7-mediated glucuronidation clearance for morphine and zidovudine 
in neonates and young children was investigated. The physiology-based modeling 
software Simcyp (Simcyp Ltd, Sheffield, UK) allowed for the determination, in strictly 
quantitative manner, of the influence of distinct system-specific and drug-specific 
parameters on the ontogeny pattern of the clearance of existing and hypothetical drugs in 
various populations, including the paediatric population. Using Simcyp the underlying 
maturational changes in liver volume, milligram microsomal protein per gram of liver, 
hepatic blood flow, plasma protein concentration, and ontogeny of UGT2B7 expression 
and function were disentangled and the main drivers of the net observed changes in 
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it was uncovered how physicochemical drug properties like the molecular mass, the 
octanol/water partition coefficient (logP), the acid dissociation constant (pKa), influence 
the magnitude and the ontogeny pattern of UGT2B7-mediated clearance in order to 
define specific drug properties that would preclude the direct application of the semi-
physiological developmental model for paediatric drug glucuronidation.
1.4 Paediatric Model Evaluation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Population modeling allows for the analysis of sparse data, but when data are limited 
there are risks of drawing erroneous conclusions. This could have far-reaching 
consequences, especially when population models are used for simulation purposes, for 
instance to optimize clinical trials in drug development, to derive dosing algorithms for 
application in clinical practice as was illustrated in Section II, or to extrapolate paediatric 
covariate models between drugs as was illustrated in Section III of this thesis. Under 
these circumstances proper assessment of both the descriptive and predictive properties 
of a model is imperative. This is however often neglected both in the adult and the 
paediatric population [21,22]. Section IV of this thesis therefore focuses on the evaluation 
of paediatric population models.
Numerous tools for the evaluation of population models currently exist. 
However, these tools may not always directly suffice for the evaluation of paediatric 
population models, due to distinctive patient and study characteristics in this special 
population. The paediatric population is for instance relatively small and can be 
regarded as a population consisting of multiple subpopulations due to the heterogeneity 
in maturational status. Additionally, since data in this population are usually obtained 
during routine clinical practice the variability in dosing and sampling schemes is high, 
while limitations in sampling size and frequency may cause data to be sparse. A new 
framework was therefore developed in Chapter 8 for the systematic assessment of the 
descriptive and predictive properties of paediatric covariate models. In this framework, 
existing numerical diagnostics, prediction-based diagnostics, and simulation-based 
diagnostics are placed into context and adjusted for application to paediatric population 
models where necessary. Additionally, a new tool to specifically evaluate paediatric 
covariate models is presented. As an illustration, this new framework was applied to two 
peer-reviewed, published, paediatric population models for morphine and its two major 
glucuronides that were based on an identical dataset, but developed with fundamentally 
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In recent years, several studies on the maturation of morphine clearance, using 
a wide array of different data analysis approaches leading to different pharmacokinetic 
models, have been published. This raises important questions with regard to the model 
that best predicts morphine concentrations in the pediatric population. In Chapter 
9 advantages and disadvantages of different data analysis techniques to describe and 
quantify the in vivo maturation of morphine clearance in the paediatric population, like 
traditional methods, population pharmacokinetic modeling and physiologically-based 
pharmacokinetic modeling, are discussed. Subsequently, the accuracy of morphine 
clearance predictions by multiple published paediatric pharmacokinetic models that 
were based on a variety of datasets and modeling approaches were reviewed. This is 
important because the value of paediatric pharmacokinetic models mostly depends on 
clearance predictions and population concentration predictions. Special attention was 
paid to the accuracy of morphine concentration predictions across different age-groups 
and the level of evidence supporting each model either in the original publication or in 
succeeding publications. 
1.5 Summary, Conclusion and Perspectives
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Finally, in Chapter 10 of Section V, the results of the studies presented in this thesis 
are discussed in conjunction with each other and perspectives of future research are 
presented.
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The onset and maturation, so-called ontogeny, of hepatic glucuronidation is important 
for the clearance of a number of drugs in children. The current review discusses methods 
for studying the ontogeny of liver enzyme systems and specifically focuses on the results 
obtained with these methods for uridine 5’-diphosphate glucuronosyltransferases 
(UGTs). The number of contributing components in the biological system increases in 
going from mRNA transcription, to enzyme expression, in vitro enzyme activity, and 
in vivo glucuronidation clearance. This may result in different conclusions on UGT 
ontogeny when different methods are used. Various metrics to quantify glucuronidation 
activity, like linear or allometric scaling based on bodyweight, further disperse the 
conclusions on UGT ontogeny. Generally, it can be concluded that the onset of UGT 
expression and activity occurs after 20 weeks of gestation with a boost in expression 
and activity occurring in the first weeks of life. Maturation rates vary between the UGTs, 
but may well extend beyond the age of two years. Compared to adults, absolute doses 
of drugs eliminated via glucuronidation should be reduced in children. However, since 
the UGT isoenzymes mature differently, since substrate specificities are overlapping and 
since many external factors influence drug glucuronidation, it is not possible to derive 
general dosing recommendations for the paediatric population for these drugs. This can 
be improved by obtaining system specific information on each UGT isoenzyme on the 
basis of validated in vivo models that describe the ontogeny of glucuronidation and the 
influence of other patient characteristics like genetic polymorphisms and co-morbidities 
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2.1 Introduction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Hepatic metabolic plasma clearance is to various extents influenced by 1) intrinsic 
clearance, 2) hepatic blood flow and perfusion, 3) plasma protein binding, and 4) active 
hepatic influx and efflux mechanisms, and intra-cellular transport processes. Intrinsic 
clearance is the maximum capacity to eliminate drugs in the absence of rate-limiting 
factors. Intrinsic clearance through hepatic biotransformation is determined by enzyme 
expression and enzyme activity in the liver. 
Numerous enzymes responsible for the biotransformation of endogenous and 
exogenous compounds are present in the liver. Phase I metabolism, which entails the 
oxidation, reduction or hydrolysis of compounds to make them (more) polar, is carried 
out by various enzyme systems. Of these, the cytochrome P450 monooxygenases (CYPs) 
are oxidizing enzymes that have been extensively studied, since they are responsible for 
the majority of drug metabolism. Phase II metabolism comprises various conjugation 
reactions, like UDP-glucuronic acid, sulfate, glutathione, methyl and acetyl conjugation. 
Conjugation promotes passive renal elimination by increasing the solubility of 
compounds as well as active excretion of compounds through renal tubular secretion. 
These conjugation reactions usually result in the biological deactivation of endogenous 
compounds, drugs or phase I metabolites, although some examples of pharmacological 
active phase II metabolites are known, like for instance the morphine glucuronides [1]. 
The uridine 5’-diphosphate glucuronosyltransferases (UGTs) are the most important 
phase II enzymes in humans and they are the focus of the current review.
In the human genome four UGT families with glucuronidation capacity have 
been identified, namely the UGT1, UGT2, UGT3, and UGT8 families. The members of the 
UGT1 and UGT2 family are predominantly involved in detoxification of compounds and 
in humans the UGT1A and UGT2B subfamily have been studied most extensively in this 
respect. Within these two subfamilies 16 functional isoforms have been identified (see for 
latest nomenclature update Mackenzie et al. [2]). The UGTs are high-capacity, low-affinity 
enzymes that are mainly expressed in the liver, however isoforms have also found to 
be expressed extrahepatically [3–6]. Together, the UGTs glucuronidate many endogenous 
and exogenous compounds. Substrate specificities of the UGTs are broad and they may 
overlap, indicating that one isoform may glucuronidate a wide range of compounds and 
that one compound may be metabolized by multiple isoforms. Table I gives an overview 
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Table I. Overview of UGT substrates and substrate specificities.
UGT 
isoform
substrate UGT specific substrate references
1A1 paracetamol, 1-naphthol, thyroxine, 
4-methylumbelliferone, carvediol
bilirubin, SN-38 (irinotecan 
metabolite)
[7–12]
1A3 1-naphthol, 4-methylumbelliferone, thyroxine R-lorazepam [10,12,13]
1A4 valproic acid trifluoperazine, lamotrigine, 
imipramine
[13–16]
1A5 So far no substrates have been identified 
for this isoenzyme.
1A6 paracetamol, 1-naphthol, valproic acid, 
4-methylumbelliferone, chloramphenicol
serotonin [9,10,17–19]
1A7 1-naphthol, 4-methylumbelliferone [10]
1A8 1-naphthol, 4-methylumbelliferone, valproic 
acid
[10,15]
1A9 paracetamol, 4-methylumbelliferone, 
1-naphthol, indomethacin, valproic acid, 
propofol, R-oxazepam, chloramphenicol
[9,10,13,18–21]
1A10 1-naphthol, 4-methylumbelliferone, valproic 
acid
[10,15]  
2B4 androsterone, carvediol [11,22]
2B7 1-naphthol, 4-methylumbelliferone, valproic 
acid, indomethacin, testosterone, androsterone, 
estradiol, lorazepam, carbamazepine, 
R-oxazepam, epirubicin, carvediol, 
chloramphenicol
morphine, zidovudine [10,11,15,19–29]
2B10 amitriptyline, imipramine, clomipramine, 
trimipramine
[30]
2B11 4-methylumbelliferone, 1-naphthol, 
4-nitrophenol, 4-hydroxyesterone, 
4-hydroxybiphenyl, methol, estriol, 
2-aminophenol, 2-hydroxyesteriol.
[31]
2B15 4-methylumbelliferone, testosterone S-oxazepam, S-lorazepam [10,13,22,28,32]
2B17 4-methylumbelliferone, testosterone, 
dihydrotestosterone, androsterone
[10,22]
2B28 eugenol, 1-naphthol, testosterone, 
4-methylumbelliferone
[33]
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The ontogeny of the hepatic glucuronidation system, which in the current 
review refers to the onset and maturation of hepatic glucuronidation activity in the 
paediatric population, is considered to be an important determinant for the hepatic 
clearance of a number of drugs in children. Detailed description of the ontogeny of the 
hepatic glucuronidation system will therefore facilitate the accurate prescription of these 
drugs in the paediatric population. The current review discusses the age-related changes 
in drug glucuronidation clearance and in the underlying physiological processes of drug 
glucuronidation in the paediatric population. It is specified what part of the causal chain 
between gene expression and phenotypical hepatic clearance is studied with available 
techniques and various aspects that influence these techniques and the physiological 
processes on the causal chain of events are discussed to provide insight in factors that can 
cause discrepancies between findings obtained using different techniques. 
2.2 Methods to Determine the Ontogeny of Enzyme Systems 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The ontogeny of enzyme systems can be determined at different levels ranging from in 
vitro mRNA transcription to the intrinsic hepatic clearance of a model compound, also 
known as a probe, in vivo. Figure 1 gives an overview of the processes that are studied 
at the different levels. Going from left to right in the diagram, the complexity of and 
variability in the studied biological systems increase due to the increasing number of 
factors that contribute to the functionality of the enzymes, and therefore the ultimate 
contribution of each process to in vivo drug clearance decreases going from right to left.
 Studying enzyme ontogeny at different levels enables a mechanistic 
interpretation of the clinically observed developmental changes in the functionality of 
drug metabolizing enzymes. By going backwards on the causal chain of events different 
characteristics of the biological system are studied and the number of factors that 
contribute to the functionality of metabolizing enzymes are reduced. By simplifying the 
system noise is reduced and physiological insight in the characteristics of the system is 
obtained. However, due to the influence of contributing factors further down the causal 
chain, the contribution of a particular process to the overall biological system may be 
negligible. These contributing factors may also result in different findings when studying 
ontogeny at different levels. By studying more complex systems only the net influence of 
all underlying physiological processes are taken into account and they might therefore 
represent clinical observations of the drug clearance process better. However, due to 
the high complexity, more data and advanced statistical tools are required to identify 
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Figure 1.  Schematic representation of the processes that can be studied to determine the ontogeny of enzyme 
systems.
2.2.1 In Vitro Methods
The in vitro methods to study enzyme ontogeny include the determination of RNA 
transcription, enzyme expression, and enzyme activity using human liver tissue 
obtained from academic or commercial liver banks. Metabolism of compounds takes 
place in hepatocytes, which are specialized cells that make up 70 to 80% of the liver’s 
mass. When these cells are lysed in the laboratory, vesicles called microsomes are formed 
from the endoplasmic reticulum in which CYP and UGT enzymes are located. Liver 
homogenates, isolated hepatocytes, and microsomes can serve as experimental systems 
for in vitro studies of ontogeny of hepatic drug metabolism.
The origin of the liver tissue samples used in in vitro studies varies. In the past 
they were mostly obtained post mortem from liver donors that could not be matched 
to a recipient. Whereas currently paediatric liver tissue material is still predominantly 
obtained from deceased children, adult liver tissue material nowadays originates more 
often from tissue adjacent to removed (cancer) lesions [34]. Since only a couple of hundred 
milligrams of liver tissue are necessary for these in vitro techniques, multiple experiments 
can be performed with the samples of one individual. This not only allows for replication 
of studies or for the testing of different conditions in the same individual, it also allows for 
the study of various processes like RNA transcription, enzyme expression and enzyme 
activity within tissue of the same individual. 
Prior to using the liver tissue samples in the in vitro studies, they are checked for 
morphological and histological anomalies and often other biological and serological tests 
are performed on donor material to prevent the use of diseased liver samples, although 
this is not always possible in the paediatric population due to the limited number and 
size of the samples. In addition to pathophysiological changes of the liver, numerous 
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These factors include 1) demographics and characteristics of the donor, like for instance 
age, gender, ethnicity, and genetic polymorphisms, 2) life style of the donor, such as 
alcohol use, smoking habits, general drug use, and dietary preferences, 3) perimortem or 
procedure related drug use and disease or trauma status in the donor prior to obtaining 
the tissue sample, and 4) harvesting, storage, and experimental conditions. The first two 
represent factors that are present in the clinical situation as well and therefore give a 
reflection of the variability that can be expected within a population, the second two 
factors mainly add noise to the data. Pooling in vitro material from various donors allows 
for the description of average trends in enzyme ontogeny, this approach will however 
not allow for the quantification of variability in the population nor will it allow for 
identification of the sources of the variability. Information on variability is as important 
as information on general trends and can be obtained by performing experiments in 
multiple samples of different individuals to obtain a measurement range rather than 
a single value. This can also be used to identify patient characteristics (covariates) that 
influence the ontogeny process.
2.2.1.1 RNA Transcription
The beginning of every physiological process is the transcription of the DNA sequence 
that encodes the enzymes that catalyze a process, into messenger RNA (mRNA). 
Studies on the onset of UGT mRNA transcription and on age-related changes in mRNA 
transcript levels are therefore an obvious approach to determine UGT ontogeny. The 
UGT1A isoforms are formed by alternative splicing of an mRNA transcript originating 
from a single gene, whereas the UGT2B isoforms are all encoded by independent genes 
[2]. mRNA samples therefore contain distinct mRNA copies for each UGT isoform that can 
be uniquely identified. But it is important to keep in mind that UGT mRNA levels have 
been reported to be reduced under hepatic inflammation conditions [35]. 
There are various techniques to detect and quantify gene transcription of which 
Northern blotting and quantitative real time polymerase chain reaction (qrt-PCR) are 
most frequently used. Northern blotting is an older technique that separates the different 
mRNAs in an isolated hepatic mRNA mixture by length on an agarose gel. A radio-
labeled RNA probe that is complementary to the mRNA sequence of the UGT of interest 
will hybridize with the mRNA transcript of the UGT and the band strength of the 
labeled RNA on the image of the gel is then measured by autoradiography and used as a 
quantitative measure for specific mRNA expression. 
With qrt-PCR, complementary DNA (cDNA) templates are created from an 
isolated hepatic RNA sample by reverse transcription. The cDNA template of the UGT of 
interest is subsequently amplified in successive cycles of the polymerase chain reaction 
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strands. With the amount of DNA being doubled in every cycle, the cycle in which a 
certain threshold in fluorescence is reached can be used to quantify the amount of mRNA 
in the initial sample. The DNA amplification cycles allow qrt-PCR to detect much smaller 
mRNA amounts than Northern blotting.
PCR analysis has revealed that there are no mRNA transcripts of UGT1A1, 1A3, 1A4, 
1A5, 1A6, 1A7, 1A8, 1A9, 1A10, 2B4, 2B7, 2B10, and 2B15 present in fetal liver at 20 weeks 
of gestation. In livers of infants with a postnatal age of 6 months, transcripts of UGT1A1, 
1A3, 1A4, 1A6, 2B7, 2B10 and 2B15 were detected at levels similar to adults. At 6 months 
of age detectable levels of transcripts of UGT1A9 and 2B4 were present, but at lower 
levels than in adults. These levels further increased with age, with UGT1A9 transcript 
levels reaching adult values around 1.5 years and UGT2B4 transcript levels not reaching 
adult levels before the age of 2 years [36].
2.2.1.2 Enzyme Expression 
mRNA transcripts are translated into amino acid chains that subsequently fold into active 
enzymes. However, not necessarily all mRNA transcripts are translated into enzymes, 
as some mRNA may be intracellularly degraded before being translated. Additionally, 
degradation of formed enzyme also influences the net amount of enzymes available for 
catalyzing cellular processes. By measuring the ontogeny of UGT enzyme expression one 
is therefore one step closer to the ontogeny of in vivo drug glucuronidation on the causal 
chain of events.
 Techniques to detect and quantify enzyme expression, like Western blotting (also 
known as protein immunoblotting) and enzyme-linked immunosorbent essay (ELISA), 
involve the use of antibodies against the specific enzyme of interest in an isolated enzyme 
sample from the liver sample. Antibodies usually have very specific targets to which 
they bind, allowing for the detection of specific enzymes. Quantification occurs by using 
a label (e.g. radioactive, fluorescent) on the antibody that is detected after binding of the 
antibody to the enzyme. Quantification with ELISA is more precise than with Western 
blotting. Currently, the availability of UGT specific antibodies is scarce, which hampers 
the quantification of certain specific UGT isoenzymes in an enzyme sample. 
  
Using rat antibodies that recognize a broad range of UGTs in a Western Blot analysis of 
human liver microsomes, it was revealed that at 18 and 27 weeks of gestation a UGT of 
53 kDa is present. At term birth 3 isoforms could be observed and all isoforms that could 
be identified in adults with this experimental setup were found to be present at three 
months of age, albeit at only approximately 25% of the adult levels [37]. Unfortunately 
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the different UGTs had not been identified and classified the way they are currently 
classified.
More recently, differences were found in the enzyme expression levels of 
UGT1A1, 1A6 and 2B7 between adults and children ranging from 7 months to 2 years 
of age with Western blotting. These results for enzyme expression were in agreement 
with finding on mRNA transcription in the same study [36]. Another study using a similar 
experimental setup showed an age-dependent increase in UGT2B7 enzyme expression 
in infants and young children. Adult expression levels of UGT2B7 enzymes in this study 
were only reached in the oldest paediatric age category ranging from 12 to 17 years [38].
 
2.2.1.3 Enzymatic Activity
After translation, enzymes can be further modified, for instance by phosphorylation and 
N-glycosylation, which may either enhance or inhibit the activity of an enzyme. It has for 
instance been suggested that UGT1A1 requires phosphorylation for the metabolism of 
some, but not all, of its substrates [39] and that N-glycosylation may influence the enzymatic 
activity of some of the enzymes of the UGT2B subfamily [40], but not on all of them [41]. 
Additionally, as reviewed by Ishii et al. UGTs can form homo- or heterodimers with each 
other or form complexes with other enzymes [42], and UGT activity is also influenced by 
the lipid composition of the membrane in which they are integrated [43]. Post-translational 
modifications and enzyme and lipid interactions can be studied independently, but this 
is not commonly done in studies of the ontogeny of enzyme systems. Rather, the net 
influence of gene expression, post-translational modifications, enzyme interactions and 
other possible contributing factors on enzymatic activity is often studied. 
Contrary to the more quantitative measurements of mRNA and enzyme 
abundance, enzyme activity studies are of a more qualitative nature. These methods 
depend on the measure of either the formation of an enzyme product or the depletion 
of an enzyme substrate in a hepatocyte or microsome sample or liver homogenate. 
Individual UGTs can be investigated by using substrates specific for the UGT of interest, 
however due to the overlapping substrate specificities of the UGTs, few isoform selective 
substrates have been identified (see table I). Additionally, activity findings are neither 
absolute nor generalizable in that the results are specific for a particular combination of 
a certain enzyme and substrate and may be different for another substrate of the same 
enzyme. With enzyme kinetics generally being non-linear, different results are often 
obtained at different substrate concentrations, so it is also important to use physiologically 
relevant substrate concentrations in the experimental set up. 
By tracking the initial formation rate of a metabolite at various substrate 
concentrations, the Michaelis-Menten parameters Vmax (maximum reaction rate) and 
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be used to determine the intrinsic clearance (Clint), which is the maximum metabolic 
capacity in the absence of rate-limiting factors:
 6 
instance been suggested that UGT1A1 requires phosphorylation for the metabolism of 
some, but not all, of its substrates 
[39]
 and that N-glycosylation may influence the 
enzymatic activity of some of the enzymes of the UGT2B subfamily 
[40]
, but not on all of 
them 
[41]
. Additionally, as reviewed by Ishii et al. UGTs can form homo- or heterodimers 
with each other or form complexes with other enzymes 
[42]
, and UGT activity is also 
influenced by the lipid composition of the membrane in which they are integrated 
[43]
. 
Post-translational modifications and enzyme and lipid interactions can be studied 
independently, but this is not commonly done in studies of the ontogeny of enzyme 
systems. Rather, the net influence of gene expression, post-translational modifications, 
enzyme interactions and other possible contributing factors on enzymatic activity is often 
studied.  
Contrary to the more quantitative measurements of mRNA and enzyme 
abundance, enzyme activity studies are of a more qualitative nature. These methods 
depend on the measure of either the formation of an enzyme product or the depletion of 
an enzyme substrate in a hepatocyte or microsome sample or liver homogenate. 
Individual UGTs can be investigated by using substrates specific for the UGT of interest, 
however due to the overlapping substrate specificities of the UGTs, few isoform selective 
substrates have been identified (see table I). Additionally, activity findings are neither 
absolute nor generalizable in that the results are specific for a particular combination of a 
certain enzyme and substrate and may be different for another substrate of the same 
enzyme. With enzyme kinetics generally being non-linear, different results are often 
obtained at different substrate concentrations, so it is also important to use 
physiologically relevant substrate concentrations in the experimental set up.  
By tracking the initial formation rate of a metabolite at various substrate 
concentrations, the Michaelis-Menten parameters Vmax (maximum reaction rate) and Km 
(Michaelis-Menten constant) can be determined and equation 1 can subsequently be used 
to determine the intrinsic clearance (Clint), which is the maximum metabolic capacity in 
the absence of rate-limiting factors: 
mK
V
Cl maxint =      (Equation 1) 
It is important to characterize the relationship between substrate concentration and 
enzyme reaction rate in detail, since the enzyme kinetic parameters that describe this 
relationship are directly correlated with the intrinsic clearance.  
There is increasing evidence that some UGTs do not follow the typical non-linear 
behavior described by the Michaelis-Menten equation with some of their substrates 
[44–46]
. 
This is indicative of the presence of allosteric effector sites, simultaneous binding of two 
substrate molecules to the enzymes active site, or cooperation with other enzymes and 
proteins in complexes. Technically, different methodologies should be used to accurately 
determine intrinsic clearance for enzymes that follow non-typical behavior, but this is not 
often done. Additionally, it is not clear how to correlate such non-typical in vitro 
behavior to the in vivo situation. 
As an alternative, substrate depletion rates can be measured at a low 
concentrations (below Km) as kinetics can then be assumed to be linear and 
measurements at a single substrate concentration suffice. The elimination rate constant 
(ke) is used together with the distribution volume (V) to determine the intrinsic clearance 
according to equation 2:  
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The elimination rate constant is derived either from the elimination half-life of the 
substrate, or from the ratio between substrate concentrations at the beginning and at the 
end of the experiment. The distribution volume is composed of the volume of the 
incubation medium, the volume of the cells (4·10
-9
 mL per cell 
[47]
), and the binding of 
the substrate to various components of the experimental system. In these studies, 
unspecific binding of the substrate to the experimental system or cellular uptake of the 
substrate without metabolism of the substrate, will increase the substrate disappearance 
rate at the beginning of the incubation period and will also result in over-prediction of the 
distribution volume. Since only one substrate concentration is used in this methodology it 
is very important to use relevant substrate concentrations to get physiologically 
meaningful results. 
 
In the in vitro activity studies described above, the use of microsomes is easier and 
cheaper than the use of hepatocytes, however experimental protocols for microsomes are 
often optimized for CYP enzymes and not for UGTs 
[48]
. Numerous incubation conditions 
influence measured glucuronidation rates 
[49]
 and it has proven to be difficult to get good 
results for glucuronidation processes using microsomes 
[50]
. Other, general advantages of 
using hepatocytes over microsomes for these studies are that all cofactors needed in the 
metabolic process are present at physiological concentrations and that the physical 
structure of the hepatocyte, including drug-binding cell compartments, cell membranes 
and transporters, is still in tact. Disadvantages of hepatocytes are that the expression and 
activity of many enzymes and transporters decline within hours. 
The hepatocytes used in in vitro studies usually either originate from fresh liver 
samples or from cryopreserved samples. Various steps in the cryopreservation process 
influence the results obtained with cryopreserved hepatocytes, as reviewed by Hengstler 
et al. 
[51]
. This may influence the findings on the correlation between results obtained in 
fresh and cryopreserved hepatocytes. Some found a good correlation for CYPs and UGTs 
[52]
, whereas others obtained ambiguous results for the correlation of UGT activity 




In the late seventies and eighties of the 20
th
 century, it was found that glucuronidation 
activity per gram of liver towards bilirubin and 2-aminophenol in fetal and neonatal liver 
homogenates was about 1% of the activity observed in adult liver homogenates. This 
study described an exponential increase in glucuronidation activity with age, to reach 
adult values three months postnatally. No differences were observed between term and 
preterm neonates 
[54]
. More detailed investigation of the perinatal development of human 
hepatic UGT1A1 glucuronidation towards bilirubin revealed glucuronidation activity to 
be at 0.1% of adult activity levels between 17 and 30 weeks of gestation. Between 30 and 
40 weeks of gestation activity levels increased to 1% of adult activity levels and after 
birth a rapid increase was observed to reach adult levels at 14 weeks of age. This 
postnatal increase was again found to be independent from gestational age, indicating that 
birth-related factors and not age-related factors are the main driving force for this 
increase 
[55]
. In another study using microsomes the findings for bilirubin were 
substantiated. In term and preterm infants glucuronidation activity towards bilirubin was 
low and at 8 to 15 weeks activity values close to adult values were observed 
[37]
.  
 (Equation 2) 
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often optimized for CYP enzymes and not for UGTs [48]. Numerous incubation conditions 
influence measured glucuronidation rates [49] and it has proven to be difficult to get good 
results for glucuronidation processes using microsomes [50]. Other, general advantages 
of using hepatocytes over microsomes for these studies are that all cofactors needed in 
the metabolic process are present at physiological concentrations and that the physical 
structure of the hepatocyte, including drug-binding cell compartments, cell membranes 
and transporters, is still in tact. Disadvantages of hepatocytes are that the expression and 
activity of many enzymes and transporters decline within hours.
The hepatocytes used in in vitro studies usually either originate from fresh liver 
samples or from cryopreserved samples. Various steps in the cryopreservation process 
influence the results obtained with cryopreserved hepatocytes, as reviewed by Hengstler 
et al. [51]. This may influence the findings on the correlation between results obtained 
in fresh and cryopreserved hepatocytes. Some found a good correlation for CYPs and 
UGTs [52], whereas others obtained ambiguous results for the correlation of UGT activity 
between cryopreserved hepatocytes and fresh hepatocytes [53]. 
In the late seventies and eighties of the 20th century, it was found that glucuronidation 
activity per gram of liver towards bilirubin and 2-aminophenol in fetal and neonatal liver 
homogenates was about 1% of the activity observed in adult liver homogenates. This 
study described an exponential increase in glucuronidation activity with age, to reach 
adult values three months postnatally. No differences were observed between term and 
preterm neonates [54]. More detailed investigation of the perinatal development of human 
hepatic UGT1A1 glucuronidation towards bilirubin revealed glucuronidation activity to 
be at 0.1% of adult activity levels between 17 and 30 weeks of gestation. Between 30 and 
40 weeks of gestation activity levels increased to 1% of adult activity levels and after birth 
a rapid increase was observed to reach adult levels at 14 weeks of age. This postnatal 
increase was again found to be independent from gestational age, indicating that birth-
related factors and not age-related factors are the main driving force for this increase [55]. 
In another study using microsomes the findings for bilirubin were substantiated. In term 
and preterm infants glucuronidation activity towards bilirubin was low and at 8 to 15 
weeks activity values close to adult values were observed [37]. 
Experiments in microsomes on general glucuronidation activity have 
yielded inconsistent results. Glucuronidation of 4-methylumbelliferone, a compound 
glucuronidated by multiple UGT isoforms, was found to reach adult levels at 20 months 
of age [14]. Yet, in another study, the rate of glucuronidation of a series of 18 compounds 
including steroids, antidepressants, analgesics, opioids, flavones and coumarines, was 
found to not have reached adult values at 2 years of age and the difference between 
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did however find mRNA transcription levels and enzyme expression of most UGTs to 
have reached adult values by the age of 6 months, underscoring the importance of other 
contribution factors of enzyme activity. Glucuronidation activity in microsomes towards 
testosterone and 1-naphthol, both compounds that are glucuronidated by a range of 
UGT isoforms, was found to be low at preterm and term birth and to slowly increase. 
At 1 year of age adult values were found not to have been reached [37]. Another study 
also found the glucuronidation capacity towards testosterone and 1-naphthol as well as 
towards bilirubin, androsterone, oestrone, 2-aminophenol and 4-nitrophenol to be low 
in the fetus and neonate [56]. 
Interestingly, in microsomes glucuronidation capacity towards serotonin, 
a substrate for UGT1A6, was found to be higher than adult levels in both fetal and 
neonatal liver [56]. A study in liver cells, however showed no detectable paracetamol 
glucuronidation in fetal liver [57], while paracetamol is also metabolized by UGT1A6, in 
addition to the isoforms 1A1 and 1A9 [9]. One explanation for these observations is that 
enzyme activity not solely depends on the enzyme, but on the combination of the enzyme 
and substrate together. However, based on the limited mRNA expression for all UGTs 
in the fetus, it is more likely that alternative hepatic elimination routes are available for 
serotonin in fetuses and neonates that are not or less abundantly present in adults livers. 
 Morphine is considered to be a specific substrate for UGT2B7 [23,25]. Microsomal 
glucuronidation activity towards morphine was found to be 6 tot 10 times lower in fetal 
liver samples obtained between 25 to 27 weeks of gestation, than in liver samples from 
adults. Within this age-range a correlation with gestational age was lacking [58].
2.2.2 Genetic Variation in UGT Expression and Activity
Even before gene transcription and translation, the causal chain of events for drug 
glucuronidation starts with a genetic code on a chromosome. Mutations can occur in the 
promoter region of a UGT gene, potentially influencing the transcription of the gene and 
thereby the enzyme abundance. Additionally, mutations in genes of transcription factors 
that regulate UGT gene expression may also influence DNA transcription and enzyme 
abundance. Regulation of UGT gene expression and the influence of polymorphisms on 
this process have been reviewed by Mackenzie et al. [59]. 
Polymorphisms in the coding regions of UGT enzymes have been identified as 
well. Such mutations may or may not influence enzyme activity. Mutations involved in 
the catabolism of endogenous compounds may lead to congenital diseases. A wide range 
of different mutations in the UGT1A1 isoform leads for instance to various degrees of 
unconjugated hyperbilirubinaemia as observed in Crigler Najjar syndrome and Gilbert’s 
syndrome [60], which in newborns may also lead to kernicterus. In case a mutation leads 
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or both. Therefore, other than the presence or absence of functional changes in mutant 
enzymes, the extent of the functional changes may also be substrate specific [8,11,28,29,61–73]. 
Additionally, some mutations may cause functional changes in glucuronidation activity 
by impacting the ability of UGT enzymes to interact with other membrane components 
to form complexes [74]. Since UGT1 isoforms are alternatively spliced from the same 
mRNA transcript, the isoforms of this subfamily share part of their genetic code. A 
certain polymorphism can therefore affect multiple UGT1 isoforms [75].
Genetic differences in elimination capacity prevail throughout life and studies 
on the impact of genetic variation on UGT enzyme expression and activity are generally 
performed in (tissue from) the adult population or in artificially synthesized in vitro 
enzyme systems. It is possible that (unknown) mutations in UGT genes have influenced 
some of the findings on UGT ontogeny, this is however not further discussed or 
considered in the current review.
2.2.3 Prediction of In Vivo Hepatic Clearance Based on In Vitro Enzyme Activity 
Enzyme ontogeny is predominantly studied to make inferences about the maturation 
rate of in vivo drug elimination in the paediatric population. Various approaches are 
available to make inferences on in vivo hepatic clearance based on in vitro data obtained 
in hepatic material, these approaches do however not take into account extra-hepatic 
sources of drug glucuronidation and elimination.
It can be envisioned that in vitro enzyme behavior in a non-physiological 
medium that may lack necessary co-factors is different from the enzyme behavior in vivo. 
However when predicting in vivo clearance from in vitro data, in vivo and in vitro intrinsic 
clearance per unit of enzyme are assumed to be the same. Subsequently, milligram of 
microsomal protein per gram of liver (MPPGL) and number of hepatocytes per gram of liver 
(HPGL) can be used in a straightforward manner to determine the rate of metabolism per 
gram of liver from microsomal or hepatocyte in vitro clearance respectively. This in turn 
can be multiplied by liver weight to give an estimate of total hepatic intrinsic clearance. 
For MPPGL most commonly a value of 45 mg/g is used, however a recent meta-
analysis, showed geometric mean MPPGL values to be 32 mg/g in Caucasian adults 
with high inter-individual variability and a weak negative correlation with age [76]. No 
differences were found between microsomes from fresh and frozen liver samples [77]. 
A later analysis included data from 4 Caucasian paediatric livers (age 2, 4, 9, and 13 
years) and 11 fetal livers. The geometric mean of MPPGL in fetal livers was found to 
be 26 mg/g. The geometric mean of MPPGL in the paediatric livers was 28 mg/g and 
increased to 40 mg/g at the age of 28 years, after which it slowly decreased again [77]. It 
should however be noted that this age-effect could only explain 10% of the observed 
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In Caucasian adults the geometric mean of HPGL values was found to be 99·106 
cells/g, with high inter-individual variability [76]. For HPGL there was also a negative 
correlation observed with age in adults, however no information is currently available 
on HPGL in paediatric livers.
As reviewed by Johnson et al. [78], many models exist to describe liver volume 
or liver weight as a function of body surface area (BSA), bodyweight, age or other 
covariates. Meta-analysis of these data revealed that the median liver weight in children 
younger than 2 years was 3.5% of the total bodyweight, whereas in adults this was only 
2.2%. The authors propose the following equation to predict liver volume (LV) in the 
paediatric population:
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In this study a value of 1.08 kg/L for liver density was used to derive liver weight from 
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. Reference values of the International Commission on Radiological 
Protection (ICRP) for paediatric liver weights are 130, 330, 570, 830, and 1300 gram for 




In addition to scaling in vitro obtained intrinsic clearance per gram of enzyme to in vivo 
intrinsic clearance of the full liver, other contributing factors can be taken into account to 
derive in vivo hepatic clearance. Figure 2 provides a schematic representation of the 
mechanisms involved in in vivo hepatic drug metabolism that were already mentioned in 
the introduction. In vitro-in vivo extrapolation methods that consider the different 
mechanisms described in figure 2 are available to make quantitative predictions of in vivo 
hepatic clearance based on in vitro intrinsic clearance obtained with microsomes, 
hepatocytes or liver homogenates.  
Physiology-based pharmacokinetic software (e.g. Simcyp, PK-sim, PKQuest, 
GastroPlus) can integrate a wide range of in vitro and in vivo data on drug parameters and 
physiological parameters to aid the prediction of hepatic clearance based on historic and 
experimental data, first attempts to include pathological conditions like liver cirrhosis 
have been made as well 
[80]
. In addition to the derived intrinsic hepatic clearance, 
physiology-based models may also use information on the age-related changes in hepatic 
blood flow and plasma protein binding.  
Commonly used models to derive whole-blood hepatic drug clearance (ClH,B) are 
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In addition to the intrinsic clearance of the full liver, which should be based on unbound 
drug concentrations (Cluint), these models also take the unbound drug fraction in blood 
(fu,B) and hepatic blood flow (QH,B) into consideration. Modifications of these equations 
are necessary to determine the more commonly used plasma drug clearance instead of 
whole-blood drug clearance 
[81]
. 
Both the well-stirred model and the parallel-tube model grossly divide the liver 
into sinusoids, vascular channels in which arterial blood and blood from the portal vein 
combine, and hepatocytes, the cells that surround the sinusoids and that are responsible 
for the drug metabolism. The two models assume the physiological extremes in the extent 
of mixing of drug concentration in the sinusoids and hepatocytes. The well-stirred model 
assumes drug concentrations in the sinusoid and hepatocytes to be equal, whereas the 
parallel-tube model assumes the liver to be composed of parallel tubes along which the 
drug concentration decreases and the concentration driving the hepatic drug uptake to be 
the logarithmic mean sinusoidal concentration 
[82]
. Both models assume that plasma 
  (Equation 3)
In this study a value of 1.08 kg/L for liver density was used to derive liver weight from 
liver volume [78]. Reference values of the International Commission on Radiological 
Protection (ICRP) for paediatric iver weig ts re 130, 330, 57 , 830, and 1300 gram for 
respectively neonates and children of the ages of 1, 5, 10, and 15 years [79].
Figure 2.  Schematic representation of the mechanisms involved in in vivo drug glucuronidation by the liver: 
(1) intrinsic clearance by the enzymes, (2) blood flow and perfusion, (3) plasma protein binding, and (4) 
active hepatic influx and efflux mechanisms.
In addition to scaling in vitro obtained intrinsic clearance per gram of enzyme to in vivo 
intrinsic clearance of the full liver, other contributing factors can be taken into account 
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mechanisms involved in in vivo hepatic drug metabolism that were already mentioned 
in the introduction. In vitro-in vivo extrapolation methods that consider the different 
mechanisms described in figure 2 are available to make quantitative predictions of in 
vivo hepatic clearance based on in vitro intrinsic clearance obtained with microsomes, 
hepatocytes or liver homogenates. 
Physiology-based pharmacokinetic software (e.g. Simcyp, PK-sim, PKQuest, 
GastroPlus) can integrate a wide range of in vitro and in vivo data on drug parameters 
and physiological parameters to aid the prediction of hepatic clearance based on historic 
and experimental data, first attempts to include pathological conditions like liver 
cirrhosis have been made as well [80]. In addition to the derived intrinsic hepatic clearance, 
physiology-based models may also use information on the age-related changes in hepatic 
blood flow and plasma protein binding. 
Commonly used models to derive whole-blood hepatic drug clearance (ClH,B) 
are the well-stirred model (Equation 4) and the parallel-tube model (Equation 5). 
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ratio predictions with the well-stirred model are generally lower than with the parallel-
tube model. 
In these models, commonly used adult values for hepatic blood flow are 1.35 L/
min for females and 1.5 L/min for males. It has however hardly been studied whether 
and how hepatic blood flow changes with age in the paediatric population. Some have 
suggested that there are no major differences in hepatic blood flow between neonates and 
adults [83], this seems however unlikely, since the relative liver size decreases with age, 
which would imply liver blood perfusion per kilogram of liver to be lower in children 
compared to adults. Other possible assumptions that are often made in this case are: 1) 
hepatic blood flow per kilogram bodyweight is the same in children and adults, 2) hepatic 
blood flow per kilogram of liver is the same in children and adults, 3) hepatic blood 
flow is proportional to metabolic rate (parameterized by BSA), and 4) the percentage 
of cardiac output directed to the liver remains constant with age. Opportunely, the 
decreased metabolic capacity of the liver in young children decreases the drug extraction 
ratio, thereby making hepatic clearance less dependent on hepatic blood flow, making 
knowledge of paediatric hepatic blood flow less vital in the predictions of paediatric 
hepatic clearance. Finally, it has to be remembered that an unclosed ductus venosus can 
impair hepatic drug clearance in neonates, by allowing part of the blood flow to bypass 
the liver. 
The unbound drug fraction in the paediatric population is also (potentially) 
influenced by various factors, namely 1) increases in the concentration of drug-binding 
plasma proteins from 76.7% of the adult value in neonates for human serum albumin 
(HSA) and 53.4% of the adult value in neonates for α 1-acid glycoprotein (AGP). The 
increases in the concentrations of these proteins with age have been described by various 
functions [84,85], 2) increases in bilirubin and free fatty acid concentrations shortly after 
birth, and 3) differences in the protein binding affinity of drug between children and 
adults [86,87]. Therefore, the value for the unbound drug fraction in blood obtained in 
adults cannot automatically be used in these equations for children.
With information on paediatric hepatic blood flow and plasma protein binding 
lacking, there is another approach that is sometimes applied to derive in vivo paediatric 
hepatic clearance based on in vitro data by the used of the well-stirred or parallel-tube 
model. In this approach in vitro intrinsic clearance is determined in paediatric hepatic 
material, this value together with adult values of the other parameters in the well-stirred 
or parallel-tube model are used to obtain a value for hepatic clearance. Paediatric hepatic 
clearance (ClH,B,paed) is subsequently derived from this value by the use of allometric 
scaling as illustrated in equation 5:
 (Equation 6)
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In this model, the bodyweight of the individual (Wi) is divided by the bodyweight of 
a ‘standard adult’ (Wstd) usually taken to be 70 kg. When the individual weight of the 
paediatric liver donor is unknown, a value can be derived from growth charts based on 
the age and sex of the donor. The application of allometric scaling on the organ level is 
however controversial [88]. 
So far it has proven to be difficult to characterize the influence of hepatic uptake 
and transporter mechanisms on drug clearance, even in adults [89]. This information is 
therefore rarely incorporated in physiology-based models. Pgp efflux transporters were 
found to be expressed in the human hepatocytes and this expression was suggested 
to be initiated by birth [90], however quantitative information on age-related changes 
in expression of hepatic uptake and transporter proteins is missing. Since hepatic 
transporters are already present in hepatocytes, the influence of ontogeny of transporter 
proteins on clearance only becomes relevant when dealing with intrinsic clearance values 
obtained with microsomes.
Both the well-stirred and parallel-tube model generally yield under-predictions 
of in vivo intrinsic clearance of unbound drugs up to ten-fold or even higher [49,91,92]. The 
assumption in both models that plasma protein binding is at steady state conditions 
instead of in a dynamic state has been proposed as an explanation for this under-
prediction. This under-prediction is less when data obtained in hepatocytes are used 
compared to data obtained in microsomes, possibly because cellular uptake proteins 
are functionally present in hepatocytes but not in microsomes. Recently it has been 
found that the accuracy of the predictions of in vivo clearance with hepatocytes could be 
improved to some extent by incubating the cells with serum instead of buffer solution 
[93]. This system approaches the physiological situation better as drug binding to plasma 
proteins is already incorporated in the experimental setup, thereby eliminating the need 
for separate studies of the unbound drug fraction in blood. In microsomal studies the use 
of serum is however thought to be un-physiological, since the unbound drug fraction in 
microsome incubation is not an analogue for the unbound drug fraction that is available 
for in vivo metabolism. It has been suggested that the under-predictions with microsomal 
data could be corrected by an empirical scaling factor [46,92]. 
Microsomal studies on UGT1A4 activity in which trifluoperazine depletion was used as a 
marker for product formation to obtain Michaelis-Menten parameters, showed UGT1A4 
activity to reach adult levels by 1.4 years. However, calculating hepatic clearances from 
the obtained in vitro intrinsic clearances by the use of both the well-stirred and parallel-
tube model and subsequent allometic scaling, suggested in vivo UGT1A4 mediated 
hepatic glucuronidation to reach adult values only at the age of 18.9 years [14], which was 








































38  |  Chapter 2
Using epirubicin as specific substrate for UGT2B7 in a study determining 
Michaelis-Menten parameters with human microsomes, a small age-dependent increase 
in UGT2B7 activity was found over the paediatric age-range, but activity in all paediatric 
age categories was lower than in adults. UGT2B7 enzyme expression levels in this study 
showed a good correlation with UGT2B7 activity levels, however adult expression levels 
were already reached at 12 – 17 years. By applying the allometric model directly to the 
in vitro clearances, the differences between the different paediatric age categories and 
between adults and the paediatric categories disappeared [38]. 
2.2.4 In Vivo Methods
To make reliable predictions of in vivo clearance based on in vitro methods requires 
information on a large number of parameters, not all of which can be determined 
experimentally in adults, let alone in children. In addition to that, in vitro hepatocytes 
have lost normal cell attachment, polarity and have a bigger surface area than in the 
in vivo situation and the architecture of the liver also changes with age. Therefore 
the ontogeny of in vivo drug glucuronidation may be best determined in vivo. In vivo 
studies can be performed in both animals and humans, however animal models are not 
considered in the current review, as the extrapolation potential from animals to humans 
in ontogeny studies is unknown. Also, differences in substrate specificity between 
animals and humans have been reported [94].
 In vivo enzyme ontogeny studies can be performed by determining drug 
metabolism in neonates, infants and children of various postnatal and postmenstrual 
ages. By looking at changes in total drug elimination from plasma, the influence of 
maturation in all clearance routes combined (i.e. glucuronidation, metabolism other 
than glucuronidation, biliary excretion and unchanged renal clearance) is determined. 
It is therefore important to either ensure that glucuronidation is the major route of 
elimination for the drug of interest or to determine the contribution of each route to 
the overall clearance. It should also be considered, that in vivo drug metabolism is not 
restricted to hepatic metabolism and that metabolism in organs other than the liver is also 
measured. The latter does not necessarily pose a problem, since the reason to study drug 
metabolism is generally to determine how quickly a parent drug is cleared, for instance 
to determine the dosing regimen, or how quickly certain metabolites are formed, which 
is especially important when the metabolites are pharmacologically active or toxic.
In vivo glucuronidation clearance can be derived from concentration-time profiles. 
With traditional methods, clearances are calculated by dividing dose by the area under 
the concentration-time curve (AUC). AUCs can only be derived from full concentration-
time profiles, which cannot be obtained from very small children for practical and ethical 
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clearance can be obtained by dividing the drug infusion rate by the steady state plasma 
concentration, however it may take a while for the parent drug to reach steady state 
concentrations and even longer for drug metabolites. Additionally, determining whether 
steady state has been reached may proof to be difficult. Other drawbacks of traditional 
studies are that often only a limited number of patients are included and that usually 
differences in clearance capacity between groups instead of individuals are quantified, 
making the results on maturation processes partially dependent on the stratification of 
the study population.
In the past few decades advanced statistical tools have been developed to 
aid in the analysis of sparse and unbalanced data that are often obtained in paediatric 
pharmacology studies. As described by De Cock et al., the population approach using non-
linear mixed effects modeling is currently the preferred tool, as it analyses individuals as 
constituents of a population, thereby allowing for the analysis of sparse and unbalanced 
data and also for the identification of both within- and between-subject variability [95]. 
By investigating trends in the glucuronidation clearance of different individuals in the 
population, the best descriptor for the maturation rate can be identified. This allows 
for the continuous quantification of changes occurring throughout the paediatric age-
range. Since incorrect conclusions can be easily drawn from sparse data, thorough model 
validation is imperative to ensure that the models obtained with this method are reliable.
When a drug is metabolized through multiple routes, the contribution of the 
glucuronidation to the total systemic clearance has to be determined. With the traditional 
methods the recovery of the metabolites of a drug dose in urine would be determined to 
establish the contribution of each route to the overall systemic drug clearance. Alternatively 
the drug:metabolite ratio in blood or urine would be traced in time. The latter is however 
not recommended as this ratio not only depends on the glucuronidation rate, but also 
largely depends on the fate of the metabolite. With the population approach information 
on the metabolites can be incorporated into the model, describing all pharmacokinetic 
parameters relating to both the parent drug and the metabolite, thereby allowing for the 
quantification of each individual elimination route, including glucuronidation.
One of the first and archetypical examples of the impact of UGT ontogeny on paediatric 
pharmacology was the observation in the fifties of last century that lack of UGT activity 
causes the grey baby syndrome in neonates that are treated with chloramphenicol [96]. 
Around that time it was also observed that the recovery of the acetanilide glucuronide 
in urine is significantly reduced in neonates and that the recovery in preterm neonates 
is lower than the recovery in the term neonates. The glucuronide recovery was found 
to increase with age, with faster maturation rates for term neonates compared to their 
preterm counterparts. Adult recovery levels of the glucuronide were reached around 3 
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Studies on paracetamol [98–100] and salicylamide [99] in the seventies of the last 
century, showed the ratio of sulphate and glucuronide metabolites in urine to differ with 
age, while the total drug elimination did not increase dramatically. The sulphate fraction 
was found to be higher in children for both drugs, probably to compensate for the reduced 
glucuronidation capacity in this age-group. In 7 to 10 year old children glucuronidation 
fractions where found not to have reached adult values [99], whereas in 12 year-old children 
adult fractions appeared to have been reached [98]. In more recent studies paracetamol 
glucuronidation was found to increase with both postmenstrual and postnatal age [101–
108]. These changes were quantified in different ways. Glucuronide:sulphate ratios were 
found to increase with gestational and postnatal age [101,106] and to reach adult values at 3 
years of age [103]. The maturation half-life of total paracetamol clearance was found to be 
close to 3 months for term and preterm neonates [102,104], whereas the maturation half-life 
of paracetamol glucuronidation in specific was found to be 8.09 months [103]. It is however 
important to note that these half-lives do not reflect the maturation of absolute clearances, 
but of the clearances that are allometrically scaled to average adult bodyweights of 70 kg. 
Therefore, when after 4 to 6 half-lives adult clearance values are assumed to have been 
reached in a child, it means that clearance would be at adult values had the child been 
of average adult bodyweight. However, absolute clearance values in this child are still 
low and increasing due to the physiological increase in size (bodyweight). According 
to the Centers for Disease Control and Prevention (CDC) in the US, males on average 
reach a bodyweight of 70 kg around 18 years of age, whereas the average female does 
not reach this bodyweight [109]. Based on urine recovery studies in neonates, it has been 
suggested that paracetamol glucuronidation is up-regulated with multiple doses [106], 
something that has also been observed in adults [110], However, our group has suggested 
that this observation is a possible artifact of a slower glucuronidation rate compared to 
the elimination rates of other routes, since this slower glucuronidation rate causes the 
fraction of a drugs glucuronide recovered in urine to increase at later time-intervals [111].
Morphine is a UGT2B7 specific substrate and the maturation of its glucuronide 
formation in neonates, infants and children has been widely studied. Studies on 
morphine and its glucuronides using traditional methodologies were not unambiguous. 
It is generally recognized that even at a gestational age as young as 24 weeks, neonates 
can glucuronidate morphine [112–114]. In neonates, total morphine clearance per kilogram 
bodyweight was reported to be positively correlated with birth weight and gestational 
age [113,115], however others could not identify an effect of gestational age on morphine 
pharmacokinetic parameters in neonates [114]. Morphine clearance per kilogram 
bodyweight is lower in neonates compared to infants, children and adolescents [112,116,117]. 
Adult clearance values were reported to be reached between 1 to 3 months [118] or between 
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found to be minor in neonates and to decrease further with age [119]. It is suggested that 
the increase in the fraction that is glucuronidated is predominantly responsible for the 
observed increases in morphine clearances. The fraction of morphine that is cleared 
through glucuronidation was found to be lower in neonates than in older patients  [112,120] 
and in these neonates this fraction was found to increase with birth weight [113]. Others 
reported however that sulphation and unchanged renal excretion are still important 
morphine elimination routes in infants and children [116] and yet another group found the 
contribution of each elimination pathway to total morphine clearance to already be at 
adult ratio’s in preterm neonates [114]. 
The maturation of morphine glucuronidation in the first three years of life has 
been quantified in different ways with the use of population modeling. In all studies 
absolute morphine glucuronidation clearance was found to continuously increase in 
this population. Two studies scaled clearances allometrically to 70 kg and subsequently 
described this maturation either with an exponential equation based on postnatal age 
[121] or with a sigmoidal equation based on postmenstrual age that was different for 
term and preterm neonates [122]. A third study by our group found that the changes in 
glucuronidation clearance was best described by a bodyweight-based exponential 
equation with an estimated exponent of 1.44 and that glucuronidation was decreased 
by about 50% in neonates younger than 10 days of age while there were no differences 
between term and preterm neonates except those resulting from the differences in 
bodyweight (Chapter 3). 
For zidovudine, which is also mainly metabolized by UGT2B7, clearance has 
been reported to mature rapidly with postnatal age in the first weeks of life [123,124]. 
Adult clearance values have been reported to be reached after two to eight weeks [123,124], 
whereas others report a slower increase in clearance for a subsequent two years, which 
is then followed by an even slower increase of absolute clearance rates during the rest 
of childhood and adolescence [125]. In preterm neonates clearance is lower [126,127] and 
maturation is slower [124] than in their term counterparts. In the preterms both bodyweight 
[126,127] and gestational age [127] have been reported to correlate with clearance rates.
The pharmacokinetics of propofol, which is mainly eliminated through 
glucuronidation by UGT1A9, has also been broadly studied in the paediatric and neonatal 
population. Studies have shown propofol metabolism in neonates to be different from 
adults and mainly suggest age-related changes in glucuronidation capacity for this drug 
in early life [128,129]. Kataria et al. have found propofol clearance per kg bodyweight to 
increase linearly with bodyweight in children ranging between the ages of 3 and 11 years 
[130], and Wang et al. described multi-directional age-related changes in total propofol 
clearance over the entire human age-range [131]. However, cautions is warranted when 
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extraction ratio causing its clearance to be limited by liver blood flow rather than enzyme 
capacity, especially after maturation of the metabolic clearance is complete around the 
age of 2 years [132]. 
Additionally, some of the drugs used for the treatment of epilepsy (e.g. 
lamotrigine, carbamazepine, valproic acid) are also, at least partially, glucuronidated. 
Since these drug are often used in combination with each other and since issues with 
UGT-(auto) induction or inhibition are frequently encountered in this drug class [16], these 
drugs are also considered not to be very suitable as in vivo probes for glucuronidation.
2.2.4.1 Other Factors that Potentially Influence Pharmacokinetics In Vivo 
When deriving paediatric drug dosages from enzyme maturation rates, it is important to 
consider that drug concentrations after single bolus doses or after loading doses not only 
depend on elimination rates but also on distribution volume. Additionally, age-related 
changes in the unbound drug fraction may influence the hepatic drug extraction ratio 
and thereby elimination rates, as well as drug effects. 
In addition to maturational changes in drug glucuronidation rates and genetics, 
environmental factors, comedication, comorbidities and medical treatments and 
procedures may influence drug glucuronidation capacity. The latter three are especially 
important in paediatrics since ethically it is difficult to perform studies in healthy 
subjects. Maternal smoking for instance may influence glucuronidation capacity in the 
first few days of life [133]. A number of compounds have been identified to induce the 
activity of a variety of UGT isoenzymes [134], whereas on the other hand phenobarbital 
and phenotoin were found to decrease paracetamol glucuronidation in the offspring 
[135]. Hypothermia to treat hypoxic ischemic encephalopathy was found to reduce 
morphine clearance in neonates [136]. Additionally, morphine clearance was found to be 
different in infants undergoing cardiac surgery versus patients undergoing non-cardiac 
surgery [137] and the type of cardiac surgery was found to further influence morphine 
clearance [138]. Extracorporeal membrane oxygenation (ECMO) generally influences drug 
pharmacokinetics in numerous ways [139]. In neonates and infants morphine clearance 
was reported to be reduced in patients on ECMO [140–142], however others have reported 
no change in morphine concentration after initiation of ECMO treatment [143]. In neonates, 
maturation rates of morphine glucuronidation were found to be faster in patients 
on ECMO compared to non-cardiac post-operative infants, with a combination of 
bodyweight and postnatal age as descriptors for this process [140,141]. It cannot be excluded 
that changes in maturation rates observed during medical treatments are the result of 
improvements in the medical status of the patient rather than changes in maturation. 
Finally, clinical studies on the maturation rates of metabolic pathways are generally 
restricted to patients with unimpaired liver function, leaving the influence of liver failure 
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2.3 Discussion and Conclusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The different methodologies discussed in the current review measure different 
characteristics of the developing biological system. The in vitro methods provide 
mechanistic insight in different underlying processes of the clinically observed 
developmental changes in drug glucuronidation in the paediatric population and all 
methods should be regarded as complementary to each other. Table II gives a summary of 
the findings on maturation of the specific UGT isoenzymes with the various techniques, 
as discussed in the current review. 
It can be seen in table II that the physiological processes in gene expression may 
have their own unique pattern of onset and maturation, this may be due to differences in 
contributing factors. Therefore different in vitro techniques may yield different answers 
to the onset and maturation of hepatic glucuronidation, even when the samples used 
with the various techniques are obtained from the same individual. This is nicely 
illustrated in the study by Strassburg et al., where differences in glucuronidation activity 
were observed between paediatric and adult samples, while mRNA and enzyme levels 
in the same paediatric samples where already indistinguishable from adult values [36]. 
Also Zaya et al. showed the age-related increase in the enzyme expression of UGT2B7 
to be more pronounced than the increase in UGT2B7 activity, and adult expression 
levels to be reached at 12-17 years of age, whereas activity levels remained below adult 
values throughout the paediatric age-range [38]. These findings imply that the ontogeny 
of UGT activity does not solely depend on the ontogeny of UGT gene expression (i.e. 
transcription and translation). Since UGT activity is influenced by post-translational 
modifications [39–41], maturation of UGT activity is therefore also dependent on the age-
related changes in these processes. Additionally, UGT activity was found to be dependent 
on the formation of complexes with other UGTs, other enzymes and other proteins and 
on the lipid composition of the membrane it is integrated in [42,43], age-related changes in 
the expression of these components may thus further influence the ontogeny of the UGT 
enzyme activity. Moreover, genetic polymorphisms have also been found to influence 
UGT activity and alter glucuronidation capacity in adults in a substrate specific way 
[144–146]. 
It is also important to consider the fundamental differences between the 
methods that measure mRNA and enzyme quantities and the more qualitative methods 
that measure enzyme activity. As long as primers and antibodies are specific enough, 
absolute amounts of mRNA and enzyme can be quantified relatively unambiguously. 
The difference in the qualitative measurement of enzyme activity is that it is substrate-
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absolute enzyme activity, they rather describe the characteristics of a specific enzyme-
substrate combination. This may limit the potential to extrapolate findings on enzyme 
activity from one enzyme-substrate combination to a combination of the same enzyme 
and another substrate. Likewise, genetic mutations may cause functional changes of an 
enzyme towards one substrate and not towards another.
Table II also shows that the methods that are used to derive in vivo clearances 
from in vitro results by incorporating various contributing components in different 
ways further diversify the findings on glucuronidation ontogeny. In in vivo studies, 
where external factors also influence drug glucuronidation capacity, the influence of 
contributing components is largest, but this setup resembles the clinical situation best. 
Here different scaling techniques to quantify glucuronidation capacity disperse the 
conclusions on glucuronidation ontogeny. In the paediatric population clearance is often 
expressed per kilogram or it is allometrically scaled to values of a 70 kg ‘standard adult’. 
When clearance values expressed per kilogram or per 70 kg have reached adult values, 
absolute clearance values are often still low and increasing. In the study of Zaya et al. 
in vitro glucuronidation activity expressed per mg enzyme did not reach adult values 
before adulthood, whereas none of the paediatric activity levels could be discerned from 
adult levels when the activity levels were allometrically scaled to in vivo values of a 70 
kg individual [38]. When expressed per 70 kg, morphine glucuronidation has reached 80% 
of adult levels at the age of 6 months and at 1 year adult values have been reached [121], 
whereas absolute glucuronidation rates have been found to be still low and exponentially 
increasing at least up to the age of 3 years and probably even further (Chapter 3). 
Most findings suggest that absolute doses of drugs that are glucuronidated 
should be reduced in neonates, infants, and children and possibly also in adolescents. 
It is however not possible to derive more general dosing guidelines, as various UGT 
isoenzymes mature differently, as substrate specificities overlap and as there are many 
external factors that may influence drug glucuronidation. A proposed method to improve 
this situation is to develop validated population pharmacokinetic models for probe drugs 
that are metabolized by specific UGT isoenzymes. From these models information that is 
describing the biological system can be derived, which may include information on the 
maturation rate of glucuronidation in the population but also information on the influence 
of other factors that significantly contribute to the variability in glucuronidation capacity. 
It is hypothesized that this information of the biological system can be extrapolated 
between drugs that are metabolized by the same UGT isoenzyme [147]. Due to the fact that 
enzyme activity is a property of both the enzyme and its substrate, absolute clearance 
values can most likely not be extrapolated between drugs, however the extrapolation 
potential of maturational changes in clearance from one enzyme specific substrate to 
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[148]. The feasibility of these types of studies relies on the identification of suitable probes. 
Since it is largely unknown how age-related changes in the biological system affect 
enzyme specificities the assumption is often made that enzyme specificities are similar 
between artificial or adult-derived enzyme sources in vitro and in children in vivo.
In conclusion, gaps in our knowledge on UGT ontogeny at the various in vitro and in 
vivo levels still exist. Enzyme expression and in vitro and in vivo enzyme activity have 
been studied more frequently in fetuses, neonates and infants than in older children 
and adolescents. The various studies that investigated UGT ontogeny at different levels 
generally suggest that the onset of UGT expression and hepatic glucuronidation occurs 
after 20 weeks of gestation, with a boost in expression and activity in the first weeks of 
life. The maturation rate of glucuronidation varies between the different UGT isoforms, 
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Background and objective: A considerable amount of drug use in children is still 
unlicensed or off-label. In order to derive rational dosing schemes, the influence of aging 
on glucuronidation capacity in newborns, including preterms, infants and children 
under the age of three years was studied using morphine and its major metabolites as a 
model drug. 
Methods: A population pharmacokinetic model was developed with the nonlinear 
mixed-effects modeling software NONMEM V, on the basis of 2159 concentrations of 
morphine and its glucuronides from 248 infants receiving intravenous morphine ranging 
in bodyweight from 500 g to 18 kg (median 2.8 kg). The model was internally validated 
using normalized prediction distribution errors.
Results: Formation clearances of morphine to its glucuronides and elimination clearances 
of the glucuronides were found to be primarily influenced by bodyweight, which was 
parameterized using an allometric equation with an estimated exponential scaling factor 
of 1.44. Additionally, a postnatal age of less than ten days was identified as a covariate for 
formation clearance to the glucuronides, independent of birthweight or postmenstrual 
age. Distribution volumes scaled linearly with bodyweight.
Conclusions: Model-based simulations show that in newborns, including preterms, 
infants and children under the age of three years, a loading dose in mg/kg and a 
maintenance dose expressed in mg/kg1.5/h, with a 50% reduction of the maintenance dose 
in newborns younger than ten days, results in a narrow range of morphine and metabolite 
serum concentrations throughout the studied age range. Future pharmacodynamic 
investigations are needed to reveal target concentrations in this population, after which 
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3.1 Background
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Despite initiatives of both the US and the European Union (i.e. Pediatric Rule (FDA, 
1998), Best Pharmaceuticals for Children Act (FDA, 2002), Paediatric Regulation (EMEA, 
2007), and 7th Research Framework Programme (EU, 2007 - 2013), a considerable number 
of drugs prescribed in children are still unlicensed or used in an off-label manner, in a 
newborn intensive care setting this even amounts to 90% of the prescriptions [1]. Although 
it is often stated that ’children are not small adults’, dosing schemes for this population 
are frequently empirically derived from studies restricted to adult patient groups, using 
linear extrapolations on the basis of bodyweight. To account for differences in drug 
disposition and/or drug response between children and adults and between children 
of different ages, higher or lower dosages per kilogram bodyweight are regularly 
recommended in different age-groups. While labeled information for children and 
(preterm) neonates in particular, is often lacking, investigations into developmental 
changes in pharmacokinetics (PK) and pharmacodynamics (PD) in the growing child are 
of utmost importance [2].
 Our group aims at developing a series of PK-PD models that describe the 
influence of developmental changes on drug disposition, efficacy and safety, which will 
ultimately be used to develop rational dosing schemes with a predictable efficacy and 
safety profile for the individual child of varying age. In the current, study the influence of 
age on glucuronidation capacity of the UGT2B7 enzyme in newborns, including preterms, 
and infants up to three years was studied using morphine and its two major metabolites 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) as model drugs. 
Although it concerns many endogenous and exogenous substrates [3–8], the maturation 
of conjugation catalyzed by uridine diphosphate glucuronosyltransferases (UGT), has 
historically received less attention than oxygenation by the cytochrome P450 enzyme 
system [3,4]. We hypothesize that information obtained for morphine glucuronidation 
may be of value for other substrates metabolized through this route.
3.2 Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Study Design. This analysis was performed based on observations obtained in preterm 
and term neonates, infants and toddlers from two different blind randomized controlled 
trials evaluating the analgesic effects of morphine. Both study protocols were approved 
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The study designs are described in detail in the articles of 1) Simons et al. [9], and 2) Van 
Dijk et al. [10], and are shortly repeated as relevant to this article. 
 1) Preterm and term neonates with a postnatal age of less than three days that 
were on artificial ventilation for less than eight hours and had an indwelling arterial 
catheter were eligible for inclusion. Exclusion criteria were severe asphyxia, severe 
intraventricular hemorrhage, major congenital of facial malformations, neurological 
disorders or use of neuromuscular blockers. Patients were randomly allocated to receive 
a loading dose of 100 μg/kg morphine followed by a 10 μg/kg/h morphine infusion or 
sodium chloride infusion. COMFORT-B and VAS scores [11] were obtained twice daily. 
When patients were judged to be in pain or distress they were given an additional 
morphine dose. Arterial blood samples were obtained once or twice daily where possible 
during routine clinical monitoring. 
 2) Neonates with a postmenstrual age (PMA) > 37 weeks and a bodyweight 
³1500 g and infants aged up to three years undergoing major thoracic or abdominal 
surgery were eligible for inclusion. Exclusion criteria were use of analgesic or sedative 
co-medication, use of neuromuscular blockers, hepatic or renal dysfunction, seriously 
compromised neurological status or altered muscle tone. At the end of surgery all 
patients received an intravenous loading dose of 100 mg/kg morphine. Patients were 
randomly allocated to receive either a continuous morphine infusions of 10 mg/kg/h or 
three-hourly iv boluses of 30 mg/kg. Additional morphine doses were given if patients 
were judged to be in pain or distress based on COMFORT-B and VAS scores [11] that were 
assessed every three hours. Arterial blood samples were taken at baseline, 5-10 minutes 
after the loading dose and at 6, 12, and 24 hours after surgery. An additional sample was 
taken 24 hours after the last morphine dose or after discontinuation of the morphine 
infusion.
Analytical Method. Morphine, M3G and M6G serum concentrations were determined 
using an HPLC-MS method as described by Van der Marel et al. [12]. Intra- and inter-assay 
variability were lower than 10%.
Pharmacokinetic Analysis. NONMEM V (Globomax LLC, Hanover, MD) with Splus 
(version 6.2; Insightful software, Seattle, WA) for the visualization of the data, was used. 
The concentrations of morphine, M3G and M6G were expressed as μg morphine units 
per L, logarithmically transformed, and fitted simultaneously. Missing data were 
omitted from the modeling procedure. Model development was performed in four steps: 
1) choice of the structural model, 2) choice of the error model 3) covariate analysis 4) 
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 A decrease in objective function of more than 7.9 points between different (sub)
models was considered to be statistically significant: this correlates with a value of p<0.005 
based on a χ2 distribution. In addition, the following plots were used for diagnostic 
purposes: A) observed versus individually predicted, B) observed versus population-
predicted, C) time versus weighted residuals, D) population predictions versus weighted 
residuals. As the model was developed for prospective use, special focus was on plot 
B instead of the most commonly used A. Furthermore, the confidence interval of the 
parameter estimates, the correlation matrix and visual improvement of the diagnostic 
plots were used to evaluate the model.
Covariate Analysis. Covariates were plotted independently against the individual post-
hoc parameter estimates and the weighted residuals to visualize potential relationships. 
Covariates were tested in linear or allometric equations (equation 1 with k fixed to 1 or 
estimated) or as subpopulations in which a separate parameter is estimated for two or 
more subpopulations.
       
 3 
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every three hours. Arterial blood samples were taken at baseline, 5-10 minutes after the 
loading dose and at 6, 12, and 24 hours after surgery. An additional sample was taken 24 
hours after the last morphine dose or after discontinuation of the morphine infusion. 
 
Analytical method. Morphine, M3G and M6G serum concentrations were determined 
using an HPLC-MS method as described by Van der Marel et al.
 [12]
. Intra- and inter-
assay variability were lower than 10%. 
 
Pharmacokinetic Analysis. NONMEM V (Globomax LLC, Hanover, MD) with Splus 
(version 6.2; Insightful software, Seattle, WA) for the visualization of the data, was used.  
The concentrations of morphine, M3G and M6G were expressed as g morphine units 
per L, logarithmically transformed, and fitted simultaneously. Missing data were omitted 
from the modeling procedure. Model development was performed in four steps: 1) choice 
of the structural model, 2) choice of the error model 3) covariate analysis 4) validation of 
the model.  
 A decrease in objective function of more than 7.9 points between different 
(sub)models was considered to be statistically significant: this correlates with a value of 
p<0.005 based on a χ2 distribution. In addition, the following plots were used for 
diagnostic purposes: A) observed versus individually predicted, B) observed versus 
population-predicted, C) time versus weighted residuals, D) population predictions versus 
weighted residuals. As the model was developed for prospective use, special focus was 
on plot B) instead of the most commonly used A). Furthermore, the confidence interval 
of the parameter estimates, the correlation matrix and visual improvement of the 
diagnostic plots were used to evaluate the model. 
 
C vari te analysis. Covariates wer  plotted independently against the individual post-
hoc paramet  estimates and the weighted residuals to visualize potential relationships.  
Covariates were tested in li ear or allometric equations (equation 1 with k fixed to 1 or 
estimated) or s subpopulations in which a separate parameter is estimated for two or 
more subpopulations. 
k
dardstanpi CovCovPP )/(⋅=        (Equation 1) 
In this equation Pi and Pp represent individual and population parameter estimates 
respectively, Cov represents the covariate and Covstandard represents the standard value of 
the covariate. k represents the exponential scaling factor. 
Based on the post-hoc plots the following covariates were tested: bodyweight, 
bodyweight at birth, body surface area, gender, postnatal age, postmenstrual age, 
bilirubin serum concentration, creatinine clearance, and mechanical ventilation (linear, 
 (Equation 1)
In this equation Pi and Pp represent individual and population parameter estimates 
respectively, Cov represents the covariate and Covstandard represents the standard value of 
the covariate. k represents the exponential scaling factor.
 Based on the post-hoc plots the following covariates were tested: bodyweight, 
odyweight at birth, body surface area, gende , postnatal age, postmenstrual age, 
bilirubin serum concentration, creatinine clearance, and mechanical ventilation (linear, 
allometric or subpopulations). Additionally, trial number (1 or 2), surgery versus non-
surgery, and type of surgery were investigated as covariates (subpopulations). Missing 
information on covariates was indicated with a “.”(dot) in the data file.
 Potential covariates were separately incorporated into the model and considered 
statistically significant if the objective function decreased 7.9 points or more and the 95% 
confidence interval of the additional parameter did not include 0 (assuming normal 
distribution). When more than one significant covariate for the simple model was found, 
the covariate-adjusted model with the largest decrease in objection function was chosen 
as a basis to sequentially explore the influence of additional covariates with the use of the 
same criteria. 
Internal Validation. There was a wide range in number and time points of drug 
administrations, and drug dosing for the individuals. Additionally observations were 
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Prediction Distribution Errors (NPDE) method recently developed by Brendel et al. 
[13,14] is very suitable. This method was implemented using the NPDE add-on software 
package that was run in R. Each observation was simulated 2000 times. The software then 
assembled the predictions in a cumulative distribution function (F) and determined the 
prediction discrepancy, which is defined as the value of F at the observed concentration. 
Prediction distribution errors were obtained by making decorrelations for multiple 
observations in one patient. These prediction distribution errors are expected to follow a 
uniform distribution over the interval [0,1]. Applying the inverse function of the normal 
cumulative density function subsequently yielded normalized prediction distribution 
errors which are expected to follow a normal distribution. The software performed 
standard statistical tests on the normal distribution. The Wilcoxon signed rank test 
indicates whether the mean of the NPDE is significantly different from 0, with the Fisher 
test for variance it is determined whether the variance is significantly different from 1.
Simulations. Generally, morphine is dosed on a μg per kg basis. With the developed 
pharmacokinetic model, it was simulated to what serum concentrations of morphine, 
M3G and M6G this practice leads in children with a postnatal age less than ten days 
weighing 0.5, 1, 2, 2.5, or 4 kg, and children with a postnatal age of ten days or older 
weighing 0.5, 1, 2, 2.5, 4, 10, or 17 kg, after they received a loading dose of 100 μg/kg 
morphine followed by a 10 μg/kg/h infusion, as was the case in the two studies.
 Additional simulations were performed to establish morphine dosing regimens 
for children in these age and weight ranges that lead to more predictable serum 
concentrations of morphine and its metabolites. Serum concentrations were simulated 
in the same set of individuals that received a loading dose of 100 μg/kg followed by 
a 10 μg/kg1.5/h infusion. As target concentrations in the population are yet unknown, 
this amount for the infusion was chosen arbitrarily. To determine what dose reduction 
in neonates was needed to obtain similar morphine and metabolite concentrations in 
children above and below the age of ten days, simulations were performed in which the 
children with a postnatal age below ten days received reduced maintenance doses.
3.3 Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients. The analysis was based on 792 morphine, 644 M3G and 722 M6G serum 
concentrations obtained from 248 newborns, including preterms, and infants. Patient 
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Table I. Demographic and clinical characteristics of the studied patient population
Preterm
 neonates







1 – 24 months
n = 113
Children
 2 – 3 years


















































Boy 36 (56) 38 (64) 66 (58) 4 (33) 144 (58)
Girl 28 (44) 21 (36) 47 (42) 8 (67) 104 (42)
Number of Available Samples
Morphine 199 142 406 45 792
M3G 156 82 362 44 644




















(134 – 234) 
3 unknown





6.0 (5.0 – 7.3) 38 (6 – 140)
Ventilateda
Yes 64 (100) 42 (71) 23 (20) 2 (17) 131 (53)
No 0 (0) 17 (29) 90 (80) 10 (83) 117 (47)
Surgicala
No 55 (86) 8 (14) 0 (0) 0 (0) 63 (25)
Yes (superficial) 0 (0) 4 (7) 8 (7) 1 (8) 13 (5)
       (thoracic) 3 (5) 10 (17) 13 (12) 2 (17) 28 (11)
       (abdominal) 6 (9) 35 (59) 89 (78) 8 (58) 138 (56)
       (thoracic &   
        abdominal) 0 (0) 2 (3) 3 (3) 1 (8) 6 (3)
a Data are represented as median (25% - 75% percentile) or as n (%).
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Model Optimization. The time course of the morphine serum concentrations was best 
described by a two-compartment model (V1, V2, and Q) and glucuronidation clearances 
Cl1 and Cl2. Morphine elimination through other routes (Cl0) was found to be not 
significantly different from zero. V1 and V2 were initially estimated separately, and found 
to be not significantly different from each other. They were therefore fixed to be equal. 
The PK of the formed metabolites M3G and M6G was described by one-compartment 
models with volumes of distribution V3 and V4, and elimination clearances Cl3 and Cl4, 
respectively. The volumes of distribution V3  and V4 were estimated as a fraction of V1 and 
found not to be significantly different from each other. They were therefore also fixed to 
be equal. In figure 1 a schematic representation of this model is shown.
 Concerning inter-individual variability, log-normal distribution was found 
to describe the data most adequately. For the residual or intra-individual variability, 
a proportional error model was found, with a different error for morphine, M3G and 
M6G. On the concentrations that were determined 24 hours after discontinuation of the 
infusion an additional additive error with a similar value for morphine, M3G and M6G 
was found.
Figure 1. Schematic representation of the 
pharmacokinetic model for morphine and its 
glucuronides. M=morphine, M3G=morphine-
3-glucuronide, M6G=morphine-6-glucuronide, 
V1=volume of distribution of central compartment 
of M, V2= volume of distribution of peripheral 
compartment of M, V3=volume of distribution 
of M3G, V4=volume of distribution of M6G, 
Q=inter-compartmental clearance of M, Cl0= M 
excretion by routes other than glucuronidation 
(not observed), Cl1=formation clearance of M3G, 
Cl2=formation clearance of M6G, Cl3=elimination 
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Covariate Analysis. In the covariate analysis, bodyweight proved to be the most 
predictive for the formation clearances to M3G (Cl1) and M6G (Cl2), the elimination 
clearances of M3G (Cl3) and M6G (Cl4) and for the volumes of distribution. The influence 
of bodyweight on the clearances was best described using an allometric equation in 
which the exponential scaling factor (k) was estimated to be 1.44. Estimating different 
values for k for the different clearance parameters did not result in a significant decrease 
in objective function. The exponential scaling factor of the volumes of distribution was 
not significantly different from 1, indicating a linear relationship between bodyweight 
and volume of distribution. 
Table II. Population pharmacokinetic parameter estimates
Parameter Value CV (%)
Fixed Effects
k = exponential scaling factor 1.44 2.92
Cl1 PNA<10d (ml/min/kgk) 3.48 5.89
Cl1 PNA>10d (ml/min/kgk) 8.62 8.82
Cl2 PNA<10d (ml/min/kgk) 0.426 11.1
Cl2 PNA>10d (ml/min/kgk) 0.67 12.6
Cl3 (ml/min/kgk) 2.02 6.68
Cl4 (ml/min/kgk) 1.05 11.2
Q (ml/min) 29.6 17.8
V1 = V2 (l/kg) 1.81 7.62











σ2,add(post infusion sample) 10.3 31.2
Cl=clearance, Q=inter-compartmental clearance, V=volume of distribution, PNA=postnatal age, 
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 Postnatal age less than ten days proved to be an additional covariate for 
formation clearance to M3G and M6G, which was found to be independent of birth 
weight or postmenstrual age. Defining postnatal age as a continuous variable resulted 
in minimization difficulties. Selecting a period of ten days resulted in a lower objective 
function compared to 3, 7, 14 and 21 days. No other covariates could be identified. In 
table II all the parameter estimates obtained with the FOCE method are listed. 
 Figure 2 depicts the observed concentrations versus individually predicted (A) 
and model-predicted (B) concentrations of morphine and its glucuronides for the final 
model. Plots of weighted residuals versus PNA and PMA for term and preterm neonates 
are depicted in figure 3. In figure 4 estimated individual and population formation 
clearances to M3G (Cl1) are plotted against bodyweight for children with a postnatal 
age more or less than ten days. After incorporation of the covariates inter-individual 
variability in the formation clearance to M6G (Cl2) was not significantly different 
from zero. Figure 5 shows the estimated individual and population predictions of the 
elimination clearances of M3G (Cl4) and M6G (Cl5) versus bodyweight.
Validation. Figure 6 depicts the histograms of the NPDE for morphine and its metabolites. 
The lines indicate the normal distribution. The value of the mean and variance are 
given below each graph, with * and ** indicating a significant difference from 0 and 1 at 
respectively the p<0.05 and p<0.01 level as determined by the Wilcoxon signed rank test 
and Fisher test for variance. Plots of NPDE versus time after first dose and NPDE versus 
the log of the concentration for morphine and its metabolites are also shown.
Simulations. The model-based simulations depicted in figure 7a show the range of 
morphine, M3G and M6G serum concentrations predicted in children with a bodyweight 
varying between 0.5 and 17 kg and postnatal ages above (solid line) or below (dotted line) 
ten days that received a loading dose of 100 μg/kg morphine followed by a maintenance 
dose of 10 μg/kg/h. 
 A considerably narrower range of serum concentrations of morphine and it 
metabolites are predicted in this population when maintenance doses are given in μg/
kg1.5/h. Nevertheless, due to the lower glucuronide formation rates in children less than 
ten days of age, the concentrations obtained in these children are noticeably different 
from the concentrations obtained in children older than ten days (data not shown). A 
50% reduction of the maintenance dose in the children younger than ten days resulted 
in an even narrower range of morphine and metabolite serum concentrations. Figure 7b 
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0 5000 10000 15000
Figure 4. Morphine formation clearance to morphine-3-glucuronide (M3G) (=Cl1) versus bodyweight. 
Population prediction in children younger than ten days (dotted line) and older than ten days (solid line) and 
individual obtained values in children younger than ten days (triangles) and older than ten days (circles), on 


























































0 5000 10000 15000
Figure 5. Elimination clearance of morphine-3-glucuronide (M3G) (=Cl3) and morphine-6-glucuronide 
(M6G) (=Cl4) versus bodyweight. Lines are population predicted (solid for CL3 and dotted for CL4), symbols 












































Figure 6. Results of the internal validation with the Normalized Prediction Distribution Error (NPDE) 
method. The histograms show the NPDE distribution for morphine (top), morphine-3-glucuronide (middle), 
and morphine-6-glucuronide (bottom) and the solid line indicates a normal distribution. The value for the 
mean and variance of the NPDE distribution are given below each graph, with * indicating a significant 
difference of a mean of 0 and a variance of 1 at the p<0.05 level. The distribution of NPDE versus time after 
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3.4 Discussion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
To our knowledge, the population PK model developed in this study is the first that 
simultaneously describes and predicts morphine and its main metabolite concentrations 
in children ranging from preterm and term neonates up to infants approximately 
three years of age. Herewith, the model covers a wide and common age-group of the 
neonatal and paediatric intensive care, which is characterized by large maturational and 
developmental changes. The influences of these changes on the PK of morphine are now 
described in a quantitative manner. This study also proves that an adequate PK model 
can be developed based on sparse and unbalanced data obtained from routine clinical 
practice. Whereas often, both in adult and paediatric population pharmacokinetic 
models, proper internal validation is lacking [15,16], the model presented here is internally 
validated using an advanced tool for model validation. 
 Because the ontogenesis of clearance is believed to be the most critical 
determinant of a pharmacological response in infants and children [17], there is a specific 
interest in this parameter. An overview of morphine clearances in neonates and infants 
reported in the past two decades is given in table III. 
It was found in this study that bodyweight, rather than body surface area or age, is the 
most predictive covariate for glucuronidation capacity of morphine under the age of 
three years. This glucuronidation capacity increases more than linearly with bodyweight 
and is best parameterized by a bodyweight-based power equation with an exponential 
scaling factor of 1.44. Recently, the allometric equation based on bodyweight with an 
exponential scaling factor of 0.75 has gained in popularity in the field of paediatrics. 
Originally designed to describe metabolic rates between different species covering 
a range of bodyweight of many orders of magnitude [32], this function is now being 
applied to parameterize the influence of changes in body size on clearance parameters 
within the human weight-range. After clearances are expressed as per 70 kg bodyweight 
an additional age-based equation needs to be estimated to describe maturation [33]. 
This method has been applied to morphine in a previous study that did not include 
preterm neonates. This model required, in addition to age, the use of two additional 
parameters (i.e. creatinine and bilirubin concentrations) to describe the time course of 
morphine across the whole age range [19]. Rather than incorporating a scaling function for 
bodyweight and subsequently estimating a function that describes maturation processes 
as a function of age, in the current study one single function based on bodyweight was 
estimated to describe the influence of all maturational and developmental changes 
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influence of bodyweight on glucuronidation clearance with an estimated scaling factor 
of 1.44, the influence of other covariates such as age, renal function and liver function 
became not significant, except for the influence of age on glucuronidation capacity in the 
first ten days of life.  
 For clearance we found the value of the allometric scaling factor to be higher 
than 1. Functions with an exponential scaling factor below 1 are characterized by a 
relatively high initial slope that levels-off (dome-shaped curve), whereas functions with 
an exponential scaling factor above 1 are characterized by a relatively low initial slope 
that increases (concave-shaped curve, see figure 4 and 5). Contrary to a previous study 
on morphine PK in young children [19], in the current study data from preterm neonates 
with a very low bodyweight were included. In preterm neonates, the initial maturation 
rate of elimination pathways is supposed to be very slow [34], a bodyweight allometric 
equation with an exponential scaling factor higher than 1 can therefore be expected across 
this population. By optimizing the influence of bodyweight with an exponential scaling 
factor of 1.44 the influence of other covariates was limited to a decreased glucuronidation 
rate in neonates with a postnatal age of less than ten days.
 The increase in glucuronidation capacity will level-off at a certain age and 
bodyweight. This is not incorporated in the current model and therefore one of the 
limitations of the model is that no extrapolations can be made beyond the upper 
boundaries in bodyweight of our studied population.
 The UGT2B7 isoenzyme is thought to be the major contributor to morphine 
glucuronidation [6,7,35]. The fact that the same scaling factor was found for formation 
clearance to both M3G and M6G appears to confirm that these metabolic routes mature 
at the same rate, which has been suggested before by others [36,37]. We found morphine 
metabolism to increase exponentially with bodyweight in the first three years of life, 
additionally we found a major increase ten days after birth. Interestingly, in concordance 
with these results, studies on zidovudine, the first antiviral drug approved for the treatment 
of HIV and AIDS in the paediatric population that is also predominantly glucuronidated 
by UGT2B7 [7,8], showed that its glucuronidation capacity increases dramatically in the 
first two weeks of life followed by a period of slower capacity increase of two years [38,39]. 
This suggests that the influence of maturational changes on morphine metabolism found 
in this study can be extrapolated to other exogenous and possibly endogenous substrates 
metabolized by the UGT2B7 enzyme, although this requires further study.
According to our model maturation of morphine glucuronidation is independent of 
PMA. Table III shows that reports on the influence of gestation on the maturation rate 
of morphine are ambiguous [18,21,29]. Additionally, Capparelli et al. [40] found zidovudine 
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Figure 3 shows no trend in weighted residuals versus PNA and PMA for term and 
preterm neonates in our model, corroborating that with the current model morphine 
glucuronidation can be accurately predicted based on bodyweight and postnatal age 
alone.
Although reports are inconclusive, it has been suggested that especially in neonates, 
morphine is also partially cleared through sulphation [27,30] and unchanged renal 
excretion [19]. In this study Cl0, which represents all elimination pathways other than 
glucuronidation to M3G and M6G, was found not to be statistically different from 0. 
Even in the preterm or very young neonates this parameter was not found to have any 
significance, suggesting that these pathways do not play a significant role in morphine 
clearance in the studied population.
In most publications, observed concentrations of a drug are often compared to individual 
model predictions, however especially when PK-PD models are developed for 
prospective simulations, it is important to also have accurate and unbiased population 
predictions. As the metabolites of morphine also possess pharmacological properties, 
it is not sufficient to be able to only predict morphine concentrations accurately, it is 
imperative to be also able to accurately predict the concentrations of the metabolites. 
Figure 2 shows accurate and unbiased distribution of both the individual and population 
predictions of morphine and its metabolites with the current model.
 The internal validation procedure further corroborates the predictive value 
of the model developed in this article. Even though the statistical tests indicate a 
significant difference from the mean of 0 and variance of 1, this can be the result of the 
NPDE method not being fully optimized yet. The developers indicate that especially for 
large datasets the graphic output should be considered as well to determine whether 
the model sufficiently describes the data [14]. According to the histograms in figure 6 the 
model can quite accurately predict median concentrations in the population, however 
the variability appears to be slightly over-predicted by the model. Additionally figure 6 
shows no trend in NPDE over time or over the concentration range. Considering that on 
average only four samples were available for each individual, we believe the results to 
be remarkable. Since for the simulations in this article only population predictions were 
used, this model deficiency has no substantial effect on the inference made here. Future 
inferences made on model based simulations could be influenced by the over-prediction 
of the variability, however we believe model based predictions would always be on the 
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The model based simulations in figure 7a demonstrate that a wide concentration 
range is predicted for both morphine and its glucuronides, when dosing morphine 
in mg per kg bodyweight in children weighing less than 17 kg. Because distribution 
volume was found to change linearly with bodyweight and clearances was found to 
change exponentially with a scaling factor close to 1.5, a dosing regimen with a loading 
dose in μg/kg and a maintenance dose in μg/kg1.5/h was expected to yield drug and 
metabolite serum concentrations in a narrower range for all the children in this weight 
range. Indeed, simulations prove this to be the case. The influence of the reduced 
glucuronidation capacity on morphine serum concentrations in the first ten days of 
life can be compensated by a 50% reduction of the maintenance dose in patients with 
a postnatal age of less than ten days. This dose reduction also results in more similar 
M3G and M6G serum concentrations between patients younger and older than ten 
days, although there is still a marked difference in the metabolite serum concentrations 
between these patient groups (figure 7b). 
 One should bear in mind that the optimal dosing regimen should result in safe 
and effective pharmacological responses which may not per se mean a similar drug serum 
concentration across the whole population. Therefore the influence of the developmental 
stage of a child on the relationship between drug concentration and drug effect needs to 
be determined. As M6G, like morphine, is believed to exert analgesic actions with high 
potency through binding to the μ-opioid receptor [41–43] and as there is some evidence that 
M3G may functionally antagonize the analgesic effect of morphine [44,45], both metabolites 
need to be incorporated in this PD analysis. This investigation will be part of future 
studies of our group and will yield evidence-based and age-specific target concentrations 
of morphine for our study population. The current PK model can then be used to define 
final dosing recommendations. Additionally, the clinical importance of the differences in 
metabolite concentrations that still exist in the current model between the patients older 









































84  |  Chapter 3
3.5 Conclusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Based on an analysis of sparse data in newborns, including preterms, and infants under 
the age of three years, using morphine as a model drug, maturation of glucuronidation 
by the UGT2B7 enzyme was described. It was found that this glucuronidation capacity 
as well as elimination clearance of morphine glucuronides can be best described by a 
bodyweight-based power equation with an exponential scaling factor of 1.44 in this 
population. Within this power equation clearances to glucuronides are decreased in 
neonates younger than ten days. Model-based simulations showed that a narrow range 
of morphine and metabolite concentrations is obtained across the studied population 
when morphine infusions are administered per kg1.5 per hour with a 50% reduction in 
neonates younger than ten days. Definitive dosing recommendations for morphine can 
be made after safe and effective target concentrations of morphine and its metabolites 
in this population are determined and after prospective studies have been performed. 
Additionally, the investigation of the possibility to extrapolate the findings on UGT2B7 
maturation to other drugs metabolized by the same enzyme is part of future investigations. 
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In which A represents the amount of morphine equivalents in the designated compartment 
(M1 and M2 for the central and peripheral compartment of morphine respectively, M3G 
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In which A represents the amount of morphine equivalents in the designated compartment 
(M1 and M2 for the central and peripheral compartment of morphine respectively, M3G 
for morphine-3-glucuronide and M6G for morphine-6-glucuronide). t represents time, 
Rinfusion represents the morphine infusion rate, and Q represents the equilibrium constant 
In which A represents the amount of morphine equivalents in the designated compart ent 
(M1 and M2 for the central and peripheral compartment of morphine r spectively, M3G 
for morphine-3-glucuronide and M6G for morphine-6-glucuronide). t repres nts time, 
Rinfusion represents the morphine infusion rate, and Q represents the equilibrium constant 
for the two morphine compartments. Clearances are indicated by Cl, subscripts 1 and 
2 indicate formation clearances of M3G and M6G respectively and subscripts 3 and 4 
indicate elimination clearances of M3G and M6G.  For the formation of the metabolites 
a different value for CLpop is calculated for children older and younger than ten days. 
Distribution volumes are indicated by V, subscripts M1 and M2 indicating respectively 
the central and peripheral compartment for morphine and M3G and M6G indicating 
the metabolite compartments. Individual and population parameters are indicated by 
subscripts ind and pop respectively. ω indicates the inter-individual variability on the 
3.5 Conclusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Based on an analysis of sparse data in newborns, including preterms, and infants under 
the age of three years, using morphine as a model drug, maturation of glucuronidation 
by the UGT2B7 enzyme was described. It was found that this glucuronidation capacity 
as well as elimination clearance of morphine glucuronides can be best described by a 
bodyweight-based power equation with an exponential scaling factor of 1.44 in this 
population. Within this power equation clearances to glucuronides are decreased in 
neonates younger than ten days. Model-based simulations showed that a narrow range 
of morphine and metabolite concentrations is obtained across the studied population 
when morphine infusions are administered per kg1.5 per hour with a 50% reduction in 
neonates younger than ten days. Definitive dosing recommendations for morphine can 
be made after safe and effective target concentrations of morphine and its metabolites 
in this population are determined and after prospective studies have been performed. 
Additionally, the investigation of the possibility to extrapolate the findings on UGT2B7 
maturation to other drugs metabolized by the same enzyme is part of future investigations. 
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Equations for the final model in NONMEM ADVAN5.
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designated parameter. BW stands for bodyweight and k is the exponential scaling factor. 
The distribution volumes of the metabolites are calculated as a fraction of VM1 the value 
of which is estimated and represented by fraction_of_ VM1.
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Background and Objective: Model validation procedures are crucial when models are to 
be used to develop new dosing algorithms. In this study, the predictive performance of 
a previously published paediatric population pharmacokinetic model for morphine and 
its metabolites in children younger than three years (original model) is studied in new 
datasets that were not used to develop the original model.
Methods: Six external datasets including neonates and infants up to one year were 
obtained from four different research centres. These datasets contained postoperative 
patients, ventilated patients and patients on extracorporeal membrane oxygenation 
(ECMO) treatment. Basic observed versus predicted plots, normalized prediction 
distribution error analysis, model refitting, bootstrap analysis, subpopulation analysis 
and a literature comparison of clearance predictions were performed with the new 
datasets to evaluate the predictive performance of the original morphine pharmacokinetic 
model.
Results: The original model was found to be stable and the parameter estimates were 
found to be precise. The concentrations predicted by the original model were in good 
agreement with the observed concentrations in the four datasets from postoperative 
and ventilated patients, and the model-predicted clearances in these datasets were in 
agreement with literature values. In the datasets from patients on ECMO treatment 
with continuous venovenous haemofiltration (CVVH) the predictive performance of 
the model was good as well, whereas underprediction occurred, particularly for the 
metabolites, in patients on ECMO treatment without CVVH.
Conclusion: The predictive value of the original morphine pharmacokinetic model is 
demonstrated in new datasets by the use of six different validation and evaluation tools. 
It is herewith justified to undertake a proof-of-principle approach in the development 
of rational dosing recommendations – namely, performing a prospective clinical trial in 
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4.1 Background
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Adequate validation studies to establish the predictive performance of population 
pharmacokinetic (PK) and/or pharmacodynamic (PD) models are often lacking both in 
the adult and paediatric population [1,2]. Validation procedures are crucial when models 
are to be used for simulation exercises. Model simulations can for instance be used to 
optimize dosing algorithms that take individual characteristics such as bodyweight 
and age into account. Additionally, simulations can be useful in setting-up clinical 
trials optimizing the information that is obtained while minimizing the burden to each 
individual in the trial by reducing the number of blood samples that need to be obtained. 
Without proper validation a model can only be regarded descriptive, limiting the safe 
use of these models for clinical and research applications. 
Validation methods have been classified into three categories [2]: (i) basic internal 
methods (e.g. basic goodness-of-fit plots, uncertainty in parameter estimates and model 
sensitivity to outliers); (ii) advanced internal methods (e.g. data splitting, resampling 
techniques and Monte Carlo simulations); (iii) external validation (comparing 
observations in a new external dataset to predictions obtained using the model that was 
built on an internal dataset). Additionally, the aptness of model-based dosing algorithms 
should be assessed in confirmatory prospective clinical trials [3].
Ethical and practical constraints in paediatric studies may complicate the 
validation steps of paediatric models. Firstly, paediatric studies are often performed 
during routine clinical practice leading to high variability in drug administration due 
to different individual needs. Standard validation tools such as a visual predictive 
check may then not suffice and more sophisticated tools are required. Additionally, 
the paediatric population is relatively diverse due to the many maturational changes 
between preterm newborns and 18 year old adolescents, therefore diagnostic tools 
should not only be applied to the dataset of the population as a whole but also to various 
(age) subgroups in a dataset. Finally, the limited number of studies performed in this 
population makes external datasets less available and due to limited numbers of patients 
in paediatric studies the use of part of the dataset for model building and the other part 
for the external validation is often not viable either. 
Recently a population PK model for morphine and its two major metabolites 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) was developed 
based on data from postoperative and ventilated neonates (including preterms), infants 
and children up to the age of three years (Chapter 3). This model was validated internally 
using basic and advanced validation methods and will be referred to as the ‘original 
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for simulation purposes is assessed in an external validation study with six new external 
datasets using basic and advanced validation methods. 
4.2 Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients and Data
For the external validation study six datasets were available [4–10]. All studies had been 
approved by local ethic committees and informed parental consent was obtained. 
The datasets contained patient data not linked to identifiable patient information. An 
overview of the internal and external datasets is given in table I. 
The studies were performed at four different centers, in three different countries 
and two different morphine salts were administered. To compare the administered doses 
the amount of administered morphine base was calculated for each individual.
Original Model
A schematic representation of the original model is shown in figure 1. In this model 
distribution volumes are scaled linearly with bodyweight. Formation clearances 
(CL1 and CL2) and elimination clearances (CL3 and CL4) of the morphine metabolites 
were best described by a bodyweight-based allometric equation with an estimated 
exponential scaling factor of 1.44. Additionally, within this power-function formation of 
the metabolites (CL1 and CL2) is reduced in neonates younger than ten days.
Figure 1. Schematic representation of the 
original peadiatric population PK model for 
morphine and its glucuronides in children 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































94  |  Chapter 4
Model Validation and Evaluation
NONMEM VI (ICON, Ellicott City, MD) was used for all model-based simulations and 
model fitting in the current study.
Simulations were performed based on dosing regimen, bodyweight and postnatal 
age of the children in the new external datasets, to obtain model-based population 
predicted concentrations. These predicted concentrations were then plotted versus the 
concentrations that were actually observed in these datasets. As population predicted 
concentrations are based on the fixed effects of the model, this analysis allows for the 
assessment of the predictive performance of both the structural model, encompassing 
the parent drug and metabolite model, and the covariate model, encompassing the 
relationships between the patient characteristics bodyweight and age and the model 
parameters clearance and distribution volume. 
Additionally, a normalized prediction distribution error (NPDE) analysis was 
performed using the add-on software package that was run in R [13,14]. One-thousand 
model-predicted concentrations were generated for each observation in the external 
datasets with simulations based on dosing regimen, bodyweight and age of the patients 
and with the parameter values (including the inter-individual and residual variability) 
that were obtained for the original model. The observed concentrations in the external 
datasets were subsequently compared to these 1000 predicted concentrations [13,14]. In 
addition to assessing the structural and covariate model, this validation tool also allows 
for the assessment of how well the model predicts variability within the population.
When the plots of the predicted versus observed concentrations and the NPDE 
analysis showed no trends or bias in the external datasets of the postoperative and 
ventilated patients (Ext.1 – 4), these datasets were merged and analyzed together. These 
four external datasets were then combined with the internal datasets used to develop the 
original model and refitted to this model simultaneously. The resulting parameters could 
then be compared to the parameters obtained in the original model fit. Additionally, 
this combined dataset was used in a bootstrap analysis using the PSN software package 
[15]. For the bootstrap analysis the combined dataset was resampled 500 times and these 
resampled datasets were subsequently refitted to the model. All parameter estimates 
were then summarized as means and standard errors and could be compared to the 
results of the original model fit. Both the model refit and the bootstrap analysis give 
insight into model stability and the uncertainty of the parameter estimates of the model. 
The performance of the covariate model was evaluated in the combined 
internal and external dataset by investigating subpopulations. It was examined whether 
bodyweight or age is the best descriptor for the maturation of the PK parameters by 
plotting post hoc PK parameter values obtained from the simultaneous refit versus 
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(SGA) and appropriate for gestational age (AGA) neonates. Neonates are considered 
to be SGA when their birth weight is below two standard deviations of the mean birth 
weight at that gestational age. All other neonates are considered to be AGA. 
Lastly, model-predicted total morphine clearances for both the internal and 
merged external datasets were compared to morphine clearances published in the past 
twenty years. These reference values were derived from population PK models [16,17] or 
obtained non-parametrically [7,18–27]. For the original morphine model, total morphine 
clearances were calculated for each individual in the combined internal and external 
dataset as the sum of both metabolite formation clearances (CL1 and CL2) obtained in 
the simultaneous model refit. This was done for both population parameter estimates 
and individual post hoc parameter estimates. Population clearance parameters 
from publications that used a model-based approach and average clearances from 
publications that used a non-parametric approach were used together with individual 
patient characteristics (i.e. bodyweight, age and bilirubin concentrations), to calculate 
the reference total morphine clearances. This was only calculated for individuals in 
the combined internal and external dataset that met the inclusion criteria of the study 
described in a particular reference publication. All obtained clearance parameters were 
subsequently plotted versus bodyweight.
Although the original model was not based on data of patients on extracorporeal 
membrane oxygenation (ECMO) treatment, the predictive performance of the original 
model was also tested in two datasets with ECMO patients (Ext. 5 & 6). The datasets 
were evaluated individually by making plots of population predicted concentration 
versus observed concentrations and by performing an NPDE analysis as described above. 
Due to the inconclusive results on the predictive performance of the model in these two 
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4.3 Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The external datasets included a total of 37 non-cardiac postoperative patients, 53 
ventilated patients, and 30 patients on ECMO treatment, with a total of 705 morphine, 
668 M3G, and 681 M6G concentrations. Detailed information on the internal datasets 
(Int. 1 & 2) and the new external datasets (Ext. 1 – 6) is given in table I. 
No trends or biases were observed in the predicted versus observed plots 
and the NPDE results of the four external datasets with postoperative and ventilated 
patients (Ext. 1 – 4). Figure 2a depicts a plot of the model-based population predicted 
concentrations versus the observed concentrations in these dataset using different 
symbols for the different datasets. In figure 3 the results of the NPDE analysis are shown, 
including the NPDE frequency distribution with the mean and standard deviation of 
this distribution, the NPDE distribution in time and the NPDE distribution versus the log 
value of the concentration. The plots show limited trends or biases in the predictions by 
the model. 


























































Figure 2. Results of the external validation representing the concentration predicted by the original model 
versus the concentrations observed in the external datasets of postoperative and ventilated patients (Ext.1 
– Ext.4) for morphine, morphine-3-glucuronide and morphine-6-glucuronide.  = Ext.1 preterm neonates 
on artificial ventilation [4], r = Ext.2 non-cardiac postoperative term neonates and infants [5], s = Ext.3 
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Table II. Parameter estimates obtained in the original fit of the model based on the internal dataset (Int. 1 & 
2), and the refit and bootstrap of the combined internal and external datasets for postoperative and ventilated 
patients (Int. 1 & 2 and Ext. 1 – 4).
Parameters original model fit 
internal dataset
refit of the model
internal & external 
dataset 
Bootstrap
internal & external 
dataset
Value (CV%) Value (CV%) Value (CV%)
Fixed effects
k = exponential scaling factor 1.44 (2.92) 1.44 (2.69) 1.44 (2.62)
Cl1 PNA < 10 d (ml/min/kgk) 3.48 (5.89) 3.09 (5.15) 3.07 (8.37)
Cl1 PNA > 10d (ml/min/kgk) 8.62 (8.82) 8.25 (8.18) 8.27 (8.09)
Cl2 PNA < 10d (ml/min/kgk) 0.426 (11.1) 0.408 (11.4) 0.410 (10.8)
Cl2 PNA >10d (ml/min/kgk) 0.67 (12.6) 0.699 (12.4) 0.714 (11.8)
Cl3 (ml/min/kgk) 2.02 (6.68) 2.19 (5.43) 2.19 (5.53)
Cl4 (ml/min/kgk) 1.05 (11.2) 1.11 (11.5) 1.12 (11.0)
Qeq (ml/min) 29.6 (17.8) 28.9 (16.6) 29.7 (16.1)
V1 = V4 (l/kg) 1.81 (7.62) 1.99 (6.48) 1.99 (6.43)
V2 = V3 (fraction of V1) 0.121 (18.2) 0.119 (17.2) 1.22 (17.1)
Inter-individual variability
ω2 Cl1 0.0671 (25.9) 0.104 (18.4) 0.103 (18.5)
ω2 V1 0.196 (17.4) 0.23 (18.1) 0.223 (17.9)
ω2 Cl3 0.253 (20.1) 0.258 (16.7) 0.253 (16.4)
ω2 Cl4 0.146 (13.9) 0.185 (14.2) 0.184 (14.2)
ω2 Cl3-Cl4 interaction 0.164 (13.7) 0.178 (13.4) 0.177 (13.2)
Residual error
σ2, prop (morphine) 0.406 (13.3) 0.371 (5.94) 0.368 (11.7)
σ2, prop (M3G) 0.217 (24.7) 0.206 (19..4) 0.204 (19.0)
σ2, prop (M6G) 0.0844 (13.6) 0.0967 (12.0) 0.0959 (12.0)
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Table II gives an overview of (i) parameter estimates obtained in the original 
model fit (Chapter 3); (ii) parameter estimates of the model refit of the combined internal 
and four merged external datasets (Int. 1 & 2 and Ext. 1 – 4); (iii) the parameter estimates 
obtained in the bootstrap of the model with the combined internal and external dataset. 
In the combined internal and external datasets, there were 168 neonates of which 
birthweight and gestational age at birth was known. Of these neonates 24 (=14%) were 
SGA. In figure 4 the individual post hoc parameter estimates of four model parameters 
are plotted versus bodyweight and postmenstrual age using different symbols for SGA 
and AGA neonates. The figure shows that when distribution volume (V1) and M3G 
formation (CL1) are plotted versus bodyweight, the individual post hoc estimates for SGA 
neonates are in line with the post hoc estimates for the AGA neonates, which is not the 
case when they are plotted versus postmenstrual age. Additionally the individual post 
hoc parameter estimates of the elimination clearance of M3G and M6G (CL3 and CL4) of 
the SGA neonates are shifted to the left compared to the post hoc estimates of the AGA 
neonates when plotted versus bodyweight. When plotted versus postmenstrual age the 
post hoc estimates of the elimination of the morphine metabolites of the SGA neonates are 
more in line with the values of the AGA neonates.
Figure 5 shows total morphine clearance values versus bodyweight. Population 
and individual post hoc predictions from the original model are shown in solid and open 
black circles respectively. The two lines represent children that are older and younger 
then ten days. Clearances calculated based on previously published clearance values are 
depicted with grey solid circles.
Figure 6 shows the plot of population predicted concentrations versus observed 
concentrations for the two datasets that included children on ECMO treatment (Ext.5 & 
6) using different symbols for the two datasets. Predictions for dataset 6 are less biased 
than for dataset 5, particularly for the metabolites. In figure 7 the results of the NPDE 
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Figure 3. Results of the external validation with the NPDE method using external datasets of postoperative 
and ventilated patients (Ext.1 – Ext.4). The histograms show the NPDE frequency distribution in the merged 
external dataset for morphine, morphine-3-glucuronide and morphine-6-glucuronide, the solid line indicates 
a normal distribution. The values for the mean and variance of the NPDE distribution are given below each 
histogram with * indicating a significant difference of a mean of 0 and a variance of 1 at the p < 0.05 level as 
determined by the Wilcoxon signed rank test and the Fisher test of variance. The distribution of NPDE versus 
time after first dose and NPDE versus the log of the concentration are also shown. The dotted lines represent 
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Figure 5. Total morphine clearance 
values versus bodyweight for the 
patients in the internal and external 
datasets (Int. 1 & 2 and Ext. 1 – 4). 
 = population predictions from 
the original model,  = individual 
post hoc estimates from the original 
model.  = values reported in 















































































Figure 6. Results of the external validation representing the concentrations predicted by the original model 
versus observed concentrations in the external datasets of patient receiving ECMO treatment for morphine, 
morphine-3-glucuronide, and morphine-6-glucuronide.  = Ext.5 term neonates on ECMO treatment 
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Figure 7. Results of the external validation with the NPDE method using external dataset 6 (neonates on 
ECMO treatment with CVVH). The histograms show the NPDE frequency distribution in the merged 
external dataset for morphine, morphine-3-glucuronide and morphine-6-glucuronide, the solid line indicates 
a normal distribution. The values for the mean and variance of the NPDE distribution are given below each 
histogram with * indicating a significant difference of a mean of 0 and a variance of 1 at the p < 0.05 level as 
determined by the Wilcoxon signed rank test and the Fisher test of variance. The distribution of NPDE versus 
time after first dose and NPDE versus the log of the concentration are also shown. The dotted lines represent 
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4.4 Discussion 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In many publications on population PK and PD models results of even basic validation 
procedures are lacking. In adults only 28% of the population PK models and 26% of 
the population PD models were found to be adequately evaluated [1]. In the paediatric 
population advanced internal evaluations are performed on merely 16% of the models 
and external validations are performed on only 9% of the models [2]. Our group recently 
developed a population PK model for morphine glucuronidation in neonates (including 
preterms) infants and children up to three years which was validated internally using 
basic and advanced methods (Chapter 3). The internal validation procedure showed 
that the model can adequately describe the dataset used to develop the model, but 
when a model is to be used to derive dosing algorithms, descriptive properties are not 
enough. Therefore the predictive performance of the original model and thereby the 
validity of the use of the original morphine PK model for simulation purposes in this age 
group needed to be established as well. This can only be done in an external validation 
procedure for which in the current analysis six external datasets were available and 
basic and advanced validation methods were used. Moreover, the predicted morphine 
clearances are compared to literature values published in the past twenty years.
Two of the external datasets (Ext.3 & 4) originate from medical centers other than 
the centers from which the internal datasets were obtained. Irrespective of the center 
at which the studies were performed or the morphine salt that was administered, the 
predictive performance of the original morphine PK model was found to be good in 
the external datasets of postoperative and ventilated patients younger than one year. 
Figure 2 shows that the model can predict morphine and metabolite concentrations 
without bias in all individuals in the external datasets on the basis of dose, bodyweight 
and postnatal age alone. The spread in the observed data, which reflects the variability 
within the overall population, is equally large above and below the line of unity. The 
NPDE analysis in figure 3 confirms that the original model predicts morphine and 
metabolite concentrations accurately and detects only a slight over-estimation of the 
variability which was also observed in the internal validation procedure. The refit of 
the combined internal and merged external datasets (Int. 1 & 2 and Ext. 1 – 4) and the 
bootstrap analysis performed with this entire dataset show the original PK model for 
morphine in these young patients to be stable and the estimated parameters to be precise 
(table II). This means that the concentrations that were measured upon blood collections 
in these external datasets could have been adequately predicted based on individual 
characteristics that are readily available in clinical practice (bodyweight and age), thereby 
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The results of this external validation also strengthen the confidence in the 
obtained covariate relationships. This is important because in the paediatric population 
there is a strong correlation between bodyweight and age, leading to an ongoing debate on 
which of these characteristics to use as a descriptor for maturational changes in population 
PK models in this population. Some incorporate bodyweight a priori as a covariate using 
a bodyweight based allometric equation with fixed exponents of 0.75 for clearance and 
1 for distribution volume [28]. The paediatric population PK model that is evaluated in 
the current study was developed by regarding bodyweight and age as conventional 
covariates in a systematic covariate analysis. In model development bodyweight was 
found to be a better descriptor of the maturation of morphine PK parameters than age 
and its influence was best described by a bodyweight based allometric equation with 
an estimated exponent of 1.44 for clearance and 1 for distribution volume (Chapter 3). 
Additionally, within this power-function metabolite formation was found to be reduced 
in neonates younger than ten days. In this external validation procedure, the original 
model showed to generate adequate predictions in a patient population up to one year 
of age.
The current analysis also demonstrates that the correlation between bodyweight 
and age is different in neonates that are SGA compared to their AGA counterparts. 
Therefore insights into the use of bodyweight or age as descriptors for maturational 
changes on drug PK can be obtained by studying these two subpopulations. For M3G 
formation clearance (CL1) and distribution volume (V1), the same relationship for SGA 
and AGA neonates was found when plotted versus bodyweight, which is not the case 
when plotted versus postmenstrual age (figure 4 a and b). Although shrinkage was 26.3% 
and 31.7% respectively, which renders plots using post hoc parameter estimates less 
reliable, this suggests that that bodyweight is indeed the most appropriate descriptor 
to describe maturational changes in the distribution volume and glucuronidation of 
morphine. For the elimination clearance of M3G and M6G (CL3 and CL4) the relationship 
with bodyweight is different for SGA and AGA neonates while the relationship between 
CL3 and CL4 and postmenstrual age in SGA and AGA neonates is more similar (figure 4 
c and d). With 14.6% and 13.0% respectively, shrinkage was sufficiently low for the post 
hoc estimates of these parameters to be reliable. Bodyweight appears not to be the most 
optimal descriptor of the maturation rate of the elimination of the morphine metabolites 
and age may be a better descriptor. Based on these results an age-based exponential 
equation for the elimination clearances was tested, but this did not significantly improve 
the model (data not shown). According to the rule of parsimony this was therefore not 
incorporated into the model. An explanation for this could be the strong correlation 
between bodyweight and age in this population. Possibly the use of either of the two 
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The influence of the limited number of SGA neonates at the low end of the age and 
weight-range is then too small to significantly affect the overall model fit of the entire 
population. 
This example illustrates that in paediatrics, in addition to looking at the 
population as a whole, subsets of the population should also be investigated. Despite 
the fact that postmenstrual age was not included into the final PK model for statistical 
reasons the subpopulation analysis in this study demonstrates that the best physiological 
descriptor for maturational changes (e.g. bodyweight or age) may be different for different 
PK parameters of the same drug, providing evidence against the a priori inclusion of 
bodyweight as a covariate in paediatric PK models. As it cannot be known beforehand 
what the best descriptor for maturational changes in PK parameters is, a systematic 
covariate analysis is always required. 
As dosing algorithms are predominantly derived from clearance parameters it is 
important to assess how well a model can predict these parameters. A direct comparison 
between model-predicted clearances and ‘actual clearances’ is however difficult, since 
clearances can only be derived indirectly from population models or through non-
parametric methods that require either steady state or dense data. As an alternative the 
model-predicted clearances were compared to previously reported values from literature. 
All but two previously published clearance values scaled linearly with bodyweight, 
which is reflected in figure 5 by identical slopes in the lines of published clearance 
parameters. Figure 5 also shows these lines to shift upwards with increasing bodyweight, 
indicating an increased clearance with increased bodyweight. The clearances predicted 
by the original morphine model increase exponentially with bodyweight, resulting in 
a different slope. Also this model predicts higher clearances for children older than ten 
days compared to their younger counterparts. The model predicted clearances fall nicely 
within the range of previously published clearances, increasing the confidence in the 
model-predicted clearances, although the ultimate validation is a prospective clinical 
study.
The relatively limited availability of suitable data in the paediatric population 
may hamper the validation of population models in this population. By using existing 
data, as was done in the current analysis, the number of unnecessary studies in this 
vulnerable population can be significantly reduced [29,30]. This often requires data sharing 
but unfortunately there are limiting ethical and practical issues that at present still need 
to be addressed by the scientific community and society as a whole [31]. Compared to 
neonates and infants younger than one year, children between one and three years of 
age are encountered relatively infrequently in paediatric ICUs, and they are less often 
included in clinical trials. For this population no datasets were available for the external 
validation of the original morphine model evaluated in this study, leaving this model 
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Two external datasets (Ext.5 & 6) included a patient population that was not included 
in the learning dataset for the original model, namely neonates undergoing ECMO 
treatment. ECMO is an invasive procedure that may influence PK parameters, most often 
increasing distribution volume and decreasing clearance [32–35]. Additionally, morphine 
doses were on average higher in these studies compared to the studies of the internal 
and other external datasets (Ext. 1 – 4). The predictive performance of the original model 
was investigated in this patient population as well to determine whether, despite these 
differences, the dosing algorithm in μg/kg1.5/h derived from the covariate relationships in 
the original morphine PK model could still be beneficial in patients on ECMO treatment. 
The predictive performance of the original model proved to be good for external ECMO 
dataset 6, although considerable bias towards under prediction, particularly for the 
morphine metabolites, was observed in external ECMO dataset 5. The duration of the 
study of dataset 5 was longer than the study of dataset 6 and therefore accumulation was 
expected, however the NPDE analysis of this individual dataset showed no such trend 
in time (data not shown). An important difference between the two studies was that the 
study of dataset 6 was a more recent study and at that time the augmentation of ECMO 
treatment with continuous venovenous hemofiltration (CVVH) was routine practice, in 
contrast to the study of dataset 5. Morphine metabolites are eliminated through renal 
clearance and since CVVH complements renal function this could explain the under-
prediction of morphine metabolites by the original model in dataset 5. In fact previous 
analysis of this dataset showed CVVH augmentation to increase metabolite elimination 
but not morphine elimination in ECMO treated neonates [9].
Augmentation of ECMO treatment with CVVH has been shown to improve 
clinical outcome of the treatment and reduce costs [36], therefore CVVH during ECMO has 
become standard clinical practice in our institution. Since the two ECMO datasets could 
not be merged due to the conflicting results and as the conditions seen in the study of 
dataset 6 resemble current clinical practice best, only the NPDE analysis performed with 
this dataset is shown (figure 7). The NPDE analysis of this dataset indicates a reasonable 
prediction of median morphine and metabolite concentrations with limited bias over 
time and over the log value of the concentration range in patients on ECMO treatment 
with CVVH. Bearing in mind the considerable difference in the patient populations in 
the internal dataset and in this dataset this result is quite remarkable. 
 Previously two population PK models for morphine in patients on ECMO 
treatment were developed based on dataset 5 [8,9]. These studies showed ECMO 
treatment to affect some of the clearance parameters and the distribution volumes. 
Also the maturation rates of some of these parameters were shown to be different from 
postoperative and ventilated patients. Possibly the influence of changes in clearance 
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in morphine and metabolite concentrations that are similar to those observed in 
postoperative and ventilated neonates. 
The validation of the predictive performance of the original morphine PK model 
in these datasets does not imply this model to be optimal in this population, as such 
optimization would require a laborious separate analysis. The sole purpose of performing 
this validation procedure was to investigate whether the model-derived dosing 
algorithms, which are based on the covariate model, could also be suitable in patients 
on ECMO treatment. By confirming the models predictive performance in neonates on 
ECMO treatment augmented by CVVH, it is suggested that dosing morphine in μg/
kg1.5/h could be appropriate in these patients as well.
4.5 Conclusion 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In the current analysis the predictive performance of a previously published paediatric 
PK model for morphine and its metabolites was tested externally in new datasets 
from postoperative patients, patients on artificial ventilation and patients on ECMO 
treatment ranging from preterm and SGA neonates to infants of one year. The predictive 
performance was found to be good in the postoperative and ventilated patients and in 
patients on ECMO treatment with CVVH. Herewith the suitability of the original model 
for simulation purposes is confirmed. The establishment of the predictive performance of 
the model in this study justifies the next step in developing new dosing recommendations, 
namely a prospective clinical trial. Dosing algorithms previously derived from the 
original model (Chapter 3) are currently being evaluated at our facilities in postoperative 
patients younger than one year (Dutch trial registration number NTR1438 [37]) and in 
neonates on ECMO treatment with CVVH (NTR2180 [37]).
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Context: Validated morphine dosing algorithms are lacking for neonates and infants. 
A paediatric population pharmacokinetic model showed morphine clearance to non-
linearly increase with bodyweight and be reduced by 50% in neonates younger than ten 
days. 
Objective: Prospectively evaluate a morphine IV dosing algorithm that was derived 
from a population pharmacokinetic model, in term neonates up to infants of one year 
of age. 
Design: Single-centre, prospective, study (March 2008 – July 2010, 48 hrs follow-up, 
www.trialregister.nl: number NTR1438). 
Setting: Level III pediatric intensive care unit.
Patients: 38 patients after major non-cardiac surgery, including 18 term neonates younger 
than ten days and 20 older patients. 
Interventions: Postoperative continuous morphine IV infusion of 2.5 μg/kg1.5/h in 
neonates younger than ten days and 5 μg/kg1.5/h in older patients. Morphine IV rescue 
according to a validated age-appropriate pain protocol. 
Main outcome measures: 1) morphine rescue dose; 2) average actual morphine infusion 
rate; 3) morphine and metabolite concentrations.  
Results: For young neonates compared to older patients, patients needing morphine 
rescue was 27.8% vs. 90% (p<0.001) and total rescue dose was 0 (0 - 539) μg/kg vs. 193 
(0-1183) μg/kg (median (range), p<0.001). Median actual morphine infusion rate was 
4.4 (3.6 – 5.0) μg/kg/h vs 14.4 (7.4 – 15.7) μg/kg/h (median (range), p<0.001), and the 
number of patients needing more than 125% of the initial model-derived infusion rate 
was 17% vs 55% (p<0.05). Morphine and metabolite concentrations were accurately 
predicted by the paediatric population morphine model.
Conclusions: Compared to traditional morphine dosing in μg/kg/h, the proposed 
dose in young neonates was lower but still efficacious, while the higher dose in older 
patients still yielded a substantial need for rescue medication. Improvements seem 
possible, but the model-based dosing algorithm correcting for age-related differences 
in morphine pharmacokinetics may prevent overdosing in the youngest neonates and 
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Introduction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Lack of paediatric dosing information has caused unlicensed and off-label drug 
prescription to be common practice in the paediatric population, despite the increased 
risk of suboptimal dosing or adverse drug effects [1]. Population pharmacokinetic and/
or pharmacodynamic modeling approaches, also known as non-linear mixed-effects 
modeling, strongly facilitates the development of evidence-based rather than empiric 
or consensus-based paediatric drug dosing algorithms [2]. In population analyses, 
pharmacokinetic and/or pharmacodynamic parameters can be derived from sparse, 
dense and/or unbalanced data obtained from patients during routine clinical practice. 
Moreover, the sources of variability in the population can be quantified, and in a covariate 
analysis patient characteristics that are predictive of this variability, such as for instance 
bodyweight or age, can be identified [3]. These key patient characteristics form the basis 
of model-derived dosing algorithms. Before these dosing algorithms are implemented 
in clinical practice, they should however be prospectively evaluated to ascertain that the 
observed endpoints obtained with the new dosing algorithm are in agreement with the 
model-based predictions [2].
A drug that is commonly used in paediatrics is the opioid morphine. Interestingly, 
although this drug has been used in clinical settings for a very long time, validated dosing 
guidelines across the paediatric age-range are lacking. Under or overdosing of morphine 
should be prevented to avoid inadequate pain relief, opioid-related safety issues and 
opioid-withdrawal symptoms. Recently, a population model for the pharmacokinetics of 
morphine and its two major metabolites morphine-3-glucuronide (M3G) and morphine-
6-glucuronide (M6G) was developed for a population of postoperative and ventilated 
preterm and term neonates up to children of three years of age (Chapter 3). In this 
model, clearance proved to nonlinearly increase with bodyweight. Additionally, a 50% 
reduction in morphine glucuronidation was observed in neonates with a postnatal age 
younger than ten days, which was independent the gestational age. This is similar to 
what is observed for bilirubin glucuronidation after birth. To ascertain good predictive 
model performance, this model was extensively validated, both internally and externally 
(Chapters 3 and 4). From this model it was subsequently derived that dosing morphine 
maintenance doses on the basis of μg/kg1.5/h with a 50% dose reduction in neonates 
younger than ten days, would yield similar morphine and metabolite concentrations 
across this population (Chapter 3). Compared to a traditional dosing scheme of 10 μg/
kg/h, this nonlinear dosing algorithm leads to a substantial reduction in morphine 
infusion rates in neonates (e.g. 4.3 vs 10.0 μg/kg/h for a young neonate of 3 kg), while 
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current proof-of-principle study prospectively evaluates this model-derived paediatric 
dosing regimen for morphine over 48 hours in postoperative patients under the age 
of one year, using the required morphine rescue dose administered according to a 
validated age-appropriate pain protocol as primary endpoint. Furthermore the average 
actual morphine infusion rate was evaluated and measured morphine and metabolite 
concentrations in the patients were compared to concentration predictions by the 
paediatric morphine pharmacokinetic model (Chapter 3).
Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Study Design
In a single-center, double-blind, randomized controlled trial comparing the postoperative 
analgesic efficacy of morphine and paracetamol over 48 hours in term neonates and 
infants younger than 1 year [4], the patients allocated to receive morphine as primary 
analgesic agent were dosed according to the model-derived dosing algorithm (Chapter 
3). The current analysis evaluates the efficacy of this new algorithm across the age-range 
in the morphine arm of this study in terms of required morphine rescue doses and actual 
average morphine infusion rates. Blood samples for the evaluation of model predicted 
morphine and metabolite concentrations were obtained from patients in both the 
morphine and paracetamol arm of the study. As the comparison between the analgesic 
efficacy of morphine and paracetamol and full details of this study where published 
elsewhere [4], in the present publication details are summarized as relevant to the current 
analysis. 
Patients
Term neonates and infants under the age of one year, undergoing major abdominal or 
non-cardiac thoracic surgery between March 2008 and July 2010 at the Erasmus MC – 
Sophia Children’s Hospital in Rotterdam, The Netherlands, were eligible for inclusion. 
Exclusion criteria were: 1) postconceptual age younger than 36 weeks; 2) bodyweight less 
than 1.5 kg; 3) extra corporeal membrane oxygenation (ECMO) treatment; 4) neurological 
or hepatic dysfunction or renal insufficiency; 5) pre- or postnatal administration of 
opioids or psychotropic drugs for more than 24 hours; 6) known allergy or intolerance for 
paracetamol or morphine; 7) administration of opioids in the 24 hours prior to surgery.
The study was approved by the Erasmus MC ethics review board and was 
registered in the Netherlands Trial Register under the number NTR1438 [5]. Written 
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Interventions 
Patients were stratified by age into one group that was younger than ten days and one 
group that was older than ten days, as patients in these groups would receive different 
morphine dosages. All patients received a 100 μg/kg morphine IV bolus dose 30 minutes 
before the anticipated end of the surgical procedure. In the morphine arm of the study, 
patients with a postnatal age less than ten days received a postoperative continuous 
morphine IV infusion of 2.5 μg/kg1.5/h and older patients received 5 μg/kg1.5/h, which 
was implemented using the dosing table depicted in table I. To maintain the blinding of 
the morphine versus paracetamol study, the patients allocated to the morphine arm of 
the study also received four times daily placebo saline infusions of the same volume as 
the paracetamol bolus dose a patient would receive in the paracetamol arm of the study. 
Table I. Dosing table used to implement the model-derived morphine dosing algorithm for continuous 
infusions in clinical practice. Patients younger than ten days received a dose of 2.5 μg/kg1.5/h and patients 
older than ten days received 5 μg/kg1.5/h. 
Model-derived dosing algorithm
PNA < 10 days
2.5 μg/kg1.5/h
PNA > 10 days
5 μg/kg1.5/h
Bodyweight (kg) Infusion rate μg/kg/h Infusion rate μg/kg/h
1.5 – 2 3.1 6.1
2 – 2.5 3.5 7.1
2.5 – 3 4.0 7.9
3 – 3.5 4.3 8.7
3.5 – 4 4.7 9.4
4 – 4.5 5.0 10.0
4.5 – 5 5.3 10.6
5 – 5.5 5.6 11.2
5.5 – 6 . 11.7
6 – 6.5 . 12.3
6.5 – 7 . 12.8
7 – 7.5 . 13.2
7.5 – 8 . 13.7
8 – 8.5 . 14.1
8.5 – 9 . 14.6
9 – 9.5 . 15.0
9.5 – 10 . 15.4
10 – 10.5 . 15.8
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During the first 48 hours of postoperative recovery at the intensive care unit, 
trained nurses assessed patient’s pain levels every 2 hours or when the patients appeared 
to be in discomfort, according to an age-appropriate standardized pain protocol [6], based 
on COMFORT-behavior scores [7] and Numeric Rating Scale (NRS) pain scores [8]. Open-
label morphine rescue medication was administered to patients of both the morphine 
and paracetamol arm when NRS ≥ 4. Patients younger than ten days received a bolus 
dose of 10 μg/kg and older patients received 15 μg/kg. Patients were reassessed after 
10 minutes and received additional bolus doses when necessary. If analgesia was not 
adequate after three bolus doses within one hour, the patients received an additional 
loading dose of 100 μg/kg after which the morphine infusion rate was increased by 1.25 
μg/kg1.5/h in neonates younger than ten days and 2.5 μg/kg1.5/h in older children. When 
after this increase the patient needed again more than 3 rescue bolus doses within one 
hour, another loading dose was administered and infusion rates were increased by the 
same amount again. The morphine infusion was stopped or reduced in case of morphine 
related adverse events or after 12 hours of adequate analgesia, indicated by an NRS score 
< 4. In case of discomfort, indicated by COMFORT-behaviour scores of >17 and NRS pain 
scores of < 4, midazolam was administered.
Outcomes 
The nurse-controlled open-label morphine rescue medication in the first 48 postoperative 
hours was used as the primary efficacy outcome measure. This was expressed as 
percentage of patients in need of rescue medication, the number of rescue events with 
an event being an administration of a morphine bolus dose, an additional morphine 
loading dose or an increase of morphine infusion rate, and the total morphine rescue 
dose. The two age-groups were analyzed separately and compared. Additionally, the 
average actual morphine infusion rate over the duration of the postoperative infusion 
for each patient was compared between these groups. Since there were bodyweight and 
age-related differences in the model-derived morphine dosing algorithm, the average 
morphine infusion rate in each individual patient was also compared to the initial model-
derived infusion rate for that patient, by calculating the percentage of patients that had 
an average morphine infusion rate within or outside 25% of the prescribed dose (as in 
bioequivalence studies, this is considered to be clinically significant) and the percentage 
of patients that required more than double the initial model-derived infusion rate. 
 Blood samples to determine morphine and metabolite concentrations were 
obtained to determine the accuracy of the concentration predictions by the pharmacokinetic 
model (Chapter 3) in the current set of patients that were dosed according to the model-
derived dosing algorithm in table I. A maximum of eight blood samples or a total 5% 
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when present. When possible a blood sample was taken prior to a morphine rescue 
dose or prior to a scheduled paracetamol or placebo bolus dose. Additional samples 
were taken when possible at various times, to obtain information on a wide range of the 
concentration-time curve. Blood samples were centrifuged at 3000 rpm and plasma was 
subsequently stored at -80°C till further analysis. 
Statistical Analysis
To statistically compare the analgesic efficacy of the model-derived morphine dosing 
algorithm between neonates younger than ten days and patients of ten days or older, the 
Fisher exact test was used for the dichotomous endpoints (need for rescue mediation, 
actual morphine infusion rate within or outside 25% of the prescribed dose, actual 
morphine infusion rate more than 200% of the prescribed dose). The Mann-Whitney test 
was used for the other categorical and continuous endpoints (number of rescue events 
per patient, morphine rescue dose, average actual morphine infusion rate).
 To ascertain that the patients of whom pharmacokinetic samples were obtained 
could be regarded as a representative sample of the patients that were analyzed for the 
analgesic efficacy, the demographics and clinical characteristics of the patients in these 
groups were statistically compared. For this also the Fisher exact test was used for the 
dichotomous data (sex, location of surgery, need for postoperative ventilation) and 
the Mann-Whitney test was used for the continuous data (postnatal age, bodyweight, 
duration of surgery).
Pharmacokinetic Blood Sample Analysis
The frozen plasma samples were allowed to thaw at room temperature. Proteins in 200 μl 
samples were precipitated with 700 μl acetonitrile which contained 2H3-Morphine (2H3-
M), 2H3-Morphine-3-glucuronide (2H3-M3G), and 2H3-Morphine-6-glucuronide (2H3-
M6G) (Cerilliant, Texas, USA) as internal standards and 100 μl 1 mM zinc sulphate. The 
samples were mixed for 2 minutes and centrifuged for 5 minutes at 13000 rpm. 200 μl of 
the supernatant was dried under a gentle stream of nitrogen at 50°C. The residues were 
reconstituted in 100 μl of 0.1 % (v/v) formic acid in water and 20 μl of this sample was 
injected into the HPLC system, which contained an Ultimate 3000 autosampler (Dionex, 
Amsterdam, The Netherlands), a HPG680 pump (Dionex, Amsterdam, The Netherlands), 
and a 3 μm, 120Å, 50 x 2.1 mm YMC-pack ODS-AQ column (YMC Inacom, Overberg, The 
Netherlands) with an ODS precolumn (Phenomenex, Utrecht, The Netherlands) at 30°C. 
The mobile phase consisted of 0.1 % formic acid in water with 3% acetonitril (Lichosolv) 
(Merck B.V., Amsterdam, The Netherlands) as modifier and the flow rate was 0.5 ml/
min. The system was controlled by Chromeleon (Dionex, Amsterdam, The Netherlands). 
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spectrometer (Waters, Etten-Leur, The Netherlands). Peak areas of reaction ions from 
morphine, M3G, M6G and the internal standards 2H3-M, 2H3-M3G and 2H3-M6G were 
obtained in the multiple reaction mode and integrated by data software Masslynx 
4.1 (Waters, Etten-Leur, The Netherlands). m/z was 165.0 (285.9>165.0) for morphine 
and 286.0 (461.9 >286.0)  for M3G and M6G. For the internal standards m/z was 165.0 
(288.9>165.0) for 2H3-M and m/z (464.9>289.0) for 2H3-M3G and 2H3-M6G. All analytes 
could be analyzed in one run and all samples were analyzed in triplo. The sample 
concentrations were calculated by the internal standard method with weighing factor 
1/(Y2). 
Blank pooled human serum was used for control samples and serum spiked 
with morphine, M3G, and M6G (Cerilliant, Texas, USA) in methanol/water were used 
for the calibration curve and quality controls.
Model-Based Pharmacokinetic Predictions
NONMEM VI (ICON, Ellicott City, MD, USA) was used to obtain model-based 
concentration predictions. In predicted versus observed plots, the available morphine and 
metabolite concentrations were visually compared to both the individual and population 
concentration predictions by the paediatric population pharmacokinetic model for 
morphine (Chapter 3). Individual predicted concentrations were based on a model fit 
of the individually observed concentrations to the model, based on the administered 
dose, bodyweight and postnatal age of the patient. Population predicted concentrations 
were obtained using the population parameter values of a typical individual to simulate 
concentrations based on the administered dose, specified bodyweight and postnatal age 
of the patient. 
Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Patients and Sampling
Figure 1 shows the inclusion diagram for this study. Thirty-nine patients were allocated 
to receive morphine as primary analgesic (morphine arm) of which 38 patients actually 
received continuous morphine infusions according to the model-derived dosing 
algorithm. These 38 patients were included in the current analysis of the analgesic efficacy 
of the new morphine dosing algorithm. Morphine and metabolite concentrations were 
available for 8 of these 38 patients, due to the limited number of patients with an arterial 
line. In the paracetamol arm, 33 patients were included, of which the analgesic efficacy 
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arm, morphine concentrations were available resulting upon the standard loading dose 
of morphine that was administered in all patients at the end of surgery and morphine 
rescue boluses when indicated by the standardized pain protocol.  
Figure 1. Inclusion diagram for the current analysis.
Table II summarizes the demographics and clinical characteristics of the 
patients in the group analyzed for analgesic efficacy and in the group analyzed for 
model predictions of morphine and metabolite concentrations. The table shows that the 
group of patients of whom blood samples were obtained represents the overall group 
analyzed for morphine efficacy well, as there were no statistically significant differences 
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Table II. Demographics and clinical characteristics of the patients in the analysis of the analgesic efficacy of 
the morphine dosing algorithm and the patients in the analysis of the pharmacokinetic model predictions of 
morphine and its metabolite concentrations in the current study.
Patients analyzed for  analgesic 
efficacy of the morphine dosing 
algorithm (n = 38)
Patients analyzed for  
pharmacokinetics of 
morphine (n = 15)
p-value
Postnatal age 
(days, median (range)) 20 (0 – 355) 3 (0 – 200) 0.56 
†
Bodyweight
(kg, median (range)) 3.6 ( 2.0 – 9.8) 3.3 ( 1.6 – 8.0) 0.42 
†
Sex 
(n, M / F) 26 / 12 7 / 8 0.21 
‡
Location of surgery
(n, thorax / abdomen) 11 / 27 5 / 10 0.75 
‡
Duration of surgery
(min, median (range)) 139 (27 - 480) 149 (69 – 480) 0.30 
†
Postoperative ventilation (n, %) 14 (37%) 7 (47%) 0.55 ‡
† Mann-Whitney test, ‡ Fisher exact test
Analgesic Efficacy
An overview of the need for morphine rescue medication in patients younger and older 
than ten days dosed according to the model-derived morphine dosing algorithm is 
provided in table III. 
Table III. Analgesic efficacy of the model-derived morphine dosing algorithm, expressed as need for rescue 
medication.
Patient group n Patients in need of rescue medication Rescue events 
# Total rescue dose (μg/kg) #
Total 38 23 (60.5%) 2 (0 – 14) 20 (0 – 1183)
0 – 10 days 18 5 (27.8%) 0 (0 – 10) ‡ 0 (0 – 539) †
10 – 365 days 20 18 (90.0%) 4.5 (0 – 14) ‡ 193 (0 - 1183) †
# median (range), † p < 0.05, ‡p < 0.001 
Overall, 60.5% of all patients needed rescue medication, with four out of 18 neonates 
younger than ten days (27.8%) needing rescue medication, compared to 18 out of 20 
patients (90%) who were ten days or older (p<0.001, Fisher exact test). In neonates 
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patient (median (range)) were 0 (0-10) versus 4.5 (0 – 14) (p<0.001, Mann-Whitney test) 
and the total rescue dose (median (range)) was 0 (0-539) μg/kg versus 193 (0 – 1183) 
μg/kg (p <0.001, Mann-Whitney test). Considering only the patients in need of rescue 
medication, the average number of rescue events per patient was 6 (2 – 10) versus 5.5 (1 
– 14) in patients younger and older than ten days (p=0.97, Mann-Whitney test). While 
the median rescue dose in neonates younger than ten days who were in need of rescue 
medication was lower than the median rescue dose in the older children that needed 
rescue medication 140 (20 – 539) μg/kg versus 228 (15 – 1183) μg/kg, this difference did 
not reach statistical significance (p=0.53, Mann-Whitney test). 
The average actual morphine infusion rate (median (range)) calculated over the 
duration of the post-operative infusion, consisting of the initial model-derived morphine 
infusion rate according to table I and additional morphine rescue doses that where 
required according to the standardized pain protocol, was 4.4 (2.5 – 24.6) μg/kg/h in 
neonates younger than ten days and 14.4 (7.9 – 39.3) μg/kg/h in older patients (p<0.001, 
Mann-Whitney test). In figure 2, the average morphine infusion rate during the duration 
of postoperative infusion is depicted for each individual patient (symbols) together with 
the model-derived morphine infusion rates which differentiates between children older 
and younger than ten days (solid lines). Different symbols are used for patients younger 
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for each individual patient with triangles (▲) representing neonates younger than ten days and 
squares (■) representing older children, and initial infusion rates according to the model-derived 
dosing algorithm (solid lines) in patients younger than ten days (2.5 μg/kg1.5/h) and older than 
ten days (5 μg/kg1.5/h). The dashed line represents the infusion rates according to the traditional 
dosing regimen in our facilities.
Three out of 18 neonates (17%) required less than 75% of the initial infusion rate 
versus none of the 20 older patients (p=0.10, Fisher exact test), 12 out of 18 neonates (67%) 
versus 9 out of 20 older patients (45%) had actual infusion rates within 25% of the initial 
dose (p=0.21, Fisher exact test), 3 out of 18 neonates (17%) required more than 125% of the 
initial infusion rate versus 11 out of 20 older patients (55%) (p<0.05, Fisher exact test), and 
1 out of 18 neonates required more than twice the initial infusion rate versus 7 out of 20 
older patients (p<0.05, Fisher exact test). For unknown reasons, a 1 day old boy required 
on average 5.6 times the initial morphine infusion rate during his 38 hour postoperative 
infusion. Of the older patients that need more than twice the initial morphine infusion 
rate none required more than three times the initial infusion rate.
In figure 2 a reference line representing the traditional intravenous morphine 
dose for the patient population in the current study in our unit (10 ug/kg/h – dashed 
line) was also added. This shows that initial morphine IV infusion rates were lower than 
the traditional dose in neonates younger than ten days and higher than the traditional 
infusion rate for infants older than ten days and heavier than 4 kg.
Morphine and Metabolite Concentrations
Figure 3 shows the plots of predicted versus observed concentrations of morphine (left), 
M3G (middle), and M6G (right). In the upper panels of figure 3, individual predicted 
versus observed concentrations are shown, which are based on the model fitting to the 
data. These plots indicate no bias and adequate precision of the concentration predictions. 
The graphs of the population predicted versus observed concentrations (lower panels) 
indicate no bias around the line of unity, suggesting the simulated predictions to be 
accurate in this patient population. The spread of data points around the line of unity in 
these plots indicates that the inter-individual variability in morphine pharmacokinetics 
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Discussion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The current study prospectively evaluated a model-derived dosing algorithm for 
morphine in term neonates to infants of one year of age. According to this algorithm 
initial morphine maintenance infusion rates were 2.5 μg/kg1.5/h for neonates younger 
than ten days and 5 μg/kg1.5/h in older patients (table I), resulting in a reduction 
between 50% and 75% in neonates younger than ten days compared to the traditional 
morphine dose in our unit of 10 μg/kg/h, while children older than ten days and heavier 
than four kilograms received up to 150% of our traditional morphine dose. The limited 
need for rescue medication in the very young suggests the reduced morphine dose in 
this age-group to still be efficacious, while the increased dose in the older patients still 
does not appear to yield adequate analgesia in most of these patients (table III). Figure 2 
further illustrates that the morphine infusion rate according to the model-derived dosing 
algorithm gives a good reflection of the actual morphine need in children younger than 
ten days. In older patients, the variability in average morphine consumption is higher, 
and in this group the percentage of patients requiring more than twice the prescribed 
morphine dose is also higher (35% compared to 6% in the young neonates, p<0.05). 
Moreover, figure 2 proves the morphine IV infusion rates according to the traditional 
dosing guideline to be too high for young neonates.
The morphine dosing algorithm that was evaluated in the current study 
was derived from a population pharmacokinetic model in which bodyweight and a 
postnatal age of less than ten days were identified as key patient characteristics that 
are predictive of the inter-individual variability in the clearance and distribution of 
morphine and its main metabolites (Chapter 3). Thorough external evaluation of the 
population pharmacokinetic model with four independent datasets from four different 
centers previously established confidence in the predictions by this model (Chapter 4). 
Blood samples obtained from a limited number of patients in the current study further 
confirm the accuracy of the model predictions in patients that were dosed according to 
the new dosing regimen (figure 3). It is thereby confirmed that the model-derived dosing 
algorithm indeed corrects for the developmental changes in morphine pharmacokinetics 
in this population, yielding similar steady state concentrations for morphine and its 
metabolites across the full age- and weight-range in the current study. 
According to the pharmacokinetic model, continuous morphine IV infusion 
rates should be dosed on the basis of μg/kg1.5/h, with a 50% reduction in neonates 
younger than ten days, to correct for age-related differences in morphine clearance. 
However, target concentrations needed to determine the infusion rate have not been 
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around 20 ng/ml have been suggested in postoperative neonates and infants [9,10]. The 
infusion rate in the current study was derived from clinical experience in our own unit. 
Our traditional dosing guideline for continuous morphine IV infusions for neonates and 
children up to three years of age is 10 μg/kg/h irrespective of the age of the patient, 
which is in the lower range of literature reported postoperative morphine IV infusion 
rates of 10 – 40 μg/kg/h [11]. Previous research suggested this infusion rate to be relatively 
high for neonates and young children, but often insufficient for older patients [12]. Based 
on these results a morphine dose amount of 2.5 μg/kg1.5/h in neonates younger than ten 
days and 5 μg/kg1.5/h in older patients was selected for the current study as this leads to 
a reduced dose in neonates and an increased dose in older heavier patients, compared to 
our traditional dosing guideline. Upon these doses, average steady state concentrations 
of approximately 10 ng/ml are anticipated throughout the entire study population from 
term neonates and infants to the age of one year. Even though this concentration is lower 
than the previously suggested 20 ng/ml, the results show that this target concentration 
is sufficient, particularly for neonates. 
To our knowledge no prospectively validated paediatric morphine dosing 
algorithms have been published that are based on a thorough investigation and 
understanding of the developmental changes in the pharmacology of morphine in 
this population. However, when pharmacokinetic models are used as the sole basis for 
paediatric dosing corrections, it is implicitly assumed that the pharmacodynamics of 
that drug remain constant within this population. This assumption is acceptable when: 
1) pathophysiological processes are similar throughout the population, 2) the exposure-
effect relationship can be assumed independent of age based on the mechanism of action, 
and 3) the same clinical endpoints for treatment are used throughout the populations 
[13]. It has not been proven that morphine meets the first two criteria in the current study 
population. 
The pain protocol in the current study has been specifically developed and 
validated for the population included in the current study [7,8], thereby making rescue 
medication and total morphine consumption an appropriate and objective endpoints 
for analgesic efficacy in the current study. The model-derived morphine dosing 
algorithm evaluated in the current study corrects for age-related difference in morphine 
pharmacokinetics leading to similar concentrations throughout the population. 
The observed difference in rescue medication and morphine consumption between 
younger and older patients therefore suggests age-related differences in either pain 
perception or analgesic efficacy of morphine. The latter can for instance be caused by 
differences in effect-site distribution and/or differences in sensitivity to morphine and 
its pharmacologically active metabolites. Although evidence-based corrections for age-
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paediatric morphine dosing, an investigation into morphine pharmacodynamics in this 
population could be used to further refine the morphine dosing algorithm by defining 
age-specific target concentrations.
Medicine always strives to expose patients to the lowest possible drug doses 
that are clinically effective. It is now recognized that neonates, even extreme premature 
ones, are able to experience pain that requires treatment [14–18]. With respect to short-
term outcome measures expressed using various clinical endpoints like mortality, pain, 
duration of ventilation, or general clinical outcome measures, results on the potential 
benefit of morphine or opioid administration in general have been contradictory, while 
acute respiratory, gastro-intestinal, cardiovascular, and neurological side effects as well 
as the occurrence of tolerance, dependence and withdrawal symptoms are well known. 
Animals studies have raised concerns about the long-term effects of both pain and 
morphine exposure in neonates on endpoints like brain structure, (hormonal) stress 
response, and behaviour later in life [19–21]. Data in humans are scarce, however recent 
long-term follow-up studies in cohorts of children that were exposed to morphine for the 
treatment of pain or for ventilatory support during the neonatal period showed limited to 
no difference between these children and controls on outcome measures like intelligence, 
behaviour, motor skills, memory, chronic pain, and health-related quality of life [22–24]. 
The number of patients in the current study is too small to establish the 
influence of the reduced morphine dose in young neonates on the occurrence of acute 
morphine-related side-effects, dependence or withdrawal, but it is expected that a 
morphine dose reduction positively influence these endpoints. Similarly, it could not be 
established whether the increased morphine dose in older children, yielded significant 
increases in the occurrence of acute morphine side-effects, dependence or withdrawal, 
however exposing these patients to ineffective or suboptimal doses of morphine can be 
regarded as equally unethical as over-dosing. It is also expected that optimization of the 
paediatric morphine dosing algorithm positively influences potential long-term effects 
that morphine exposure or untreated pain may have.
In conclusion, the development of evidence-based dosing regimens in the paediatric 
population is complicated by practical, ethical, and legal constraints. However population 
modeling now makes it possible to obtain drug dosing algorithms for the paediatric 
population with a similar level of scientific evidence as has been the standard requirement 
for the adult population for a long time [3]. It is envisioned that this methodology can be 
extended to other vulnerable patient populations as well. 
For morphine, the development of a paediatric dosing algorithm that corrects 
for developmental changes in the pharmacokinetics yielded a 50% to 75% dose reduction 
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majority of the patients. For children of ten days or older, the developed dosing algorithm 
prescribed an increased dose compared to the traditional dose, that still required rescue 
dosing in the majority of patients, although the total morphine requirement was still 
within 25% of the prescribed dose for almost half of the patients. Overall, the new 
morphine dosing algorithm reduces the risk of over-exposure in the youngest neonates 
as well as the risk of exposing older patients to suboptimal doses.
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Aim. New approaches to expedite the development of safe and effective paediatric 
dosing regimens are necessary. We test the hypothesis that paediatric pharmacokinetic 
covariate models describe developmental changes in the physiological system and can 
therefore be extrapolated between drugs that share elimination pathways. Morphine 
and zidovudine, both primarily eliminated through UGT2B7-mediated glucuronidation, 
were used as paradigm compounds.
Method. Two population pharmacokinetic models were developed for a dataset of 
zidovudine and zidovudine-glucuronide in neonates and infants. One model was 
based on a comprehensive covariate analysis and served as a reference model. In the 
second model, a validated covariate model for morphine glucuronidation was directly 
incorporated. The performance of this system-specific model was compared to the 
reference model.
Results. In the reference model, developmental changes in glucuronidation clearance 
were best described by postnatal age in a sigmoidal function, while the system-specific 
model used a bodyweight-based exponential equation. Nevertheless, both models 
predicted similar population clearance values for the individuals in the dataset. The 
descriptive performances of both models were good and similar between the models, as 
expressed by a difference in objective function of only 13 points and similar goodness-
of-fit plots. The predictive performance assessed by normalized prediction distribution 
errors, were good and similar as well for both models.
Conclusion. This proof-of-concept study supports our hypothesis that paediatric 
covariate models describe the physiological system quantitatively and can be considered 
to be semi-physiological. This approach may benefit paediatric pharmacokinetic analyses, 
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6.1 Introduction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
It is currently well established that the clearance of many drugs differ between adults 
and children and between children of different ages, and that these differences are a 
major cause of age-dependent differences in dose requirements [1]. However, the 
pharmacological properties of many drugs that are commonly prescribed for children 
have often not been properly investigated in this vulnerable population [2]. Therefore 
evidence-based dosing recommendations are often lacking for this patient group. 
Pharmacokinetic studies in the paediatric population are complicated by ethical, 
practical and legal constraints. These constraints can be addressed by the application of 
novel data-analysis approaches [3]. Population pharmacokinetic modelling approaches 
are based on the simultaneous analysis of data from an entire population, while still 
taking into account that different observations come from different patients. They allow 
for the simultaneous analysis of sparse and/or dense data or unbalanced data. Population 
models not only yield pharmacokinetic parameter values for the population as a whole, 
but also quantify and differentiate sources of variability in the population. By identifying 
which patient characteristics (e.g. bodyweight, age, gender, race, genetics, disease status 
etc.) are predictors of the variability in model parameters, trends in the population can be 
described. Such predictors are called covariates; the equations describing the relationship 
between a covariate and a model parameter are called covariate relationships; and a 
set of covariate relationships in a population model is referred to as a covariate model. 
Pharmacokinetic covariate relationships can serve as a basis for evidence-based dosing 
guidelines, as drug doses should be adjusted according to changes in pharmacokinetic 
parameters.
It would require tremendous resources to develop and thoroughly validate 
pharmacokinetic covariate models for every new and existing drug prescribed for the 
paediatric population. Therefore smarter and more efficient approaches to expedite the 
development of safe and effective paediatric dosing regimens are necessary. We have 
hypothesized before that validated paediatric covariate models contain quantitative 
information about the developmental changes in the underlying physiological system in 
children. This implies that covariate relationships describing the developmental changes 
in the clearance of a specific drug can be extrapolated to another drug that is cleared 
through the same pathway [4]. The extrapolation of covariate models between drugs 
would expedite the development of paediatric population models, which could serve 
in optimizing drug dosing in first-in-child studies and in facilitating the development of 
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In this analysis, morphine and zidovudine are used as paradigm compounds, 
as morphine and zidovudine are both prescribed for children of all ages and are 
predominantly metabolized through glucuronidation by the UGT2B7 isoenzyme [5–8]. The 
current proof-of-concept study shows that paediatric pharmacokinetic covariate models 
for a given metabolic pathway are semi-physiological and can therefore be extrapolated 
from one drug to another. 
6.2 Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.2.1 Study Design
To test the between-drug extrapolation potential of paediatric pharmacokinetic covariate 
models, two population pharmacokinetic models were developed for a single dataset 
of zidovudine (also known as 3’-azido-3’-deoxythimidine or azidothymidine) and its 
glucuronide metabolite:
A. Reference Model: For this model a comprehensive covariate analysis was performed 
yielding a pharmacokinetic model with a set of covariate relationships that best 
described the current data according to statistical criteria. This model will be referred 
to as the ‘reference model’.
B. System-Specific Model: In this model the internally and externally validated covariate 
model from a population pharmacokinetic model for morphine glucuronidation in 
patients under the age of three years (Chapters 3 and 4) was directly incorporated. 
This semi-physiological covariate model will be referred to as the ‘developmental 
covariate model’ and the full population model that is based on the developmental 
covariate model will be referred to as the ‘system-specific model’.
The descriptive and predictive properties of the system-specific model (B) were assessed 
by comparing them to the descriptive and predictive properties of the fully optimized 
reference model (A).
6.2.2 Patients and Data
Zidovudine
The current analysis is based on 473 zidovudine concentrations and 173 zidovudine-
glucuronide concentrations collected on 68 occasions from 29 individuals varying from 
term neonates to infants up to five months of age (PACTG 049 [9]). These data were obtained 
from a multicenter study to evaluate the safety, tolerability and pharmacokinetics of 
zidovudine as a prophylaxis to prevent mother-to-child HIV transmission in healthy 
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by institutional review boards of the participating institutions and written informed 
consent was obtained from the parents or legal guardians of each patient. 
For each patient dense data were available from multiple occasions that were 
days or weeks apart. Zidovudine was administered both intravenously and orally to 
each patient. Data were obtained after single dose administrations on separate occasions 
and for eight patients data from administrations that were part of a long-term oral dosing 
regimen were available as well. Dosing started at 2 mg/kg but could be increased to 4 
mg/kg during the course of the study as deemed appropriate by the treating physician. 
Morphine
A dataset of morphine and its glucuronides in 248 preterm and term neonates to three year 
old infants was used to obtain the developmental covariate model used in the system-
specific model (Chapter 3). In table I study and patient characteristics for the zidovudine 
dataset used for both models in the current analysis and the morphine datasets used to 
obtain the developmental covariate model are shown for comparison.
Table I. Patient and study characteristics of the zidovudine dataset that was the basis for the reference model 
and the system-specific model in the current analysis and the morphine dataset that was the basis for the 
developmental covariate relationships applied in the system-specific model.
Characteristic Zidovudine dataset [9] Morphine dataset (Chapter 3)
Number of patients 29 248
Number of samples of parent 
compound 473 792




Administration route oral and short-term iv short-term and continuous iv
Duration multiple occasions days or weeks apart single occasion of up to 5 days
Sampling dense sparse
Population healthy patients ventilated and post-operative (non-cardiac surgery) patients 
Postnatal age (range, days) 2 – 145 0 – 1071 
Postmenstrual age (range, 
weeks) 36 – 57 25 – 193 
Bodyweight (range, kg) 1.9 – 6 0.5 – 16.8 
Sex (M/F) 18 / 11 (62% / 38%) 144 / 104 (58% / 42%)
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6.2.3 Model Development
NONMEM VI (ICON, Ellicott City, MD, USA) was used to perform the data analysis, 
with PLT Tools version 3.0.0 [10] in combination with R version 2.10.0 for the visualization 
of the data. All parameter estimates were obtained with the first-order conditional 
estimation method with interaction (FOCE-I). 
Model development for the reference model and the system-specific model was 
performed in three steps: 
1. choice of structural model 
2. choice of error model 
3. choice of the covariate model 
For the reference model and the system-specific model, the first two steps in the model 
development process (i.e. the choice of the structural and error model) were the same. 
One- and two-compartment models were tested for the structural model. For the error 
model inter-individual variability on the model parameters was tested assuming a log-
normal distribution described by an exponential distribution model depicted in equation 
1. For bioavailability (F) inter-individual variability was described using equation 2 to 
avoid individual bioavailability estimates of more than 100%.
 (Equation 1)
 (Equation 2)
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In these equations Pi is the individual parameter estimate for the ith individual, θ 
represents the population parameter estimate for parameter P, and ηi is a random variable 
for the ith individual from a normal distribution with a mean of zero and estimated 
variance of ω2. For the intra-individual variability and residual error in the observed 
zidovudine and zidovudine-glucuronide concentrations proportional (equation 3), 
additive (equation 4), and combination (equation 5) error models were tested: 
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where Cobs,ij is the jth observation in the ith individual, Cpred,ij is the predicted value of 
that observation and εij is a random variable from a normal distribution with a mean of 
zero and estimated variance of σ2. 
The Likelihood Ratio, which was assumed to be χ2 distributed, was used to assess 
whether the difference between (sub)models was statistically significant. A decrease in 
the objective function corresponding to p < 0.01 was considered to be significant. In 
addition, the following basic goodness-of-fit plots were used for diagnostic purposes: (a) 
observed versus individually predicted concentrations, (b) observed versus population 
predicted concentrations, (c) conditional weighted residuals versus time, and (d) 
conditional weighted residuals versus population predicted concentrations. Furthermore, 
the 95% confidence intervals of the model parameters and the correlation matrix were 
assessed. 
The third and final step of the model development process (i.e. choice of the covariate 
model) was different for the reference model and the system-specific model:  
A. Reference model: A comprehensive covariate analysis with forward inclusion and 
backward deletion of covariates was performed to obtain a covariate model with the 
best description of the current zidovudine data according to statistical criteria. The 
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The Likelihood Ratio, which was assumed to be χ2 distributed, was used to assess 
whether the difference between (sub)models was statistically significant. A decrease in the 
objective function corresponding to p < 0.01 was considered to be significant. In addition, 
the following basic goodness-of-fit plots were used for diagnostic purposes: (a) observed 
versus individually predicted concentrations, (b) observed versus population predicted 
concentrations, (c) conditional weighted residuals versus time, and (d) conditional 
weighted residuals versus population predicted concentrations. Furthermore, the 95% 
confidence intervals of the model parameters and the correlation matrix were assessed.
The third and final step of the model development process (i.e. choice of the 
covariate model) was different for the reference model and the system-specific model: 
A. Reference model: A comprehensive covariate analysis with forward inclusion and 
backward deletion of covariates was performed to obtain a covariate model with 
the best description of the current zidovudine data according to statistical criteria. 
The following covariates were tested for significance: postnatal age, postmenstrual 
age, gestational age at birth, bodyweight, sex, and creatinine clearance. The 
continuous covariates were tested in linear equations, exponential equations with 
estimated exponents, or sigmoidal equations. A decrease in the objective function 
corresponding to p < 0.01 for the forward inclusion of covariates was considered to 
be significant. Additionally, the aforementioned diagnostic criteria were used. When 
more than 1 significant covariate was identified, the most significant covariate was 
included in the model and the resulting model served as the basis for the subsequent 
exploration of additional covariate effects. For the backward deletion of covariates 
an increase in objective function corresponding to p < 0.001 was considered to be 
significant. 
B. System-specific model: The previously obtained and internally and externally validated 
covariate model for morphine glucuronidation in children younger than three 
years (Chapters 3 and 4) was directly incorporated into the model for zidovudine. 
Specifically, a bodyweight-based exponential equation with an exponent of 1.44 for 
the formation and elimination of zidovudine-glucuronide with a reduced formation 
clearance of zidovudine-glucuronide in neonates younger than ten days was 
included, as was a linear correlation for distribution volume of the parent compound 
and metabolite (see figure 1 for equations). While this developmental covariate 
model describes the rate of developmental changes in clearance and distribution 
volume, the population values that describe the absolute values of these parameters 
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6.2.4 Model Evaluation
Model performance of the reference model and the system-specific model were 
evaluated and compared. Although the reference model and system-specific model are 
not nested, they are based on the exact same patients and data. Therefore the -2 log 
likelihood, by means of the NONMEM objective function, was used as a measure to 
statistically compare the description of the zidovudine data by the system-specific model 
to the description of the zidovudine data by the reference model. To directly compare 
clearance predictions between the two models, population clearance predictions from 
the reference model were plotted versus population clearance predictions from the 
system-specific model. As age and bodyweight change rapidly in this young population, 
estimated parameter values did not remain constant between the occasions, yielding one 
prediction per patient per occasion.
Furthermore, the descriptive properties of the models were assessed and 
compared by inspecting the basic goodness-of-fit plots of the models. These plots were 
stratified by age into a group that was younger and a group that was older than 38 
days (the median age of the individuals at the different occasions) to ascertain that the 
entire age-range was described equally well. In addition, the covariate relationships 
describing the population predicted zidovudine clearances and the individual post hoc 
clearance estimates of each individual at each separate study occasion were plotted in 
one graph for each model, to visually assess the description of the individual zidovudine 
glucuronidation clearances by the covariate relationships. Finally, bias and precision of 
the individual zidovudine glucuronidation clearance values compared to the population 
predicted clearances described by the covariate relationships were quantified by 
calculating the percentage mean prediction error (%MPE, equation 6) and the root mean 
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  (equation 7) 
To compare the predictive properties of both models, a normalized prediction distribution 
error (NPDE) analysis 
[11]
 which is a simulation-based diagnostic, was used. The entire 
dataset was simulated 1000 times in NONMEM and subsequently each observed 
concentration was compared to the reference distribution of the simulated data points 





6.3.1 Model Development 
In the first step of model development (i.e. choice of structural model) a two-
compartment model was found to best describe the time-course of zidovudine, and a one-
compartment model was used to describe the time-course of the zidovudine-glucuronide, 
as is depicted in figure 1. Zidovudine absorption from the oral depot compartment was 
described by first-order absorption (ka) and the oral bioavailability (F) was estimated. 
Zidovudine clearance through pathways other than glucuronidation was found to be not 
significantly different from 0. When estimated, the values of the distribution volume of 
the central (V1) and peripheral (V2) compartment of zidovudine were not significantly 
different from each other, these values were therefore fixed to be equal. The distribution 
volume of the glucuronide (V3) was estimated as a fraction of the central compartment of 
zidovudine (θV3).  
In the second step (i.e. choice of error model) significant inter-individual 
variability could be identified for the absorption rate constant (ka), the formation (Cl1) 
and elimination (Cl2) clearance of zidovudine-glucuronide, the distribution volume of the 
central compartment (V1), and the bioavailability (F). Additionally, in the reference 
model a correlation between the inter-individual variability of the distribution volume of 
the central compartment (V1) and the formation clearance of zidovudine-glucuronide 
(Cl1) was identified. The inter-individual variability and residual error for the reference 
model and the system-specific model were best described by a proportional error model 
(equation 3). 
The third step (i.e. choice of covariate model) was different for the reference 
model and the system-specific model. 
A. Reference model: In the comprehensive covariate analysis, age (either postnatal or 
postmenstrual age) and bodyweight were readily identified as predictive and 
statistically significant covariates for the clearance parameters. Due to the relatively 
small range in bodyweight and age of the patients in the current zidovudine dataset 
(see table I), only small differences in objective function and diagnostics between 
models using either of the three covariates or between models using these covariates 
in different equations (i.e. linear, exponential or sigmoidal) were obtained. Based on 
the objective function postnatal age was found to be the slightly superior covariate for 
 To compare the predictive properties of both models, a normalized prediction 
distribution error (NPDE) analysis [11] which is a simulation-based diagnostic, was used. 
The entire dataset was simulated 1000 times in NONMEM and subsequently each 
observed concentration was compared to the reference distribution of the simulated data 
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6.3 Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6.3.1 Model Development
In the first step of model development (i.e. choice of structural model) a two-compartment 
model was found to best describe the time-course of zidovudine, and a one-compartment 
model was used to describe the time-course of the zidovudine-glucuronide, as is 
depicted in figure 1. Zidovudine absorption from the oral depot compartment was 
described by first-order absorption (ka) and the oral bioavailability (F) was estimated. 
Zidovudine clearance through pathways other than glucuronidation was found to be 
not significantly different from 0. When estimated, the values of the distribution volume 
of the central (V1) and peripheral (V2) compartment of zidovudine were not significantly 
different from each other, these values were therefore fixed to be equal. The distribution 
volume of the glucuronide (V3) was estimated as a fraction of the central compartment 
of zidovudine (θV3). 
In the second step (i.e. choice of error model) significant inter-individual 
variability could be identified for the absorption rate constant (ka), the formation (Cl1) 
and elimination (Cl2) clearance of zidovudine-glucuronide, the distribution volume of 
the central compartment (V1), and the bioavailability (F). Additionally, in the reference 
model a correlation between the inter-individual variability of the distribution volume 
of the central compartment (V1) and the formation clearance of zidovudine-glucuronide 
(Cl1) was identified. The inter-individual variability and residual error for the reference 
model and the system-specific model were best described by a proportional error model 
(equation 3).
The third step (i.e. choice of covariate model) was different for the reference 
model and the system-specific model.
A. Reference model: In the comprehensive covariate analysis, age (either postnatal or 
postmenstrual age) and bodyweight were readily identified as predictive and 
statistically significant covariates for the clearance parameters. Due to the relatively 
small range in bodyweight and age of the patients in the current zidovudine dataset 
(see table I), only small differences in objective function and diagnostics between 
models using either of the three covariates or between models using these covariates 
in different equations (i.e. linear, exponential or sigmoidal) were obtained. Based on 
the objective function postnatal age was found to be the slightly superior covariate 
for the formation clearance (Cl1) and the elimination clearance (Cl2) of zidovudine-
glucuronide. The inclusion of this covariate in the reference model was most 
optimal in a sigmoidal relationship on Cl1 and in a linear relationship with estimated 
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Based on the statistical criteria no covariates were identified for the distribution 
volumes.
B. System-specific model: as mentioned in the methods section, the developmental 
covariate model included in the system-specific model consisted of bodyweight-
based exponential equations with an exponent of 1.44 for the formation and 
elimination of zidovudine-glucuronide with a reduced formation clearance of 
zidovudine-glucuronide in neonates younger than ten days, and linear relationships 
between bodyweight and distribution volumes (Chapter 3).
Figure 1. Schematic representation of the structural model for the zidovudine models (left) and equations 
of the covariate relationships in the reference model (middle) and the system-specific model (right). ZDV 
= zidovudine, G-ZDV = zidovudine-glucuronide, F = bioavailability, ka = absorption rate constant, V = 
distribution volume of designated compartment, Cl = clearance of designated route, Q= inter-compartmental 
clearance, θV = distribution volume of designated compartment as fraction of V1, PNA = postnatal age 
with subscript ‘median’ indicating the median value of the individuals at the different occasions, θCl1 max 
= maximum value of the zidovudine glucuronidation clearance, θPNA 50 = postnatal age at which half the 
maximum value of zidovudine glucuronidation clearance is reached, θCl2 sl = slope of the line describing age-
related changes in zidovudine glucuronide elimination clearance, θCl2 int = y-intercept of the line describing 
age-related changes in zidovudine glucuronide elimination clearance, BW = bodyweight, θCl1<10days = 
population value of zidovudine glucuronidation clearance value in children younger than ten days of age, 
θCl1>10days = population value of zidovudine glucuronidation clearance value in children older than ten days of 
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Figure 1 shows the equations of the covariate relationships in the reference model and 
the system-specific model, in addition to providing a schematic representation of the 
structural model for both models. 




Reference model System-specific model
model parameter [unit] value (CV%) model parameter [unit] value (CV%)
Fixed effects
F
θ 1.56 (21.0) θ 1.55 (30.6)
F [%] 82.6 F [%] 82.5
ka [min-1]                                              0.0307 (0.9)                                                0.031 (17.7)
V1 = V2 [l]                                         4.02 (1.3) [l/kg]                                    1.08 (11.4)
V3 [fraction of V1]                                              0.226 (20.4)                                                0.211 (18.3)
Cl1 
Cl1 max [l/min] 0.116 (7.6)  Cl1 <10days [l/min/kg1.44] 0.00435 (12.1)
Cl PNA 50 [days] 1.63 (17.9) Cl1 >10days [l/min/kg1.44] 0.00853 (11.7)
Cl2 
Cl2 sl [l/min/day] 0.00257 (17.5) Cl2 [l/min/kg1.44] 0.00231 (10.7)Cl2 int [l/min] 0.00911 (11.64)
Qeq [l/min]                                              0.0275 (11.8)                                                0.0289 (11.7)
Inter-individual variability
ω2 (F)                                     2.78 (42.5)                                                2.82 (45.0)
ω2 (ka)                                     0.625 (36.8)                                                0.607 (39.9)
ω2 (V1)                                     0.443 (56.2)                                                0.366 (49.7)
ω2 (Cl1)                                     0.328 (38.7)                                                0.255 (54.51)
ω2 (Cl2)                                     0.142 (46.3)                                                0.112 (70.3)
ω2 (V1-Cl1) 
interaction                                     0.312 (54.5)                                                -
Residual variance
σ2 (ZDV)                                    0.11 (7.2)                                                0.11 (11.5)
σ2 (G-ZDV)                                     0.158 (13.3)                                                0.152 (15.5)
F = bioavailability presented as value of θ in eq. 2 and population value of F calculated with eq. 2, ω2 
= variance of the normal distribution that quantifies the inter-individual variability on the designated 
parameter according to eq. 1 or eq. 2 for bioavailability, σ2 = variance of the normal distribution that 
quantifies the residual error of the designated observation according to eq. 3. See figure 1 for explanation 
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In table II the model parameter estimates obtained for the models are shown. 
The values for structural parameters as well as for parameters of the error model are 
similar between the reference model and the system-specific model. Additionally, for 
both models the coefficient of variation of the fixed effects remain well below 50%, 
indicating that 0 was not in the 95% confidence interval of the parameter estimates and 
that the parameters can therefore be considered significant and estimated with acceptable 
precision. The coefficient of variation of some of the variance estimates of the inter-
individual variability did exceed 50% indicating that the information in the dataset was 
uninformative for precise estimation of these parameter values. Interestingly, as shown 
in figure 2, both models estimate similar population clearance values for each individual 
at each occasion, despite the differences in covariate models.
Figure 2. Population predicted zidovudine 
clearances (Cl1) for the reference model versus the 
system-specific model for each individual at each 
separate study occasion.
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6.3.2 Model Evaluation
The reference model was statistically superior over the system-specific model in 
describing the zidovudine data, as demonstrated by a difference in objective function 
of 13 points and a 2 point difference in degrees of freedom. Although statistically 
significant, this difference is small suggesting only a small difference in the description 
of the data between the two models. This is corroborated by the goodness-of-fit plots 
in figure 3. Visual inspection of the graphs shows that both models can describe the 
observed concentrations in children older and younger than the median age of children 
at the different occasions without bias and that the difference in the plots of the two 
models is negligible. 
In addition to an unbiased description of the concentrations, the plots in figure 
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zidovudine (Cl1) in the population without bias, despite the use of different primary 
covariates as descriptors for the developmental changes. Accuracy of the individual 
zidovudine clearance values compared to the population values described by the 
covariate relationships was numerically quantified as mean percentage error and was 
20.5% for the reference model compared to 11.3% for the system-specific model. The 
precision, numerically quantified as root mean square error, was 19.2 for both the 
reference model and the system-specific model. 
In terms of predictive performance, the two models perform similar as well, as 
expressed by the results of the normalized prediction distribution error analysis shown 
in figure 5. The reference model and the system-specific model can accurately predict the 
median zidovudine concentrations, but they slightly over-estimate the variability in the 
observations. In addition, there is no bias in normalized prediction distribution errors in 
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Figure 4. Individual post hoc parameter values of the glucuronidation clearance to zidovudine-glucuronide 
(Cl1) for each individual at each separate study occasion versus the most predictive covariate, which is 
postnatal age for the reference model (left) and bodyweight for the system-specific model (right). The covariate 
relationship describing the population clearance values are indicated with lines. For the plot of the system-
specific model (right) individual post hoc parameter estimates and population estimates of children younger 
than ten days are indicated with circles and a solid line respectively, for children older than ten days triangles 
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The current investigation is a proof-of-concept study to examine the hypothesis that 
paediatric covariate models for drug clearance describe changes in the underlying 
physiological system and can therefore be extrapolated from one drug to another drug 
that is eliminated through the same pathway. Our focus was on clearance in particular, 
because the ontogeny of clearance is considered to be the main driver of differences in 
pharmacological drug response in the paediatric population [1]. Covariate models that 
describe the developmental changes of clearance pathways in paediatric population 
pharmacokinetic models are crucial to determine first-in-child or evidence-based dosing 
regimen, as the covariate relationship describing these changes can be directly used in 
drug dosing algorithms. 
Morphine and zidovudine were used as paradigm drugs in this investigation 
because they are both primarily eliminated through glucuronidation by the UGT2B7 
isoenzyme [5–8] . The developmental glucuronidation model, an internally and externally 
validated paediatric covariate model for morphine glucuronidation (Chapters 3 and 
4), was directly incorporated into the pharmacokinetic model for the glucuronidation 
of zidovudine. The descriptive and predictive properties of this system-specific model 
were compared to a reference model. The covariate model of the reference model was 
developed by a comprehensive covariate analysis of the same dataset to obtain a model 
that provided the best description of the data according to statistical criteria. The results 
of this analysis show these two models to have similar descriptive and predictive 
performances. Given that the difference in time it took to develop both models is 
measured in weeks, the system-specific model performed remarkably well. 
Observed pharmacokinetic profiles are the result of the interaction between a drug and the 
physiological system. The parameters used to describe pharmacokinetic profiles therefore 
represent drug-specific and/or system-specific aspects of this interaction. The results 
from the current study suggest that developmental changes in drug glucuronidation are 
drug-independent and are therefore indeed likely to reflect changes in the underlying 
physiological system. Other studies suggest the same to be applicable to glomerular 
filtration as well [13]. Our group previously described and defined a distinction between 
drug-specific and system-specific parameters in population models for pharmacokinetic 
and pharmacodynamic processes [14]. Based on the current analysis the context of 
system-specific properties can be extended to not only include static descriptors of the 
physiological system, but to also include temporal changes in the physiological system 
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the zidovudine model that was based on the developmental covariate model obtained 
with morphine as the ‘system-specific model’. 
With the incorporation of system-specific information into population models, 
the methodology proposed here is moving away from the empiricism of population 
modelling, towards the mechanistic approach of physiologically-based pharmacokinetic 
modelling. We envision that the developmental covariate models not necessarily only 
include the influence of age-related changes on drug pharmacokinetics, but that they 
may also include significant influences of other static and/or dynamic covariates (e.g. 
genetics, disease status etc.) on the underlying physiological system that is driving 
pharmacokinetics. It is however a prerequisite that these paediatric covariate models are 
extensively validated and that the population to which the covariate model applies is 
well defined in terms of other potentially important covariates, like for instance genetics 
or disease status. 
 Paediatric population pharmacokinetic models of hitherto unstudied drugs can 
be developed in a time-efficient manner and with limited resources, by the between-drug 
extrapolation of these semi-physiological paediatric covariate models. This methodology 
allows for the use of denser information or information from a wider age-range than may 
be available for the analysis of an unstudied drug. The developmental covariate model in 
the system-specific model of the current analysis was for instance based on the analysis 
of morphine glucuronidation in 248 patients ranging from preterm neonates to infants of 
three years, whereas in the current zidovudine analysis data from only 29 patients ranging 
from term neonates to infants of five months were available (see table I). Due to the small 
range in age and bodyweight in this zidovudine dataset, the difference in descriptive 
and predictive properties of models with different covariate relationships was small. 
In the comprehensive covariate analysis inclusion of postnatal age, postmenstrual age 
or bodyweight in either linear, exponential or sigmoidal relationships yielded models 
with similar objective functions and diagnostics, however based on statistical criteria 
postnatal age in a sigmoidal equation was selected as the final covariate model for the 
maturation of zidovudine glucuronidation. The bodyweight-based exponential covariate 
relationship identified for morphine glucuronidation was not identified for zidovudine 
in the comprehensive covariate analysis of the current zidovudine data. This is probably 
due to the indistinctive curvature of this relationship in the bodyweight-range of the 
zidovudine dataset. Nonetheless, direct incorporation of the developmental covariate 
model into the zidovudine model did provide a good description of the population and 
individual zidovudine clearance parameters as shown in figure 4. As such, information 
from one drug seems indeed to be of value for the analysis of a similar drug, which 
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The clinically observed developmental changes in drug pharmacokinetics represent 
the net result of the developmental changes in a number of processes in the underlying 
biological system. This may include changes in expression and function of drug 
metabolizing enzymes and active transporters, changes in body composition, changes 
in cardiac output and organ perfusion, changes in acid-base balance, and changes in the 
amount and composition of drug-binding plasma proteins and the presence of other 
blood components that may influence plasma protein binding [15]. The weight that each 
individual process has on the net observed changes in drug pharmacokinetics may be 
different for drugs with different molecular and pharmacokinetic properties. Morphine 
and zidovudine are quite similar with respect to these properties. Their molecular masses 
are 285 g/mol and 267 g/mol respectively. Plasma protein binding in adults ranges 
between 25% and 40% for both drugs [16,17] and their hepatic extraction ratios in adults 
range between 0.5 and 0.65 [18–20]. The pKa value for morphine is around 7.9 [21] and for 
zidovudine this value is around 9.5 [22]. Finally, logPoctanol/water values for these compounds 
were reported to be 0.75 [23] and 0.05 [24] respectively. It remains to be investigated how 
and to what extent differences in physicochemical and pharmacokinetic drug properties 
influence the between-drug extrapolation potential of the semi-physiological paediatric 
covariate models.
One of the drawbacks of the method applied in the current analysis is that 
model development for the new drug (zidovudine in this case) still relies on the 
availability of at least a limited amount of paediatric data to determine the population 
value of the clearance, which is mainly determined by the drug-specific parameters 
Km and Vmax. This does not pose a problem when a marketed drug that is unstudied in 
the paediatric population is already being used off-label in that population. However, 
when in drug development a drug has never been used in a paediatric age-range 
before, a methodology that does not rely on in vivo paediatric data of the drug under 
investigation is required. To date there is no suitable methodology based on population 
pharmacokinetic modelling available to extrapolate paediatric pharmacokinetic 
parameters from older to younger age-ranges in the drug development process [25]. With 
physiologically-based pharmacokinetic modelling the absolute value of drug clearance 
could be predicted without prior paediatric in vivo data. Unfortunately knowledge 
on all underlying physiological processes is currently incomplete especially for the 
paediatric population, which potentially impedes paediatric clearance predictions by 
physiologically-based pharmacokinetic modelling. Therefore the approach proposed 
here is combining the physiological insight from physiologically-based pharmacokinetic 
modelling with the descriptive approach of population modelling. If system-specific 
profiles on developmental changes in certain metabolic pathways were available over 
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in children of decreasing ages for unstudied drugs. These studies could then be of a 
confirmative rather than an explorative nature.
In conclusion, this proof-of-concept study supports our hypothesis that paediatric 
covariate models that describe the developmental changes in drug elimination pathways 
constitute system-specific rather than drug-specific information and can therefore be used 
for extrapolation between drugs that share an elimination pathway. This approach can 
be considered a semi-mechanistic hybrid between empirical population modelling and 
physiologically-based pharmacokinetic modelling. Between-drug extrapolation of semi-
physiological covariate models can expedite the development of paediatric population 
pharmacokinetic models that can in turn be used to derive first-in-child and evidence-
based dosing recommendations for this population. 
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
There is little insight in the extrapolation potential of paediatric covariate models 
between drugs that share a common elimination pathway. In this study, the physiological 
and physicochemical basis of a semi-physiological covariate model quantifying the 
developmental changes in in vivo UGT2B7-mediated drug glucuronidation in children 
younger than three years in population models (top-down models), was untangled using 
a physiologically-based model (bottom-up model).
Simcyp version 11 was used to simulate in vivo clearance values for morphine 
and zidovudine, both selective UGT2B7 substrates, in children younger than three 
years. The contribution of changes in system-specific parameters (hepatic blood flow, 
liver volume, microsomal protein per gram of liver, UGT2B7 ontogeny, unbound drug 
fraction) to changes in in vivo drug clearances were quantified. Additionally, the influence 
of physicochemical drug properties (molecular mass, logP, pKa) on the in vivo clearance 
of hypothetical UGT2B7-substrates was determined.
Using currently available in vitro data, morphine and zidovudine clearances 
were under-predicted by the physiologically-based model. However, the predicted 
developmental profile in glucuronidation clearance was similar to the clinically observed 
profile across the first three years of life, with the exception of the first two weeks of life. 
Changes in system-specific parameters explained 79% and 41% of the increases in in 
vivo morphine and zidovudine clearance, respectively, with the influence of liver size 
and UGT2B7 ontogeny being most pronounced. Physicochemical drug parameters did 
not affect the developmental glucuronidation profile, although logP and pKa did both 
influence the absolute value of clearance.
In conclusion, liver size and UGT2B7 ontogeny were identified as the main 
physiological drivers of the increases in UGT2B7-mediated clearance in the first three 
years of life. As physicochemical drug parameters only alter the absolute value of 
paediatric in vivo glucuronidation, the semi-physiological paediatric covariate model 
for drug glucuronidation can be used to predict the developmental clearance profile of 
other UGT2B7 substrates. Situations involving non-linear clearance as well as blood flow 
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7.1 Introduction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Research to develop evidence-based rather than empiric or consensus-based dosing 
algorithms for the paediatric population is complicated by practical, ethical, and legal 
constraints. These issues can be overcome by the application of population modeling 
approaches as is also recommended by the FDA and EMA [1,2]. Population modeling relies 
on outcome measures (i.e. observed concentrations) that can be obtained during routine 
clinical practice and allows for data analysis on the basis of sparse samples [3]. However, 
despite the multi-factorial nature of the ontogeny of drug clearance, paediatric population 
models only describe net observed changes in ontogeny with a limited number of covariate 
relationships. Therefore these models are only applicable to specific drugs in a specified 
population, requiring collection of the same type of data and full analysis of these data 
for every drug in every population of interest. Recently physiologically-based modeling 
has gained in popularity. These models use in vitro data on drug kinetics in combination 
with anatomical measurements, physiological parameters and mathematical equations 
to quantify physiological processes and the interaction of a molecule with certain 
physicochemical properties with this system. The usefulness of this type of modeling in 
paediatric pharmacokinetics has also been recognized by regulatory agencies [4]. Not all 
parameters in the physiologically-based models can be easily obtained, especially in the 
paediatric population. However, most parameters are ‘system specific’ and therefore not 
restricted to specific drugs or populations. As a result physiologically-based models are 
more generalizable. 
Only rarely have the advantages of physiologically-based modeling, known 
as the bottom-up approach, been combined with the top-down approach of population 
modeling to augment each other. We have recently developed and validated a population 
pharmacokinetic model for morphine glucuronidation in children younger than three 
years (Chapters 3 and 4). It was found that the paediatric covariate model that quantifies 
the developmental changes in morphine clearance can be directly incorporated in 
the paediatric population model for the clearance of zidovudine (Chapter 6). Since 
morphine and zidovudine are both primarily eliminated through UGT2B7-mediated 
glucuronidation, this confirmed our hypothesis that covariate relationships in paediatric 
population models quantify developmental changes in the underlying physiological 
system, and thereby constitute system-specific information that can be extrapolated 
between drugs that share a common elimination pathway. Pharmacokinetic modeling 
based on this concept was called semi-physiological modeling, as it combines 
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The current study focuses on the semi-physiological developmental 
glucuronidation model for UGT2B7-mediated glucuronidation clearance in preterm and 
term neonates to children younger than three years, which was developed using morphine 
and zidovudine as model drugs (Chapters 3, 4, and 6). We aimed to dissect the various 
sources of developmental changes in the physiological system to identify which changes 
are the main drivers of the net observed changes in UGT2B7-mediated glucuronidation 
in neonates and infants, thereby also identifying patient characteristics that potentially 
limit the applicability of the semi-physiological developmental glucuronidation model. 
Additionally, we investigated whether certain physicochemical drug properties could 
affect the utility of the semi-physiological developmental model for compounds that 
share the UGT2B7-mediated elimination pathway.
7.2. Materials and Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7.2.1 Physiologically-Based Simulations 
The physiologically-based pharmacokinetic modeling software Simcyp version 11 
(Simcyp Ltd, Sheffield, UK) was used to investigate the influence of system-specific 
and drug-specific parameters on the ontogeny of in vivo UGT2B7-mediated drug 
glucuronidation in the first three years of life. 
The paediatric database in Simcyp was selected for the physiologically-based 
pharmacokinetic simulations and parameters were set to include patients with a 
maximum age of three years. One thousand individuals were simulated and the same 
random number generation seed was used for repeated simulations. This yielded exactly 
the same set of individuals for each simulation and allowed for a direct comparison of 
clearance predictions between individuals in simulations with varying model parameter 
values. A uniform age distribution was used and the male/female ratio was set to 1. 
For each of the 1000 simulated individuals, age and sex appropriate bodyweight and 
height were determined based on UK reference growth charts taking inter-individual 
variability into account [5]. Body surface area was calculated according to Haycock et al. 
[6] for children with a bodyweight less than 15 kg and according to DuBois and DuBois [7] 
for heavier children. The parallel-tube model was used to derive hepatic drug clearances 
from in vitro intrinsic clearances. 
In the current study, morphine and zidovudine were used as model compounds. 
Both drugs are specific substrates for the UGT2B7 isoenzyme [8–10] and used in the proof-
of-concept studies for the development of the semi-physiological paediatric model 
(Chapters 3 and 6). In the simulations, intravenous bolus doses of 0.1 mg/kg morphine 
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7.2.1.1 System-Specific Parameters
Hepatic blood flow, liver volume, milligram microsomal protein per gram of liver 
(MPPGL), UGT2B7 ontogeny and unbound drug fraction were the five system-specific 
parameters of the physiologically-based pharmacokinetic model that were investigated 
in the current study. The term UGT2B7 ontogeny is used to describe the fractional 
expression and function of the UGT2B7 isoenzyme in children compared to adults. The 
percentage change of each of the five parameters was calculated for patients in i) the first 
three months of life (0 – 3 months, group I), ii) the second three months (3 – 6 months, 
group II), iii) the second half year (6 – 12 months, group III), iv) the second year (1 – 2 
years, group IV), and v) the third year (2 – 3 years, group V). This was done by calculating 
the mean parameter value of all individuals with an age in the first two weeks and the 
last two weeks of each interval and determining the percentage increase in these values 
per group.
Subsequently, one at a time, the values of each of the five system-specific 
parameters were increased within a physiologically relevant range, based on the mean 
increase in the parameter values in each of the five age-groups. For hepatic blood flow 
and liver volume this was 23%, for MPPGL this was 2%, for the UGT2B7 ontogeny factor 
this was 21%, and for the unbound drug fraction this was 0.51% for morphine and 0.33% 
for zidovudine. To quantify the influence of these changes on the in vivo drug clearance 
a ‘sensitivity ratio’ was calculated for each individual by dividing the difference in 
physiologically-based morphine or zidovudine clearance prediction by the percentage 
difference in the system-specific parameter value. This sensitivity ratio quantifies 
how sensitive in vivo drug clearance is to changes in the underlying system-specific 
parameters. For example, a sensitivity ratio of 0.80 indicates that a 10% increase in a 
system-specific parameter, would increase in vivo drug clearance by 8%. Mean sensitivity 
ratios were calculated for each system-specific parameter in each of the age-groups 
described above. By multiplying the percentage change in a system-specific parameter in 
each age-group by the mean sensitivity ratio for that age-group, the percentage change in 
in vivo glucuronidation clearance as a result of the changes in the underlying parameter 
value in that age-range was determined. 
Since the user cannot alter UGT2B7 ontogeny in the Simcyp software package, 
an alternative scenario was simulated that represents a situation with a 21% increase 
in the UGT2B7 ontogeny factor. This ontogeny factor is a scalar for the intrinsic 
glucuronidation clearance that takes place in both the liver and the kidneys. Similarly, 
liver density is a scalar for intrinsic UGT2B7-mediated glucuronidation in the liver, 
while milligram microsomal protein per gram of kidney (MPPGK) is a scalar of intrinsic 
UGT2B7-mediated glucuronidation clearance in the kidney. Therefore simulation of a 
scenario in which both liver density and MPPGK are increased by 21%, were used to 
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7.2.1.2 Drug-Specific Parameters
Morphine and zidovudine were added to the compound database in Simcyp by obtaining 
their drug-specific parameters from literature. In the simulations the assumption was 
made that there is no morphine or zidovudine elimination through other pathways than 
UGT2B7-mediated glucuronidation, that there is no biliary clearance of these drugs, and 
that there is no active drug transport into or out of hepatocytes.
The obtained drug-specific parameters for each drug are presented in Table I. 
With respect to the Michaelis-Menten parameters, values for the formation of the two 
morphine glucuronides were obtained from a study using human adult liver microsomes 
from five separate individuals [20] and values for the glucuronidation of zidovudine were 
obtained from a study using liver microsomes from four adults [14]. To verify the obtained 
drug-specific parameters, morphine and zidovudine clearances were predicted by the 
physiologically-based model for 1000 healthy adult volunteers and compared to reported 
clearance values in adults of 93 L/h for morphine [21–23] and 91.2 L/h for zidovudine 
[15,24,25]. This yielded a 75% mean under-prediction for morphine and a 71% mean under-
prediction for zidovudine. Based on literature reports that showed that for UGTs the 
presence or absence of albumin and fatty acids in in vitro assays influence Km values 
but not Vmax values [26,27], the physiologically-based clearance predictions for morphine 
and zidovudine in adults were optimized by adjusting the Km values of these drugs. For 
morphine the optimized Km value was 115.8 μM for the formation of both M3G and M6G, 
and for zidovudine this was a value of 4 μM. These were the Km values that were used in 
the subsequent paediatric simulations. 
To identify how physicochemical drug properties influence paediatric UGT2B7-
mediated glucuronidation, in vivo clearance values of hypothetical small molecular 
UGT2B7-specific substrates with various physicochemical properties, were simulated 
with Simcyp. In these simulations, the implicit assumption was made that the changes 
in physicochemical properties influenced neither the active transport of the hypothetical 
drug into or out of the hepatocytes nor the interaction of the hypothetical drug with 
the UGT2B7 isoenzyme. For the hypothetical drugs, molecular weights of 100, 200, 500, 
800, and 1000 g/mol were used in combination with octanol/water partition coefficients 
(logP) of 0.01, 1, and 5.5. Neutral compounds were simulated as well as monoprotic 
acids and bases with acid dissociation constants (pKa) of 2 or 5 and 8.5 or 12 respectively, 
and diprotic acids and bases with pKa values of 2 and 5 and 8.5 and 10 respectively. 
An ampholyte was used with a pKa of 5 and 9. These values are summarized in table 
I. The Simcyp toolbox was used to calculate the blood/plasma ratio and unbound drug 
fraction for each hypothetical drug based on logP and pKa values. The Michaelis-Menten 
parameters obtained for morphine were used and in the simulations an intravenous drug 
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Table I. Drug-specific parameters for morphine, zidovudine, and hypothetical drugs used in the 
physiologically-based simulations.
Parameter [unit] Parameter values references
Physicochemical parameters Morphine Zidovudine Hypothetical drug
molecular mass [g/mol] 285.34 267.24 100 - 1000






blood / plasma ratio 1.08 0.86 derived [13,16,17]
fraction unbound in adults 0.62 0.77 derived [13,18,19]
Enzyme kinetic parameters
Km [μM] 115.8 4 115.8





logP = octanol/water partition coefficient, pKa = acid dissociation constant, Km = Michaelis-Menten 
constant, Vmax = maximum formation rate, NA = not applicable
The influence of the changes in physicochemical drug parameters on the 
predicted in vivo clearance were assessed by changing one parameter value while 
keeping all other parameter values constant and calculating the percentage difference 
between the clearance predictions between two simulations. When the highest individual 
prediction difference was less than 5%, the parameter was classified as not significantly 
influencing drug glucuronidation. When the highest individual prediction difference 
was more than 5% and the difference between mean prediction difference of individuals 
in the first month of life and individuals in the 35th month of life was less than 5% a 
constant was classified as influencing the absolute value of drug glucuronidation. When 
the difference between mean prediction difference of individuals in the first month of life 
and individuals in the 35th month of life was more than 5%, the parameter was classified 
as influencing the ontogeny profile in addition to influencing the absolute value of drug 
glucuronidation clearance. 
7.2.2 Semi-Physiological Developmental Glucuronidation Model
The semi-physiological developmental glucuronidation model is represented by 
the covariate model quantifying the net observed developmental changes in drug 
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and term neonates. This is the model obtained and validated in a previous population 
analysis of paediatric morphine data (Chapters 3 and 4) which was also directly 
extrapolated to zidovudine (Chapter 6). In this model the overall developmental changes 
in drug glucuronidation in children younger than three years are quantified according 
to equation 1:
UGT2B7-specific substrates with various physicochemical properties, were simulated 
with Simcyp. In these simulations, the implicit assumption was made that the changes in 
physicochemical properties influenced neither the active transport of the hypothetical 
drug into or out of the hepatocytes nor the interaction of the hypothetical drug with the 
UGT2B7 isoenzyme. For the hypothetical drugs, molecular weights of 100, 200, 500, 
800, and 1000 g/mol were used in combination with octanol/water partition coefficients 
(logP) of 0.01, 1, and 5.5. Neutral compounds were simulated as well as monoprotic 
acids and bases with acid dissociation constants (pKa) of 2 or 5 and 8.5 or 12 
respectively, and diprotic acids and bases with pKa values of 2 and 5 and 8.5 and 10 
respectively. An ampholyte was used with a pKa of 5 and 9. These values are 
summarized in table I. The Simcyp toolbox was used to calculate the blood/plasma ratio 
and unbound drug fraction for each hypothetical drug based on logP and pKa values. The 
Michaelis-Menten parameters obtained for morphine were used and in the simulations an 
intravenous drug dose of 0.1 mg/kg was administered.  
The influence of the changes in physicochemical drug parameters on the predicted 
in vivo clearance were assessed by changing one parameter value while keeping all other 
parameter values constant and calculating the percentage difference between the 
clearance predictions between two simulations. When the highest individual prediction 
difference was less than 5%, the parameter was classified as not significantly influencing 
drug glucuronidation. When the highest individual prediction difference was more than 
5% and the difference between mean prediction difference of individuals in the first 
month of life and individuals in the 35
th
 month of life was less than 5% a constant was 
classified as influencing the absolute value of drug glucuronidation. When the difference 
between mean prediction difference of individuals in the first month of life and 
individuals in the 35
th
 month of life was more than 5%, the parameter was classified as 
influencing the ontogeny profile in addition to influencing the absolute value of drug 
glucuronidation clearance.  
 
7.2.2 Semi-Physiological Developmental Glucuronidation Model 
The semi-physiological developmental glucuronidation model is represented by the 
covariate model quantifying the net observed developmental changes in drug 
glucuronidation clearance in children under the age of three years including preterm and 
term neonates. This is the model obtained and validated in a previous population analysis 
of paediatric morphine data (Chapters 3 and 4) which was also directly extrapolated to 
zidovudine (Chapter 6). In this model the overall developmental changes in drug 
glucuronidation in children younger than three years are quantified according to equation 
1: 
44.1
10 BWfaCL neonate ⋅⋅= <      (eq. 1) 
in which CL represents the drug glucuronidation clearance, a is a constant that represents 
the absolute value of clearance, fneonate<10 represents a reduced glucuronidation fraction in 
neonates younger than ten days, and BW represents the bodyweight of an individual 
paediatric patient in kilograms. The absolute value of clearance for each drug (i.e. value 
of a in equation 1) is estimated from concentration-time data in a population analysis. 
The reduction in glucuronidation clearance in neonates with a postnatal age younger than 
ten days (fneonate<10) is 50% and is independent from gestational age. The final element of 
equation 1 quantifies the overall ontogeny of in vivo drug glucuronidation in this young 
 (equation 1)
in which CL represents the drug glucuronidation clearance, a is a constant that represents 
the absolute value of clearance, fneonate<10 represents a reduced glucuronidation fraction in 
neonates younger than ten days, and BW represents the bodyweight of an individual 
paediatric patient in kilograms. The absolute value of clearance for each drug (i.e. value 
of a in equation 1) is estimated from concentration-time data in a population analysis. The 
reduction in glucuronidation clearance in neonates with a postnatal age younger than 
ten days (fneonate<10) is 50% and is independent from gestational age. The final element of 
equation 1 quantifies the overall ontogeny of in vivo drug glucuronidation in this young 
population using bodyweight as a surrogate descriptor in an exponential equation with 
an exponent of 1.44. 
Using the currently available in vitro data as input parameters, the morphine and 
zidovudine clearance predictions by the physiologically-based pharmacokinetic model 
in Simcyp were compared to the clearance values according to the semi-physiological 
developmental glucuronidation model. This was done by plotting clearance values from 
both models versus bodyweight, which is the primary covariate in the semi-physiological 
developmental glucuronidation model, and by plotting the prediction difference between 
the physiologically-based clearance values and the semi-physiological clearance values 
for each of the 1000 simulated individuals versus bodyweight. Additionally, for each of 
the 1000 individuals in the simulation dataset of the current study, the morphine and 
zidovudine clearances according to the semi-physiological model were determined 
as well. The percentage increase in morphine and zidovudine clearance predictions 
in each of the five age-groups according to the semi-physiological developmental 
glucuronidation model were calculated as described above. 
7.3. Results
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7.3.1 System-Specific Parameters
Table II ranks the five system-specific parameters by their relative contribution to the 
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columns. The percentage change in clearance as a result of developmental changes in 
the underlying system-specific parameters is calculated from the percentage change in 
the system-specific parameter according to the physiologically-based model in Simcyp 
and the sensitivity ratio quantifying the sensitivity of drug clearance to these changes. It 
can be seen that the contribution of each system-specific parameter to the developmental 
changes in clearance is different for morphine and zidovudine. With respect to the 
different age-groups, the contribution of the parameters to developmental changes 
in in vivo clearance is highly non-linear and may even be bi-directional. Despite these 
differences, liver volume can overall be regarded as the main driver of developmental 
changes in UGT2B7-mediated glucuronidation, by causing an increase in in vivo 
clearance in the different age-groups between 13% and 31% for morphine and 7.3% and 
22% for zidovudine, with an especially large contribution in the first three months of 
life. The increase in in vivo morphine and zidovudine clearance as a result of UGT2B7 
ontogeny in the different age-groups ranges between 10% and 29%, and 7.4% and 18% 
respectively. The influence of hepatic blood flow on developmental changes in morphine 
clearance is below 5% in all age-groups and can therefore be regarded negligible, while 
for zidovudine clearance the contribution of changes in hepatic blood flow to increases 
in in vivo clearance ranges between 3.7% and 7.9%. For both drugs, the contribution of 
changes in MPPGL and unbound drug fraction is negligible in all age-groups. 
7.3.2 Drug-Specific Parameters 
Simulations with hypothetical small molecular UGT2B7 substrates with physicochemical 
properties in the ranges depicted in table I revealed that physicochemical drug properties 
do not influence the ontogeny profile of in vivo UGT2B7-medidated glucuronidation 
clearance. It was found that molecular mass, in the range between 100 g/mol and 1000 
g/mol, did not influence UGT2B-mediated glucuronidation clearance of the simulated 
hypothetical drugs at all, assuming that the increase in mass did not alter the uptake or 
efflux of the drug by hepatocytes or the interaction of the drug molecule with the UGT2B7 
isoenzyme. Increasing the octanol/water partition coefficient (logP) between 0.01 and 
5.5 while keeping all other parameters constant, yielded a slight decreasing trend in the 
predicted absolute value of drug glucuronidation. On the other hand, increasing the acid 
dissociation constant (pKa) between 2 and 12 while keeping other parameters constant, 
yielded a trend towards an increasing predicted absolute value of drug glucuronidation. 
No strong relationship was observed between the physicochemical properties of the 
hypothetical drugs and the absolute value of glucuronidation clearance, nor was there a 
relationship between the derived blood to plasma ratio of the hypothetical drugs and the 
absolute value of drug glucuronidation. There was however a strong linear correlation (r 
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based model for the hypothetical drugs in each of the 1000 simulated individuals and 
the unbound drug fraction of the hypothetical drug in plasma, which was derived from 
the logP and pKa value using the Simcyp toolbox. According to this relationship, while 
keeping the Michaelis-Menten parameters constant at the values obtained for morphine, 
every 0.1 increase in unbound drug fraction of the hypothetical drug resulted in an 
increase in in vivo drug clearance of 1.5 L/h.
Table II. System-specific parameters investigated in the current study. The percentage increase in parameter 
value in each of the five age-groups is given, as well as the mean sensitivity ratios of the clearance of morphine 
and zidovudine in each group. The calculated percentage change in in vivo morphine and zidovudine clearance 
as a result of the change in the underlying system-specific parameters are also presented. 
Parameter Percentage change in parameter value
Mean sensitivity ratio 
Percentage change in 
clearance as a result of 
changes in parameter 
morphine zidovudine morphine zidovudine
Liver volume 




V:   21%




V:   0.72
I:    0.58
II:   0.56
III:  0.50
IV:  0.43
V:   0.35




V:   15%




V:   7.4%
UGT2B7 
ontogeny
I:     12.7%
II:   11.4%
III:  20.2%
IV:  33.8%
V:   25.2%
I:    0.90
II:   0.90
III: 0.88
IV: 0.85
V:   0.81




V:   0.45




V:   20%




V:   11%
Hepatic blood 
flow 
I:     33%
II:   17%
III:  19%
IV:  22%
V:   24%




V:   0.127




V:   0.29




V:   3.0%









I:     0.71 %
II:   0.70%
III:  1.63%
IV:  3.3 %
V:    3.1%




V:   0.75
I:    0.62
II:   0.60
III:  0.55
IV: 0.47
V:   0.39




V:   2.3%








I:     -1.6%
II:   -0.72%
III:  -1.5% 
IV:  -0.05%
V:   1.2%
zidovudine




V:   0.74%




V:   0.85














V:   0.38%
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7.3.3 Semi-Physiological Developmental Glucuronidation Model
Figure 1 shows the total morphine glucuronidation clearance and zidovudine 
glucuronidation clearance values in children younger than three years according to the 
semi-physiological developmental glucuronidation model and the physiologically-based 
pharmacokinetic model in Simcyp. The graphs in figure 1 indicate an under-prediction 
of the morphine and zidovudine glucuronidation in children older than ten days (solid 
circles) by the physiologically-based model, which is reflected in a mean percentage 
difference for this subpopulation of -68.3% for morphine and -19.1% for zidovudine 
in the bottom graph. In children younger than ten days (asterisks), the reduction in 
glucuronidation capacity as quantified by the semi-physiological developmental 
glucuronidation model, is not observed in the predictions by the physiologically-
based pharmacokinetic model. This yields a mean percentage difference of -19.4% for 
morphine and 105% for zidovudine. These results illustrate large differences in the 
prediction of developmental changes in in vivo glucuronidation clearance between the 
semi-physiological model and the physiologically-based model in the first two weeks of 
life. In older infants and children, the prediction difference remains constant throughout 
the bodyweight-range, suggesting that in this older subpopulation the ontogeny profile 
predicted by the physiologically-based model mainly differs from the semi-physiological 
developmental glucuronidation model in absolute value while it is rather similar in 
shape.
Developmental changes in in vivo morphine and zidovudine clearance relative 
to birth are depicted in figure 2 for the semi-physiological model (grey lines) and the 
physiologically-based model (black lines), including the individual contribution of each 
system-specific parameter in the physiologically-based model (non-solid black lines). 
It can be seen that for both morphine and zidovudine, the largest contribution to the 
increase in in vivo glucuronidation is coming from the increase in liver volume (dotted 
black line) and the ontogeny of the UGT2B7 isoenzyme (long dashed black line). When 
not taking into account the rapid increase in drug glucuronidation predicted by the semi-
physiological model at the age of ten days (dashed grey line), the combined influence 
of the changes in the five system-specific parameters investigated in the current study 
explains 79% of the clinically observed increases in morphine and 41% of the clinically 
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Figure 1. Predicted in vivo morphine clearance (top left) and zidovudine clearance (top right) versus 
bodyweight in children younger than three years by the physiologically-based pharmacokinetic model (asterisk 
for neonates younger than ten days, and solid dots for children older than ten days) and the semi-physiological 
developmental glucuronidation model (lines are population predictions and shaded area indicates the 95% 
prediction interval). The prediction difference between the two models is depicted versus bodyweight for both 
drugs (bottom). The horizontal lines in these graphs show 0% prediction difference (solid line) and ± 30% 
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Figure 2. Developmental changes in in vivo morphine and zidovudine clearance in the first three years of life 
relative to birth. The solid grey line represents the total increase predicted by the semi-physiological model 
and the dotted grey line represents the clearance increase predicted by the semi-physiological model without 
taking the rapid increase at the age of ten days into account. The solid black line represents the sum of the 
changes by all five system-specific parameters with the non-solid black lines representing the individual 
contribution of each system-specific parameter. 
7.4. Discussion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The clinically observed in vivo maturation pattern for morphine glucuronidation in 
children has been extensively studied and quantified in a paediatric covariate model 
before (Chapters 3 and 4) and it was shown that this covariate model could be directly 
extrapolated to the glucuronidation of zidovudine in a semi-physiological modelling 
concept (Chapter 6). It is of interest to investigate to what extent this paediatric 
developmental glucuronidation model can be extrapolated to other patient populations 
or other UGT2B7 substrates. Therefore the current study investigated the physiological 
and physicochemical basis of the semi-physiological developmental covariate model 
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modelling software Simcyp. Detailed investigation of the influence of individual system-
specific and drug-specific parameters on the ontogeny pattern of in vivo glucuronidation 
revealed that increases in liver volume and in the ontogeny of UGT2B7 isoenzymes are 
the main physiological drivers of the developmental changes in drug glucuronidation 
(table II and figure 2). The logP and pKa of a drug, but not the molecular mass, influence 
the absolute value of the drug glucuronidation clearance without however influencing 
the pattern of developmental changes. 
In figure 1 it can be observed that the clearance predictions by the physiologically-based 
model (symbols), using the currently available in vitro information on morphine and 
zidovudine clearance, are generally lower than the clearance values obtained from 
the semi-physiological developmental glucuronidation model. Additionally, as can 
be observed in figure 2, the combined influence of the age-related increases in the five 
system-specific parameters investigated in the current study (solid black line) do not fully 
explain the clinically observed increase in morphine and zidovudine clearance (solid 
grey line), not even when the rapid increase in glucuronidation clearance predicted by 
the semi-physiological model at the age of ten days are not taken into account (dashed 
grey line). There are a number of possible explanations for the discrepancies in clearance 
values obtained by the physiologically-based model and the semi-physiological model. 
 The UGT enzyme kinetic parameters for morphine and zidovudine were 
obtained from two studies using liver microsomes described in literature. Confidence 
that these values accurately represent in vivo enzyme kinetic values is limited by the fact 
that numerous incubation conditions influence measured UGT enzyme kinetics, causing 
difficulties in obtaining good predictions on in vivo UGT enzyme kinetics from microsome 
studies [26–30]. In fact, in the current study the reported Km values had to be adjusted to 
values that yielded accurate clearance predictions by the physiologically-based model in 
adults. In a sensitivity analysis, when changing Vmax and Km values from values ten-fold 
lower to ten-fold higher than the values used in the current analysis, predicted paediatric 
glucuronidation clearances changed with a factor two for M6G formation and a factor 
twelve for both zidovudine glucuronidation and M3G formation. This illustrates, that 
imprecise in vitro values for enzyme kinetics may influence clearance predications by the 
physiologically-based model significantly. 
Further discrepancies may be the result of the assumption made in the simulations 
with the physiologically-based model. For instance, morphine and zidovudine were 
both assumed to be solely eliminated through glucuronidation. While glucuronidation 
is believed to be the major elimination pathway for these drugs, a small contribution of 
other elimination pathways cannot be excluded. Some paediatric morphine studies have 
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or unchanged elimination in the very young [31,32]. Additionally, in the physiologically-
based model active drug uptake or efflux by hepatocytes and biliary clearance of 
morphine and zidovudine were assumed to be zero. Although it is unclear how accurately 
this reflects the clinical situation, animal studies with morphine have shown energy-
dependent carrier-mediated uptake of morphine in hepatocytes [33,34], while others found 
active hepatic uptake to not limit hepatic morphine metabolism [35]. Additionally, biliary 
clearance of morphine was reported in rat livers [35].
 Of the system-specific parameters in the physiologically-based model, the 
ontogeny profile for liver volume is based on a large number of observations [36], while the 
paediatric information on other system-specific parameters is more limited, decreasing 
the level of confidence for the ontogeny profiles of these parameters in the physiologically-
based model. Especially for the ontogeny of UGT2B7, expression and function of this 
isoenzyme in the physiologically-based model increases linearly with age from 8.9% 
from adult values at birth to adult values at the age of 20 years. Review of literature 
data however, suggests the expression and function of UGT isoenzymes to increase 
rapidly in the first few weeks of life (Chapter 2). Given that morphine and zidovudine 
clearances were found to be rather sensitive to changes in the UGT2B7 ontogeny 
factor, which is expressed in average sensitivity ratios of 0.87 and 0.58 respectively, a 
suboptimal representation of this ontogeny profile may explain the discrepancy in 
the morphine and zidovudine clearance values according to the semi-physiological 
model and physiologically-based model in figure 1 and the discrepancy between the 
predicted increases in morphine and zidovudine clearances by the physiologically-based 
model (solid grey line) and the semi-physiological model (solid black line) in figure 2. 
Therefore, improving the UGT2B7 ontogeny profile in the physiologically-based model 
may improve the predictions for paediatric UGT2B7-mediated glucuronidation.
 The relatively large impact of changes in liver volume on in vivo drug 
glucuronidation observed in this study, may limit the applicability of the semi-
physiological developmental glucuronidation model in patients with a reduced liver 
size, as a result of for instance liver resection, or a reduced liver function, for instance in 
patients with hepatic dysfunction as a result of virus associated hepatic disease or liver 
cirrhosis. Literature reports have indeed shown morphine and zidovudine clearance 
to be significantly reduced in adult patients with cirrhosis [37–40]. Reduced liver size or 
liver function may have clinical implications for dosing UGT2B7 substrates in these 
patients. Interestingly, hepatic blood flow was found have a limited impact on morphine 
glucuronidation in the current study, while cardiac surgery was found to have a clinically 
significant influence on paediatric morphine clearance, which was attributed to changes 
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Physicochemical parameters that influence the ontogeny profile of drug glucuronidation 
clearance in children would limit the application of the semi-physiological developmental 
glucuronidation model to UGT2B7 substrates with these properties in a population 
modeling approach. However, assuming that changes in the physicochemical properties 
of drugs do not influence drug uptake or efflux by hepatocytes or the interaction of the 
drug molecule with the UGT2B7 isoenzyme, the molecular weight of hypothetical drugs 
did not influence drug glucuronidation, while the logP and pKa of the hypothetical 
drug molecule only influenced the absolute value of the drug glucuronidation clearance. 
The absolute value of the drug glucuronidation clearance is reflected in the value of a 
in equation 1, these results thereby further support the hypothesis that this is a drug-
specific constant. Since in a semi-physiological modeling approach for new UGT2B7 
substrates the value of this constant has to be estimated based on the population analysis 
of outcome measures, these results suggest that the semi-physiological developmental 
glucuronidation model can predict developmental changes in glucuronidation clearance 
of all small molecular substrates for UGT2B7.
 However, although results showed that the unbound drug concentration 
of hypothetical drugs in plasma is the main driver of the absolute value of drug 
glucuronidation, the Michaelis-Menten parameters were kept constant in all simulations 
with hypothetical drugs, in this case at the values used in the simulations for morphine. 
Michaelis-Menten parameters are major drivers of the absolute value of drug metabolism, 
but due to the non-linear correlation between substrate concentration and intrinsic 
drug clearance, interpretation of the results from simulations with varying Michaelis-
Menten constants is complex. These simulations were not performed in the current 
study, however such simulations are necessary to further investigate the applicability of 
the semi-physiological developmental glucuronidation model for drugs with saturable 
glucuronidation kinetics. 
 Additionally, the application of the semi-physiologically-based developmental 
glucuronidation model in scenarios of drugs with varying extraction ratios needs to be 
further investigated. The ontogeny of UGT isoenzymes may have a one to one effect on 
low extraction UGT substrates since in this case in vivo clearance closely reflects intrinsic 
clearance. High extraction UGT substrates on the other hand, may be affected less by an 
increased level in UGT activity as their clearance will be limited by hepatic blood flow. 
Morphine and zidovudine have similar extraction ratios of 0.5 and 0.65 respectively [43–45]. 
The influence of changes in the underlying physiological system is therefore expected 
to be rather similar for both drugs, which resulted in the same ranking of system-
specific parameters for both drugs in table II and the possibility to extrapolate the semi-
physiological developmental glucuronidation model between these drugs (Chapter 6). 
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explain why in table II the percentages change in morphine and zidovudine in vivo 
clearance as a result of the changes in the underlying system-specific parameters are not 
the same, and why the influence of hepatic blood flow is for example more pronounced 
for zidovudine than for morphine. It is expected that direct extrapolation of paediatric 
covariate models in a semi-physiological modelling approach between UGT2B7 
substrates is possible when both substrates that have similar extraction ratio’s, however 
extrapolation between drugs with different hepatic extraction ratio’s may require further 
deconvolution of the maturational changes in the underlying physiological processes.
5. Conclusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The current analysis illustrates that the key physiological driver of the maturation of 
UGT2B7-mediated hepatic morphine and zidovudine glucuronidation in children 
younger than three years, as quantified by the semi-physiological developmental 
glucuronidation model, are liver blood flow and ontogeny of UGT2B7 expression and 
function. The logP and pKa are two important physicochemical drug properties that 
influence the absolute value of the glucuronidation clearance, but not the maturation 
profile, with a strong correlation between the unbound drug fraction and the absolute 
clearance value for drugs with similar Michaelis-Menten parameters. The results of 
this study suggest that in patients with normal liver function, the ontogeny pattern in 
clearance of new UGT2B7 substrates in children under the age of three years can be 
predicted by the semi-physiological developmental glucuronidation model and that 
only the absolute clearance value of the new substrate needs to be estimated. The 
generalizability of the semi-physiological modelling concept to patients with reduced 
liver size or liver function and to scenarios with non-linear clearance or large differences 
in hepatic drug extraction rations requires further investigation. 
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Purpose: A framework for the evaluation of paediatric population models is proposed 
and applied to two different paediatric population pharmacokinetic models for 
morphine. One covariate model was based on a systematic covariate analysis, the other 
on fixed allometric scaling principles. 
Methods: The six evaluation criteria in the framework were 1) number of parameters 
and condition number, 2) numerical diagnostics, 3) prediction-based diagnostics, 4) 
η-shrinkage, 5) simulation-based diagnostics, 6) diagnostics of individual and population 
parameter estimates versus covariates, including measurements of bias and precision 
of the population values compared to the observed individual values. The framework 
entails both an internal and external model evaluation procedure.
Results: The application of the framework to the two models resulted in the detection 
of over-parameterization and misleading diagnostics based on individual predictions 
caused by high shrinkage. The diagnostic of individual and population parameter 
estimates versus covariates proved to be highly informative in assessing obtained 
covariate relationships. Based on the framework, the systematic covariate model proved 
to be superior over the fixed allometric model in terms of predictive performance.
Conclusions: The proposed framework is suitable for the evaluation of paediatric 
(covariate) models and should be applied to corroborate the descriptive and predictive 
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8.1 Introduction
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Whereas many diagnostic and validation tools are available for the evaluation of 
population models in the adult population, these tools may not always directly suffice 
in the paediatric population due to the heterogeneity of this special population and the 
scarcity of the datasets. In this study a framework including six evaluation criteria is 
presented for the systematic assessment of the descriptive and predictive properties of 
paediatric (covariate) models that takes these specific issues into consideration. 
 In paediatric population pharmacokinetic (PK) models, the influence of the 
many physiological changes that take place in the paediatric age-range are reflected 
in covariate relationships that are usually based on bodyweight and/or age. However, 
since bodyweight and age are naturally correlated in the paediatric population there is 
a debate on how to incorporate the influence of the physiological changes in paediatric 
population PK models. Bodyweight and age can either be regarded as regular covariates 
whose predictive properties on PK parameters are evaluated together with other 
covariates in a systematic covariate analysis by formally testing them for significance 
and only retaining them in the model if they statistically improve the model fit (Chapter 
3) [1,2]. Alternatively, bodyweight can be included a priori into paediatric PK models by 
the use of a bodyweight-based allometric equation with a fixed exponent of 0.75 for 
clearance and 1 for distribution volume. These equations can subsequently be augmented 
by estimated age-based functions of various forms [2–4].
In recent years two different population PK models for morphine and its 
two major pharmacologically active metabolites morphine-3-glucuronide (M3G) 
and morphine-6-glucuronide (M6G) in children younger than three years have been 
published (Chapter 3)[3]. The model by Knibbe et al. (Chapter 3) was developed using a 
systematic covariate analysis. The model by Bouwmeester et al. [3] was developed using 
fixed allometric scaling principles in conjunction with estimated age-based functions. As 
these models were developed using similar datasets, they provide both an example for 
the assessment of the developed framework for the evaluation of paediatric (covariate) 
models, as well as an opportunity to directly compare the performance of these two 
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8.2 Materials and Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8.2.1 Models and Data
Figure 1 shows a schematic representation of the two models that are evaluated in 
the current analysis. In the model by Knibbe et al. (Chapter 3) the maturation of the 
formation and elimination clearances of the morphine glucuronides was found to be 
best described by a bodyweight-based exponential equation with an estimated exponent 
of 1.44. Within this exponential equation the formation clearance of the glucuronides 
was found to be significantly reduced in neonates younger than ten days. Distribution 
volumes were estimated to scale linearly with bodyweight. This model will be referred 
to as the systematic covariate model. In the model by Bouwmeester et al. [3] bodyweight 
was included a priori using an allometric equation with fixed exponents of 0.75 for 
clearance and 1 for distribution volume. Three exponential equations based on postnatal 
age (PNA) augmented the model, one equation for distribution volumes, one for the 
formation of the morphine metabolites and one for the elimination of the metabolites. 
Bilirubin concentration and creatinine concentrations were also incorporated to the 
model as covariates for the formation and elimination of the glucuronides respectively. 
This model will be referred to as the fixed allometric model.
Figure 1. Schematic representation of the systematic covariate model (Chapter 3) (A) and the fixed 
allometric model [3] (B). M = morphine, M3G = morphine-3-glucuronide, M6G = morphine-6-glucuronide, 
V = distribution volume of the designated compartment, Cl = clearance of designated route, Q = 
intercompartimental clearance, PNA = postnatal age, k and m = exponential scaling constants, β = fraction 
below adult values at birth and T = maturation half-life for distribution volume (vol), formation clearance 
of the metabolites (cl), and elimination clearance of the metabolites (rf), C = plasma concentration and K = 
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The systematic covariate model (Knibbe et al. (Chapter 3)) was developed using 
two datasets [5,6], while the fixed allometric model (Bouwmeester et al. [3]) was developed 
using only one of these two datasets [5]. To allow for a direct comparison, the systematic 
covariate model was refit with the data from the one common dataset. This dataset will 
be referred to as the internal dataset of this study and consists of postoperative term 
neonates, infants and children up to the age of three years on a continuous or intermitted 
intravenous morphine regimen [5]. 
For the external evaluation of the two paediatric covariate models in the current 
analysis, five previously published datasets [6–10] were used. These external datasets 
included the same patient population as the internal dataset with the exception that their 
PNA ranged up to only one year instead of three years. In addition, two external datasets 
included preterm neonates [6][7], which is a younger age-range than the age-range in the 
internal dataset [5] used for model building. An overview of all datasets is given in table I.
Table I. Overview of the internal dataset (Int.1) and the external datasets (Ext.1-5) used for model building 
and external model evaluation.
 
Dataset Patient Population Number of Patients




Int.1. [5] Post-operative term neonates, infants and children. 183 97 (8 – 286)
4700 (3100 – 8000)
Ext.1. [8] Post-operative term neonates and infants 28 14 (0 – 70) 3100 (2550 – 4000)
Ext.2. [9] Post-operative term neonates and infants 9 10.5 (3 – 135) 3800 (3000 - 5000)
Ext.3. [10] Term neonates and infants on artificial ventilation 12 13 (6 – 80)
3050 (2675 – 6900) 
Ext.4. [6] Preterm and term neonates on artificial ventilation 63 0.4 (0.2 – 0.5) 1180 (862.5 – 1760)
Ext.5. [7] Preterm neonates on artificial ventilation 41 1 (1 – 2)
1035 (892.5 – 1295)
Int. = internal dataset, Ext. = external dataset, M = morphine, M3G = morphine-3-glucuronide, M6G = 
morphine-6-glucuronide
8.2.2 Model Evaluation
All model fitting and model-based simulations in the current study were performed 
using NONMEM VI (ICON, Ellicott City, MD).
The framework for the evaluation of paediatric population models is composed of the 
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1) total number of parameters and condition number of the model. The latter was 
obtained by taking the ratio of the largest and smallest eigenvalue of the covariance 
matrix of the estimate from the NONMEM output.
2)  numerical diagnostics by means of a bootstrap analysis using the PsN software 
package [11]. One hundred datasets were resampled with replacement from the 
internal dataset and refit to the models. The parameter estimates for fixed and 
random effects obtained in every separate run were summarized in terms of mean 
and relative standard errors (RSE) for each parameter. Runs that did not minimize 
successfully were excluded from the analysis. 
3)  prediction-based diagnostics by means of basic goodness-of-fit plots. Both the 
individual and population predicted concentrations were plotted versus the 
concentrations that were actually observed in these datasets. Plots were made for 
both the internal and external datasets and for the population as a whole as well as 
for stratified subsets based on age (0-1 month, 1 month – 1 year, 1-3 years). Mirror 
plots were created to serve as a reference for these predicted versus observed plots 
[12].
4)  η-shrinkage as defined by Karlsson and Savic. [12] , which was calculated for all 
model parameters for which inter-individual variability was estimated. 
5)  simulation-based diagnostics by means of normalized prediction distribution 
errors (NPDE) [13]. Both the internal and merged external datasets were simulated 
1000 times with inclusion of the inter-individual variability and residual error. 
Using the NPDE add-on package for R (version 1.2) [14] a cumulative distribution 
was assembled for each observation with the 1000 simulated concentrations and 
subsequently the value of the cumulative distribution at the observed concentration 
was determined. An inverse function of the normal cumulative density function 
was then applied to these data to obtain what are called the normalize prediction 
distribution errors. The NPDEs are presented in a total distribution, versus time 
and versus the concentration. This analysis was also performed on the population 
as a whole and on the stratified subsets described in item 3.
6)  Individual and population parameter estimates versus the most predictive 
covariate in the model. In both models, bodyweight was the most predictive 
covariate. Total morphine clearance was defined as the sum of Cl1 and Cl2 for the 
systematic covariate model (see figure 1A) and of Cl0, Cl1, and Cl2 for the fixed 
allometric model (see figure 1B). The elimination clearances of the metabolites 
(Cl3 and Cl4) and the distribution volume of the central morphine compartment 
(V1) were directly compared between the two models. To numerically quantify 
the bias and precision of the model predicted parameter values compared to the 
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equation 1) and the Root Mean Square Error (RMSE, equation 2) were calculated 
respectively for both models.
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Table II. Parameter estimates from the model fit, number of model parameters and parameter estimates from 
the bootstrap procedure for the systematic covariate model (A) and for the fixed allometric model (B) obtained 






(98 out of 100 successful)
Value (RSE%) Mean value (RSE%)
Fixed effects (n=10)
k = exponential scaling factor on 
clearance 1.49 (3.6) 1.49 (3.42)
m = exponential scaling factor on 
distribution volume 1 fixed 1 fixed
Cl1 PNA < 10 d (ml/min/kgk) 3.68 (9.0) 3.68 (8.15)
Cl1 PNA > 10d (ml/min/kgk) 8.04 (11.0) 8.01 (10.1)
Cl2 PNA < 10d (ml/min/kgk) 0.423 (11.1) 0.42 (14.4)
Cl2 PNA >10d (ml/min/kgk) 0.623 (10.2) 0.62 (13.0)
Cl3 (ml/min/kgk) 1.84 (9.9) 1.85 (9.73)
Cl4 (ml/min/kgk) 0.955 (9.0) 0.95 (12.6)
Qeq (ml/min) 40.8 (24.1) 43.8 (42.7)
V1 = V4 (l/kg) 1.64 (8.2) 1.65 (9.44)
V2 = V3 (fraction of V1) 0.157 (21.2) 0.161 (27.0)
Inter-individual variability (n=5)
ω2 Cl1 0.0809 (24.0) 0.0774 (22.9)
ω2 Cl3 0.256 (27.1) 0.263 (29.1)
ω2 Cl4 0.110 (15.2) 0.110 (15.5)
ω2 Cl3-Cl4 covariance 0.128 (18.2) 0.126 (19.8)
ω2 V1 0.162 (17.9) 0.168 (20.7)
Residual variance (n=3)
σ2, prop (morphine) 0.440 (14.7) 0.431 (14.0)
σ2, prop (M3G) 0.261 (27.2) 0.243 (26.0)














































(46 out of 100 successful)
Value (RSE%) Value (RSE%)
Fixed effects (n=14)
Cl0 (l/h/70kg0.75) 3.12 (117) 2.59 (43.4)
Cl1 (l/h/70kg0.75) 64.3 (18.0) 55.2 (32.3)
Cl2 (l/h/70kg0.75) 3.63 (14.0) 3.99 (65.6)
Cl3 (l/h/70kg0.75) 17.4 (16.0) 7.23 (38.0)
Cl4 (l/h/70kg0.75) 5.8 (20.2) 5.43 (23.4)
V1 (l/70kg) 136 (59.3) 147 (34.9)
V2 (l/70kg) 23 fixed 23 fixed
V3 (l/70kg) 30 fixed 30 fixed
Βcl 0.834 (6.41) 0.894 (8.35)
Tcl (days) 88.3 (37.4) 65.2 (176)
Βrf 0.832 (9.74) 0.814 (10.7)
Trf (days) 129 (49.8) 136 (45.4)
Βvol 0.391 (28.4) 0.388 (38.1)
Tvol (days) 26.3 (72.2) 26.7 (58.9)
Kage 0.0141 (140) 0.0201 (36.3)
Kbili -0.00203 (33.2) -0.00207 (35.3)
Inter-individual variability (n=16)
ω2 Cl0 1.37 (104) 1.80 (69.9)
ω2 Cl1 0.346 (20.9) 0.916 (74.9)
ω2 Cl2 0.675 (29.3) 1.21 (75.8)
ω2 Cl3 0.185 (20.8) 0.764 (41.7)
ω2 Cl4 0.545 (32.1) 1.39 (87.6)
ω2 V1 0.351 (29.1) 1.54 (121)
full omega block on all eta’s except Cl0 Data not shown Data not shown
Residual variance (n=5)
σ2, prop morphine 0.128 (11.6) 0.503 (105)
σ2, add M3G (ng/ml) 50.3 (36.2) 136 (217)
σ2, prop M3G 0.118 (27.0) 2.21 (80.0)
σ2, add M6G (ng/ml) 0.198 (26.0) 1.31 (148)
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In tables II A and B the parameter estimates obtained with the bootstrap analyses are 
presented as well. The parameter estimates of the bootstrap deviated more from the 
values obtained in the initial model fit for the fixed allometric model compared to the 
systematic covariate model. For both the model fit and the bootstrap procedure with the 
fixed allometric model, the overall precision of the parameter estimates was lower than 
the systematic covariate model as expressed by the higher relative standard error (RSE) 
of the parameter estimates. Additionally, for the bootstrap, using the fixed allometric 
model only 46 out of 100 model refits minimized successfully, whereas 98 out of 100 
model refits successfully minimized using the systematic covariate model.
Figure 2 shows the individual predicted concentrations versus observed concentrations 
for morphine and its metabolites as obtained with the internal dataset for both the 
systematic covariate model (A) and the fixed allometric model (B). This figure shows 
a slightly better description of individual concentrations by the fixed allometric model 
compared to the systematic covariate model, especially for the mother compound 
morphine. 
Figure 3 shows the population predicted concentrations versus observed 
concentrations obtained with the internal as well as the five external datasets. This figure 
shows the systematic covariate model to be superior over the fixed allometric model 
in the predictions of population concentrations in the datasets. The predictions for the 
systematic covariate model are only slightly biased and since this bias is also observed 
in the mirror plots (data not shown) this is not indicative of model misspecification. For 
the fixed allometric model on the other hand significant bias towards under-prediction 
can be observed, that did not correspond to trends observed in the mirror plots (data not 
shown). 
 For both models, stratification of the plots of the predicted versus observed 
concentrations into the different age-groups showed no differences in model performance 
(data not shown).
Table III shows the percentage of η-shrinkage for the parameters for which inter-
individual variability was identified in each of the two models. Both models have 
parameters for which shrinkage is relatively high (>20%), indicating that the individual 
data in the internal dataset is not rich in information about these parameters. 
Table III. Percentage η-shrinkage in both models for the parameters for which inter-individual variability 
was identified.
Cl0 Cl1 Cl2 Cl3 Cl4 V1
Systematic covariate model (%) - 29.6 - 8.26 5.76 30.3
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For both models the results of the NPDE analysis with the internal dataset are depicted 
in figure 4. For the systematic covariate model no trends in time or concentration are 
observed and the mean of the distribution of NPDEs is close to 0 while the variance is 
slightly lower than 1. The trends observed in the plots for the fixed allometric model are 
indicative of an under-prediction, which appears to be relatively constant over time but 
to increase with decreasing concentrations.
The results of the NPDE analysis with the external datasets confirmed the results 
obtained with the internal dataset for both models (data not shown). Stratification into 
different age-groups also revealed similar results for the three age-groups for each of the 
models (data not shown).
The plots of the individual post hoc parameter estimates and population predicted 
parameter estimates for total morphine clearance, the clearances of the metabolites 
and distribution volume of the central morphine compartment versus bodyweight for 
both models are shown in figure 5. For the systematic covariate model, total morphine 
clearance is composed of Cl1 and Cl2 (see figure 1A) which both have different population 
values for children older and younger than ten days resulting in two different lines of 
population parameter estimates. For the fixed allometric model, total morphine clearance 
is composed of Cl0, Cl1 and Cl2 (see figure 1B). The larger number of additional covariates 
(age, and bilirubin and creatinine concentration) on the structural parameters in the fixed 
allometric model results in scattered lines for the population parameter estimates of this 
model. This figure shows that for the systematic covariate model the population predicted 
values describe the individual post hoc values without bias for all parameters, whereas 
for the fixed allometric model the population predicted values are biased compared to 
the individual post hoc values for all parameters.
Table IV numerically quantifies the bias (MPE) in the population predicted 
parameter values compared to the individually observed parameter values for both 
models. The RMSE in this table quantifies the precision of the population prediction. 
It can be seen that for the systematic covariate model, mean bias in the population 
predictions stays well below 25% and remains relatively constant over the age-ranges for 
all parameters. For the fixed allometric model, bias in the population predictions reaches 
up to 250% and especially in the clearance of the metabolites an increasing trend towards 
over-prediction is observed with increasing age.
Table V shows the mean bias and precision in the predictions of the model 
parameters in the external dataset stratified in three age-groups. As can be expected, for 
both models the bias in the parameter predictions of the external datasets is generally 
larger than for the internal dataset, however for the systematic covariate model it still 
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Table IV. Bias (MPE) and precision (RMSE) of the predicted parameter values in the internal datasets 
stratified by age-group.
parameter Age-group
Systematic covariate model Fixed allometric model
MPE RMSE MPE RMSE
Total morphine 
clearance
neonates* 4.26 0.426 10.8 0.922
toddlers† -0.74 1.65 12.7 5.00
infants‡ 4.63 3.28 -2.56 7.90
M3G clearance
neonates* 19.7 0.291 -19.5 2.50
toddlers† 1.85 0.888 23.8 15.5
infants‡ 14.5 3.82 188 9.03
M6G clearance
neonates* 12.5 0.0784 -69.0 0.825
toddlers† 0.262 0.230 100 5.27





neonates* 23.2 1.30 90.6 2.93
toddlers† 15.9 3.43 22.4 7.26
infants‡ 5.90 9.27 9.35 13.4
MPE = mean prediction error, RMSE = root mean square error, 
* neonates, PNA<30 days, n= 61, 
† toddlers, PNA=1 month-1 year,  n= 87, 
‡ infants, PNA>1 year n= 35
Table V. Bias (MPE) and precision (RMSE) of the predicted parameter values in the external datasets 
stratified by age-group.
parameter age-group
systematic covariate model fixed allometric model




neonates* 17.4 0.0667 192 0.444
term neonates† 29.74 0.274 85.5 3.91
toddlers‡ 29.3 1.64 -26.6 4.22
M3G clearance
preterm 
neonates* -16.3 0.102 114 0.225
term neonates† 31.0 0.463 108 0.928
toddlers‡ 5.48 0.818 172 1.34
M6G clearance
preterm 
neonates* -12.5 0.0447 46.8 0.779
term neonates† 35.6 0.0818 31.1 0.502






neonates* -12.9 0.945 -115 1.46
term neonates† -10.3 2.03 -296 3.50
toddlers‡ 3.45 3.47 -93.1 3.22
MPE = mean prediction error, RMSE = root mean square error
* preterm neonates, (PNA < 30 days and PMA at birth < 36 weeks), n=80 
† term neonates, (PNA < 30 days and PMA at birth ≥ 36 weeks), n=40 
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8.4 Discussion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
As in childhood many physiological changes take place in quick succession, the paediatric 
population is very heterogeneous. Additionally, studies in this population are often 
performed during routine clinical practice, which increases the variability in both dosing 
and sampling schemes, while due to limitations in sample size and frequency often only 
sparse data are obtained. All these factors influence the evaluation of population and 
covariate models for this young population. In the current study a framework of six 
different evaluation criteria is proposed for the evaluation of paediatric models. Most 
tools in the framework are not necessarily new, but in the context of paediatric model 
evaluation adaptations to the standard methods are sometimes required or a shift in 
emphasize on the various tools is essential.
As an example, two previously published paediatric population PK models for 
morphine that were based on the same dataset but fundamentally different covariate 
models, were evaluated with this framework. The systematic covariate model was 
developed by regarding bodyweight and age as regular covariates in a systematic 
covariate analysis (Chapter 3). The fixed allometric model was based on allometric 
principles including bodyweight a priori using exponential functions with fixed 
exponents and estimating an age-based function [3].  
In itself the number of parameters in a model is not an evaluation criterion, however 
according to the rule of parsimony a model should have the lowest possible number of 
parameters. Large deviations of bootstrap parameter values from the original value, low 
precision in parameter estimates as expressed by high RSE values in the model fit and 
bootstrap procedures, small number of successful bootstrap runs and a condition number 
higher than 1000 are all generally indicative of model inaccuracy, model instability, and ill-
conditioning [15–18]. Testing covariates for significance and only retaining a covariate when 
it significantly improves the model adheres to the rule of parsimony, does not introduce 
specific assumptions into the model, and the resulting model is always supported by 
data. In the current example, it is shown that the systematic covariate model performs 
well on all the criteria of ill-conditioning. In case covariates in a model are not formally 
tested for significance there is a risk of over-parameterization. The results for the fixed 
allometric model in this example suggest the fixed allometric model to be an unstable 
model for which precise parameter estimates cannot be obtained. It should also be noted 
in this respect that with the increased number of fixed and random model parameters 
in the fixed allometric model, the degrees of freedom in this model are increased as 
well. More degrees of freedom improve the description of data by a model, but do not 
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As stated before, paediatric PK analyses are often based on sparse data. This is an 
important aspect to consider when evaluating paediatric population PK models, because 
when data are uninformative due to the scarcity of the data, the estimated variability 
parameters may shrink to zero causing the individual post hoc parameter estimates 
to move towards the population predictions. This shrinkage phenomenon makes 
individual parameter estimates and the diagnostics based on them less reliable or even 
misleading [12,19]. Population predictions however, are solely based on the fixed effects 
described in the structural and covariate model. As the random effects are not considered 
in the population predictions, diagnostics based on population predictions are not 
sensitive to shrinkage and therefore more reliable then diagnostics based on individual 
predictions. The two models in the current study illustrate how diagnostics based on 
individual predictions can be misleading when shrinkage is high, as, according to table 
III, was the case for some of the parameters in both models. The plots of the individual 
predicted versus observed concentrations in figure 2 inadvertently suggest the fixed 
allometric model to perform better than the systematic covariate model, since especially 
for morphine the data points are closer to the line of unity. However, in figure 3 large 
differences in the predictive performance between the two models are revealed for both 
the internal and external datasets when considering population predicted concentrations 
instead of the individual predicted concentrations. For the systematic covariate model 
there are no signs of model misspecification. The fixed allometric model on the other 
hand shows significant bias towards under-prediction throughout the total concentration 
range. Since diagnostics based on population predictions are generally more reliable, 
these should always be included in the evaluation of paediatric (covariate) models.
Simulation-based diagnostics known as posterior predictive checks (PPC) are diagnostics 
that create a reference distribution of an observation of interest by performing multiple 
model simulations with inclusion of both fixed and random effects and subsequently 
compare the actual observations to this reference distribution [20]. A visual predictive 
check (VPC) is a commonly used and easily interpretable form of a PPC that graphically 
presents the reference distribution and observed data [21]. A VPC can be used for the 
evaluation of paediatric models as well, however when data are obtained during routine 
clinical practice and variability in individual dosing and sampling schemes are high, 
the NPDE methodology [13] is often easier to perform and interpret. Shrinkage does not 
influence the results of simulation-based diagnostics [12]. The results of the NPDE analysis 
of the models in the current example demonstrate that the systematic covariate model 
can quite accurately predict median concentrations for morphine and the glucuronides, 
but that it slightly over-predicts the variability in the overall dataset. This over-prediction 
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were to be used in simulation exercises the predictions would be unbiased and the 
inferences made on the variability in the population would be on the conservative side 
as the variability is predicted to be higher than it actually is. Based on the trend towards 
under-prediction by fixed allometric model, it can be concluded that significant bias in 
the predictions would occur if this model would be used in simulation exercises. The 
under-prediction of concentrations by the fixed allometric model increases the risk of 
overdosing when deriving morphine doses based on this model. These NPDE results 
substantiate the results obtained in the population predicted versus observed plots in 
figure 3.
Due to the heterogeneity in the paediatric population it is very important to not 
only perform diagnostics on the population as a whole, but to also look at various 
subpopulations by stratifying the datasets based on bodyweight or age. 
 For both models in the example, stratification showed the same descriptive and 
predictive performance in all age-groups. For the systematic covariate model the predictive 
performance of the model was adequate in all age-ranges. The trends towards under-
prediction identified for the fixed allometric model was also similar across all age-ranges. 
Despite the fact that stratification of the diagnostics did not reveal new information in 
the current examples, this adjustment of the various validation tools remains imperative 
for the detection of previously unidentified age-related misspecifications.
To corroborate the obtained covariate relationships in paediatric models, the plots of 
individual and population parameter values versus the covariate presented here in figure 
5, together with a numerical representation of bias and precision in table IV, have proven 
to be highly informative. Even in case of high shrinkage this diagnostic will enable the 
identification of bias in the population predictions of parameters. In this study, in both 
models bodyweight was the most important covariate for clearances and distribution 
volumes. For the systematic covariate model, population predicted parameter values 
are adequately centred in the range of individual predicted values for all parameters 
and across the entire bodyweight- and age-range. However, for the fixed allometric 
model, the population predicted parameter values are biased compared to the individual 
predicted values. For some parameters this bias exists over the total weight and age-
range, for others only over part of these ranges. The results in the plots in figure 5 and 
table IV provide an explanation for the adequate individual concentration predictions by 
the fixed allometric model and the highly biased population predictions by this model, 
as observed with the other evaluation tools. Structural model misspecifications in the 
population parameter values result in biased population predictions that are corrected 
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ever published, however the information contained in these plots and tables is crucial 
and should become a standard diagnostic tool with paediatric population PK models.
Especially in drug development, population PK models in paediatric subpopulations 
are often used for extrapolations to younger age-ranges. When a model is used for 
this purpose, the obtained covariate relationships should be thoroughly evaluated, for 
instance by using the diagnostic in figure5 and table IV. In the current study, two out of 
five external datasets (Ext 4 and Ext 5) include preterm patients, a younger and smaller 
population than the population in the internal dataset. For both models the results of the 
various tools in the framework were similar irrespective of the age-range in the dataset 
that was used, indicating that the inclusion of a new patient population in the external 
validation did not influence the overall results
A systematic covariate analysis is a data driven approach, therefore the 
extrapolation potential of the resulting model cannot be known a priori. It is clear that for 
the systematic covariate model in the current analysis extrapolations to older (heavier) 
children is not possible as the bodyweight based exponential equation for clearance 
predicts rapidly increasing clearances at higher weight-ranges. Figure 5 indicates that for 
this model, population parameter predictions are unbiased in the lower weight-ranges, 
suggesting that extrapolation to smaller children could be possible. The extensive 
evaluation procedures in the current example prove this to be the case in this particular 
example.
It is claimed that the allometric equations used in the fixed allometric model 
are based on ‘sound biological principles’ [22] and that the methodology based on these 
equations therefore yields mechanistic models that can be used for extrapolations outside 
the studied age- or weight-range. It is argued that the influence of size (parameterized 
by bodyweight) and maturation (parameterized by age) on the parameters in paediatric 
population PK models are disentangled by using the fixed allometric equations 
augmented by age-based functions [4,23]. However, the theory of allometry is based on the 
empirical observation that over a wide weight-range, metabolic rates of animal species 
increase with bodyweight to the power of 0.75 [24]. The fixed allometric exponents have 
no biological or physiological meaning, although reports exist that propose possible 
physiological explanations [25–27]. Conversely, a large body of evidence exists against the 
existence of one unique value for the allometric clearance exponent [28–34] and against 
the application of these allometric equations in human paediatric PK models [35,36]. 
Additionally, the maturation function based on age, only reflects a mathematical residue 
of the age-effect that remains after the inclusion of the correlated covariate bodyweight. In 
the current study, in the fixed allometric model the model-predicted increase in clearance 
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this model can be used for extrapolations to higher weight-ranges. The prospective 
properties of this model in preterm neonates is however very poor, albeit comparable to 
the predictions in the older children that comprised the learning dataset. As a result, the 
extrapolation potential of fixed allometric models in general can neither be confirmed 
nor disputed based on the results in the current study. 
8.5 Conclusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The framework of six evaluation criteria proposed in the current study takes into 
consideration the specific issues encountered in the evaluation of paediatric population 
models. The application of this framework to two models for morphine and its two major 
metabolites in children younger than three years with fundamentally different covariate 
models demonstrates how to detect over-parameterization, which is a risk with models 
based on sparse data. Additionally it illustrates the importance of diagnostics that are 
based on population predictions rather than individual predictions, as high shrinkage 
due to sparse data may yield misleading individual prediction-based diagnostics. Finally, 
the diagnostic comparing population parameter predictions with individually observed 
parameter values proved to be highly informative in assessing obtained covariate 
relationships as in the current example it detected the cause of model misspecification by 
the fixed allometric model. Stratification of the various diagnostics did not yield much 
additional information in the current examples, however due to the heterogeneity of 
the paediatric population this adaption of standard validation tools may be of value for 
other paediatric models.
The differences observed in model performance between the systematic 
covariate model and the fixed allometric model in the current study do not imply that any 
of the two methodologies for covariate model development is superior over the other. 
The current study does however highlight the importance of corroborating results in 
evaluation procedures. It also illustrates that information in data should not be ignored 
and that one should never be guided by theories alone.
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Abstract
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The pharmacokinetics of morphine in paediatrics have been widely studied using 
different approaches and modeling techniques. In this review, we explore advantages 
and disadvantages of the different data analysis techniques that have been applied, with 
specific focus on the accuracy of morphine clearance predictions by reported paediatric 
pharmacokinetic models.
Twenty paediatric studies reported a wide range in morphine clearance values using 
traditional rather descriptive methods. Clearance values were expressed per kilogram 
bodyweight, while maturation in clearance was described by comparing mean clearance 
per kg bodyweight between age-stratified subgroups. Population modeling allows for 
the analysis of sparse data thereby limiting the burden to individual patients. Using 
this technique, continuous maturation profiles can be obtained on the basis of either 
fixed allometric scaling or comprehensive covariate analysis. While the models based 
on fixed allometric scaling resulted in complex maturation functions, all three paediatric 
population models for morphine yielded quite similar clearance predictions. The largest 
difference in clearance predictions between these three population models occurred in 
the first months of life, particularly in preterm neonates. Morphine clearance predictions 
by a physiologically-based pharmacokinetic model were based on many continuous 
equations describing changes in underlying physiological processes across the full 
paediatric age-range, and resulted in similar clearance predictions as well. Preterm 
neonates could however not be integrated in this model.
In conclusion, the value of paediatric pharmacokinetic models is mostly dependent 
on clearance predictions and population concentration predictions, rather than on 
the individual description of data. For most pharmacokinetic models however, the 
assessment of model performance was very limited and for only one model was the 
accuracy of morphine clearance predictions as well as population concentration 
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9.1 Background
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Dosing guidelines for children have originally been scaled from adult doses using 
functions related to body size (i.g. bodyweight). After years of clinical experience, these 
dosing guidelines are often formalized in (national) formularies. Research necessary 
to develop evidence-based, rather than consensus-based dosing algorithms for the 
paediatric population is complicated by practical, ethical, and legal constraints. However, 
advances in pharmacokinetic and pharmacodynamic analyses and the enormous 
increase in computing capacities of processors over the past few decades have opened 
up new possibilities in data analysis and data aggregation yielding novel opportunities 
for paediatric pharmacological investigations. 
Morphine is commonly prescribed for the paediatric population in hospital 
settings. Morphine clearance, its variability, and the maturation in this parameter have been 
extensively studied across the paediatric population. This has lead to the publication of a 
wide range of paediatric morphine clearance values, obtained with traditional methods 
as well as with the new computing-intensive modeling methodologies. Irrespective 
of the methodology used, reported clearance values should be representative for the 
studied population, because they provide the basis for paediatric dose adjustments and 
clinical decision making. Therefore, it is crucial that these values are both accurate and 
predictive for the next unstudied individual represented by the studied population. 
Morphine is predominantly eliminated through glucuronidation by UGT2B7 
[1–3], thus morphine clearance directly reflects the formation of its two major metabolites 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). The metabolites are 
cleared through renal elimination and reduced renal function may result in accumulation 
of the metabolites. Since M3G and M6G are considered to be pharmacologically active 
[4–6], the fate of the metabolites after formation through morphine glucuronidation of is of 
clinical importance. However, as only a limited number of publications have addressed 
the pharmacokinetics of the morphine metabolites in addition to the pharmacokinetics of 
morphine, the current review is limited to total morphine clearance.
In this review, reported paediatric morphine clearance values and the maturation 
in this parameter in the paediatric population are evaluated. Morphine clearance values 
obtained using the traditional methods will be discussed after which the focus will shift 
to results obtained with the more recent computing-intensive modeling approaches such 
as population pharmacokinetic modeling and physiologically-based pharmacokinetic 
modeling. General advantages and disadvantages of the different analysis approaches 
are explored and details of the different published pharmacokinetic morphine models 
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studied population, and thus the suitability of the models for simulation purposes for a 
population of patients with similar characteristics as the studied population, is assessed 
in particular. The assessment of the accuracy of model predictions is mainly based on 
the visual comparison of population concentration predictions versus clinically observed 
concentrations, while the accuracy of clearance predictions is based on the Mean 
Prediction Errors (MPE) of the population clearance values compared to individual 
clearances.  
9.2 Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Pubmed was searched in November 2011 for original research on morphine clearance 
in the paediatric population. The search was limited to the last 20 years, including 
publications from January 1991 onwards. The following key words were used: ‘morphine 
clearance’, ‘morphine metabolism’, ‘morphine glucuronidation’, ‘morphine elimination’, 
or ‘morphine pharmacokinetics’. Limits were set for age to include children between 
0 – 18 years. Case reports were excluded. Only studies with intravenous administration 
were selected, to avoid confounding issues with bioavailability in the reported clearance 
values. Since the pharmacokinetics of drugs in patients on extracorporeal membrane 
oxygenation (ECMO) may depend on various components of the ECMO circuit 
itself [7,8], studies in these patients were excluded as well. The obtained publications 
were categorized as analyzed according to 1) traditional methods, 2) population 
pharmacokinetic modeling, or 3) physiologically-based pharmacokinetic modeling.
9.3 Clearance Estimates Obtained With Traditional Methods
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9.3.1. Traditional Methods
Traditional methods to determine pharmacokinetic drug parameters in a population 
rely on firstly determining individual parameter values, using either compartmental or 
non-compartmental analysis techniques, after which each parameter is summarized as 
mean and standard deviation. As such, this yields for each pharmacokinetic parameter 
a point estimate (mean value) for the population and a measure of variability (standard 
deviation). This may be useful in early drug development, when data of a very 
limited number of patients are available. However, since intra-individual variability, 
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individual variability with this method, other methods are preferred to describe and 
quantify trends in a population when more data become available.
As the determination of individual drug clearance values with compartmental 
methods relies on densely sampled concentration-time profiles for each subject, 
this method may not always be feasible especially in the very young. Similarly, non-
compartmental methods may not be feasible as they rely either on the area under the 
concentration-time curve, which also requires dense sampling per individual, or on 
imprecise measurements of steady state concentrations. Using traditional methods, 
the maturation patterns in drug clearance are usually studied by expressing individual 
clearances per kilogram bodyweight, stratifying patients into age-groups, and comparing 
mean clearance values per kilogram bodyweight between the age-groups. This allows 
for easy comparisons between studies and between age groups, but this makes findings 
on maturation dependent on the stratification and precludes the development of 
continuous maturation profiles. Additionally, it assumes clearance to scale linearly with 
bodyweight within the age-groups, which may be a practical approximation when the 
range in bodyweight within each stratum is small, but it may not accurately reflect the 
underlying physiological changes across the entire human life-span.
9.3.2. Morphine Clearance Determined With Traditional Methods.
Table I provides an overview of paediatric morphine clearance values obtained with 
traditional methods. The reported morphine clearance values in neonates with a 
postnatal age from 0 – 30 days range from about 0.58 ml/min/kg [9] to about 16 ml/
min/kg [19], which is more than a twenty-fold difference. In infants aged 1 month to 1 
year,  morphine clearances were reported to range between 7.8 ml/min/kg [16] to 69.4 
ml/min/kg [19,20], while in children from 1 to 18 years the range in morphine clearance 
was reported to vary from about 12 ml/min/kg [23] to about 60 ml/min/kg [27]. The wide 
ranges in reported clearance values within each age-group may in part be explained by 
the differences between studies in terms of patient characteristics, sampling schemes 
or dosing schemes, but are probably mainly caused by the relative imprecision of the 
applied data analysis methods. Additionally, most studies are based on a relatively small 
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Table I. Overview of paediatric morphine clearance values reported over the past 20 years, obtained with 
traditional methods.








term ischemic neonates 
(normotherm) < 6 hr 3.3 (2.4 – 4.0)
a 6 0.89 (0.65-1.33)a 
Róka, et al. 
2008 [9]term ischemic neonates  
(hypotherm) < 6 hr 3.4 (2.5 – 4.0)
a 10 0.69 (0.58 – 1.2)a 
preterm neonates on 
artificial ventilation < 24 hr 1.3 ± 0.38
c 9 2.4b Hartley et al. 1993 [10]
term and preterm 
neonates on artificial 
ventilation 
< 24 hr 1.3 (0.77 – 4.0)a 31 2.4 ± 1.1c Saarenmaa et al. 2000 [11]
term and preterm 
neonates on artificial 
ventilation 
1 – 2 d 1.4 ± 0.6c 19




0.46 ± 0.32 c
Barrett et al. 
1996 [12]
preterm and term 
neonates on artificial 
ventilation 
1 – 4 d 2.6 (1.3 – 3.6)a 19 2.55 ± 1.65
c 
2.09 ± 1.19c
Chay et al. 
1992 [13]
preterm neonates 1 – 18 d 1.1 (0.6 – 1.6)a 8 2.82 (1.88 – 6.60)a Mikkelsen et 
al. 1994 [14]term neonates 1 – 18 d 3.4 (2.3 – 4.0)a 5 4.73 (1.75 – 6.61)a
preterm neonates on 
artificial ventilation 1 – 37 d 0.88 – 1.46
d 26 3.6  ± 0.9c Barrett et al. 1991 [15]
preterm neonates
1.1 ± 0.3b wk 
GA 26.6 ± 0.7b 
wk
birth weight 
1.0 ± 0.17c 10 2.27 ± 1.07
c
Scott et al. 
1999 [16]
1.3 ± 0.6b wk
GA 29.5 ± 1.3b 
wk
birth weight 
1.4 ± 0.24c 16 3.21 ± 1.57
c
6.1 ± 9.1b wk 
GA 32.5 ± 1.6b 
wk
birth weight 
2.1 ± 0.41c 15 4.51 ± 1.97
c
16.4 ± 31.6b wk 
GA 35.4 ± 4.8b 
wk
birth weight 





1 – 7 d - 10 8.7 ± 5.8c
Pokela et al. 
1993 [17]8 – 60 d - 10 11.9 ± 5.1
 c
61 – 180 d - 7 28.0 ± 8.9c 
term neonates and 
infants on artificial 
ventilation 
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postoperative term 
neonates and infants, 
non-cardiac surgery
1 – 7 d 
7.3 ± 5.0c
10 9.8 ( 6.3 – 16)a 
Lynn et al. 
2000 [19] 
8 – 30 d 4 13.3 
31 – 90 d 14 23.9 (16.7 – 33.3)a 
91 – 180 d 25 32.3 (18.5 – 52.1)a 
181 – 365 d  30 38.1 (18 – 69.4)a 
postoperative term 
neonates and infants, 
non-cardiac surgery
1 – 7 d
6.6 ± 2.0c
4 9.2 (6.3 – 10.4)a
Lynn et al. 
1998 [20]
31 – 90 d 6 25.3 (21.7 – 33.3)a
91 – 180 d 6 31.0 (18.9 – 59.5)a
181 – 380 d 10 48.9 (34.7 – 69.4)a
postoperative patients, 
non-cardiac surgery 3 – 12 mo 8.1 ± 1.0
c 6 19.8 ± 5.9c Haberkern et al. 1996 [21]
postoperative term 
neonates and infants
1 – 7 d 3.2 (2.5 – 3.6)a 9 5.5 (3.2 – 8.4)a
McRorie et al. 
1992 [22]
8 – 30 d 3.9 (3.2 – 4.6)a 5 7.4 (3.4 – 13.8)a
31 – 90 d 4.3 (3.5 – 5.2)a 7 10.5 (9.8 – 20.1)a
91 – 180 d 5.1 (4.3 – 8)a 11 13.9 (8.3 – 24.1)a
181 d – 2.5 y 7.2 (5.5 – 13.8)a 17 21.7 (5.8 – 28.6)a
post-operative patients, 
cardiac surgery 8 mo – 7 yr - 21 19.2 ± 7.0
c Dagan et al. 
1993 [23]
patients with leukemia 1.4 – 15.9 yr 20.0 (9.3 – 54.5)a 17 35
b [ml/min] Hain et al. 1999 [24]
patients with cancer 2.6 – 16.42 yr 32.4 ± 21.4c 7 24.8b Mashayekhi et al. 2009 [25]
patients with sickle cell 
disease 5 – 17 yr 34.6 ± 7.6





patients with sickle cell 
disease 6 – 19 yr - 18










11 40.4 ± 10c 
Robieux et al. 
1992 [28]
pubertal 
children 5 37.1 ± 9
c
post-pubertal 
children 8 28.0 ± 11
c
a median (range), b mean, c mean ± SD, d range  
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9.4 Clearance Estimates Obtained With Population Modeling
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9.4.1. Population Modeling
Increases in computing power now allow for the analysis of concentration-
time measurements from a population as a whole while considering individuals as 
constituents of this population. This method is called population or non-linear mixed 
effects modeling. As long as data are sufficiently informative, population modeling can 
be used for the analysis of dense, sparse, and/or unbalanced data. This is especially 
beneficial for the vulnerable paediatric population as it allows for the analysis of a limited 
number of blood samples per patient and for the analysis of data obtained during routine 
clinical practice. Additionally, it may allow for the meta-analysis of data from multiple 
studies with different designs, thereby reducing the burden for individual paediatric 
patients. A proper covariate analysis does however require information on the same set 
of covariates in each individual dataset. Since data from various sources can be analyzed 
simultaneously, the precision of the findings may also increase.
Population modeling can also distinguish inter-individual variability from intra-
individual variability, measurement error, and model misspecification. By identifying 
which patient characteristics (e.g. age, bodyweight, gender, race, genetics, disease status) 
are predictors of the inter-individual variability in model parameters, trends in the 
population can be identified and quantified. These predictors are known as covariates 
and the relationship between a covariate and a model parameter is known as covariate 
relationship. Typically, population pharmacokinetic modeling relies on outcome measures 
and information on covariates. Concentration data for pharmacokinetic models can be 
obtained relatively easily from blood samples. Covariate relationships in the population 
models generally include patient information that can be obtained from medical records or 
from routine clinical measurements. An important feature of population pharmacokinetic 
modelling is that it allows for the identification of continuous maturation profiles 
that do not depend on stratifications and that, when pharmacodynamic relationships 
remain constant with age, the covariate relationships describing this maturation can be 
directly used as the basis of evidence-based dosing algorithms. Since steady state drug 
concentrations are solely dependent on drug clearance and peak concentrations heavily 
dependent on distribution volume, the covariate relationships for these parameters can 
be directly incorporated in the algorithms of paediatric maintenance or loading doses 
respectively. However, since the use of sparse data may increase the risk of drawing 
wrong conclusions, population models require an advanced level of evaluation and 
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One of the approaches that can be applied for paediatric population covariate modeling 
is fixed allometric scaling [30]. Using this approach, bodyweight is included a priori in the 
model as a covariate on clearance (Cl) according to the following allometric equation:
 5
One of the approaches that can be applied for paediatric population covariate modeling is 
fixed allometric scaling 
[30]
. Using this approach, bodyweight is included a priori in the 




in which BWi is the bodyweight of the individual paediatric patient in kg, that is 
normalized to an average adult bodyweight of 70 kg and the value of the exponent b is 
fixed to 0.75 for clearance. The value of a that represents the magnitude of clearance in 
adults, is estimated. This fixed allometric equation describes the influence of changes in 
body size on drug clearance and on average predicts paediatric drug clearances with a fair 
degree of accuracy in children older than five years 
[31]
. In younger children the 
allometric equation is augmented with an age-based function called ‘maturation model’, 
to describe the remaining influence of developmental changes on drug clearance. 
Additional covariate relationships that reflect the influence of altered function of 
elimination organs (i.e. liver or kidneys) may be incorporated as well 
[30]
.  
The fixed allometric scaling approach is frequently applied, despite theoretical 
and data-driven studies challenging the hypothesis that the allometric equations 
accurately describe the influence of body size on pharmacokinetic processes 
[32–39]
. 
Additionally, with the inclusion of bodyweight, part of the influence of age is included as 
well, due to the strong correlation between bodyweight and age in the paediatric 
population. This makes the maturation model a mathematical residue of the influence of 
age that remains after the inclusion of the correlated covariate bodyweight, rather than a 
descriptor of maturation per se. Moreover, since bodyweight and age are included 
without formal testing for significance, there is a risk of over-parameterizing the models, 
leading to imprecise parameter estimates. Finally, special attention is required for the 
interpretation of these models. Due to the separation of the influence of body size 
(expressed by bodyweight) and maturation (expressed by age), the statement that 
maturation is completed at a certain age does in this context not mean that absolute 
clearance has reached adult values, as body size is usually still increasing. 
Misinterpretation of such results can lead to over-dosing when used for paediatric dose 
adjustments, and therefore the expression of the pharmacokinetic parameters per 70 kg 
may be unwarranted particularly in neonates.  
 
Another approach in paediatric population pharmacokinetic modelling is the application 
of a comprehensive covariate analysis, in which all potential covariates for 
pharmacokinetic parameter are tested in various relationships and are included into the 
model based on statistical significance. This procedure can be used to identify 
demographic factors or co-morbidities that significantly influence drug clearance. In the 
paediatric population it can also be used to identify covariate relationships that describe 
functional maturational changes in drug clearance 
[40]
. The paediatric covariate 
relationships, are usually based on bodyweight, age or a combination of both, and may 
vary in nature (e.g. exponential or linear). It should be noted however that these covariate 
relationship are empirical and that bodyweight or age should not be regarded as the 
drivers of the observed changes in drug pharmacokinetics, but as surrogate descriptors of 
the net changes in the underlying physiological system. The descriptive nature of these 
covariate relationships explicitly precludes extrapolations outside the covariate range in 
the learning dataset. 
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co-morbidities that significantly influence drug clearance. In the paediatric population it 
can also be used to identify covariate relationships that describe functional maturational 
changes in drug clearance [40]. The paediatric covariate relationships, are usually based 
on bodyweight, age or a combination of both, and may vary in nature (e.g. exponential 
or linear). It should be noted however that these covariate relationship are empirical and 
that bodyweight or age should not be regarded as the drivers of the observed changes in 
drug pharmacokinetics, but as surrogate descriptors of the net changes in the underlying 
physiological system. The descriptive nature of these covariate relationships explicitly 
precludes extrapolations outside the covariate range in the learning dataset.
9.4.2 Morphine Clearance Determined With Population Modeling 
9.4.2.1. Bouwmeester et al. (2004)
The model by Bouwmeester et al. [41] comprises morphine as well as its two main 
metabolites M3G and M6G. The model is based on data from 184 term neonates to infants 
up to the age of three years from Van Dijk et al. [42]. 
The Bouwemeester-model was developed using fixed allometric scaling 
principles described in section 9.4.1. The maturation model for the formation of morphine 
glucuronides was an exponential model based on postnatal age and serum bilirubin 
concentrations were included as a covariate on morphine glucuronidation. The set of 
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Cl ⋅=  
In these equations, Cltot is total morphine clearance in l/ h, ClM3G and ClM6G are the 
formation clearance of M3G and M6G in l/ h, and ClR is the residual clearance through 
alternative pathways in l/ h. BWi is the bodyweight of the individual paediatric patient in 
kg, PNA is the postnatal age in days, and Cbili is the serum bilirubin concentration in 
mol/l. Total morphine clearance is 71.1 l/h/70kg0.75, and from the maturation model it 
can be derived that the adult value of morphine glucuronidation is reached between the 
age of 6 to 12 months. Absolute morphine glucuronidation is however still increasing 
after that age, as a result of changes in bodyweight, which is described by the allometric 
function.  
Model performance was corroborated by plots of the ratio of observed and 
individual morphine and metabolite concentrations versus time, which showed limited 
bias. Results of other diagnostics, in particular plots of population predicted 
concentrations versus observed concentrations, were not reported. More recently, this 
model s been evaluated by our group using both the learning dataset and external 
datasets (Chapter 8). With a condition number of 10698 the model was shown to be over-
parameterized, resulting in imprecise parameter estimates that caused the bootstrapped 
parameter value for a number of parameters to deviate more than 10% from the originally 
reported values. Plots of predicted concentrations versus observed concentrations 
revealed accurate individual concentration predictions, suggesting that morphine 
concentrations can be described accurately when at least one observation per individual is 
available, although high shrinkage values render the diagnostics based on individual 
predictions to be potentially misleading. Population concentration predictions were found 
to be biased. This suggests that model-based concentration predictions based on age, 
weight, and bilirubin concentrations of a child alone are inaccurate. Additionally, 
simulation-based diagnostic showed bias towards over-prediction of morphine 
concentrations in the population as a whole. The cause of this bias was diagnosed to 
originate from structural model misspecification, since plots of individual and population 
In these equations, Cltot is total morphine clearance in l/h, ClM3G and ClM6G are the formation 
clearance of M3G and M6G in l/h, and ClR is the residual clearance through alternative 
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is the postnatal age in days, and Cbili is the serum bilirubin concentration in μmol/l. Total 
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that the adult value of morphine glucuronidation is reached bet een the age of 6 to 12 
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Model performance was corroborated by plots of the ratio of observed and 
individual morphine and metabolite concentrations versus time, which showed limited 
bias. Results of other diagnostics, in particular plots of population predicted concentrations 
versus observed concentrations, were not reported. More recently, this model has been 
evaluated by our group using both the learning dataset and external datasets (Chapter 
8). With a condition number of 10698 the model was shown to be over-parameterized, 
resulting in imprecise parameter estimates that caused the bootstrapped parameter 
value for a number of parameters to deviate more than 10% from the originally reported 
values. Plots of predicted concentrations versus observed concentrations revealed 
accurate individual concentration predictions, suggesting that morphine concentrations 
can be described accurately when at least one observation per individual is available, 
although high shrinkage values render the diagnostics based on individual predictions 
to be potentially misleading. Population concentration predictions were found to be 
biased. This suggests that model-based concentration predictions based on age, weight, 
and bilirubin concentrations of a child alone are inaccurate. Additionally, simulation-
based diagnostic showed bias towards over-prediction of morphine concentrations in the 
population as a whole. The cause of this bias was diagnosed to originate from structural 
model misspecification, since plots of individual and population parameter estimates 
versus the primary covariate bodyweight revealed that the covariate relationships 
describe the maturational changes in model parameters with bias, which was reflected in 
MPEs for the predictions of total morphine clearance in the external dataset of 86% and 
-27% in term neonates and toddlers respectively. A claimed advantage of the application 
of fixed allometric scaling principles is that it allows for predictions outside the studied 
age-range, however clearance predictions in preterm neonates were found to have an 
MPE of 192% (Chapter 8), while clearance predictions in older children have never been 
assessed. 
9.4.2.2. Anand et al. (2008)
The population pharmacokinetic model by Anand et al. [43] was based on morphine 
concentrations obtained from 875 preterm neonates as well as on the data from the 
184 term neonates and infants from Van Dijk et al. [42] that were previously analyzed 
by Bouwmeester et al.. The pharmacologically active morphine metabolites were not 
included in this model.
 The Anand-model continued to build on the concepts introduced in the 
publication by Bouwmeester et al. Fixed allometric scaling was augmented by a 
maturation model, in which the best fit was obtained with a sigmoidal model based 
on postmenstrual age, compared to an exponential model. Covariates based on organ 
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but a scaling factor to adjust morphine clearance in preterm neonates in comparison to 
term neonates was included. There is some ambiguity on which parameter this fraction 
for preterm neonates is applied, as both the standard adult value of morphine clearance 
and the postmenstrual age at which half the allometric adult value of morphine clearance 
is reached, are mentioned. Most probably, the preterm factor was applied to the standard 
value of morphine clearance, indicating that morphine clearance in preterm neonates is 
61% of the clearance in term neonates. This reduction remains constant throughout the 
full age-range described in the model. The equations below show how total paediatric 
morphine clearance is described by the Anand-model:
 7
parameter estimates versus the primary covariate bodyweight revealed that the covariate 
relationships describe the maturational changes in model parameters with bias, which was 
reflected in MPEs for the predictions of total morphine clearance in the external dataset 
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assessed (Chapter 8).  
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In these equations, Cltot,term and Cltot,preterm represent total morphine clearance in l/h in 
term and preterm patients, respectively, BWi is the bodyweight of the individual 
paediatric patient in kg, and PMA is the postmenstrual age in weeks. According to the 
maturation model, half the standard adult value of morphine clearance is reached at a 
postmenstrual age of 54 weeks. Around the postnatal age of one year, the influence of the 
maturation models becomes negligible, after which the increase in absolute clearance is 
described solely by bodyweight in the allometric equation. 
In terms of model evaluation and validation procedures, diagnostics based on 
individual as well as population concentration predictions are reported, although due to 
their layout it is difficult to assess the accuracy of the predictions from these plots. No 
other results on model evaluation and validation were reported. The Anand-model was 
further evaluated by Mahmood using external data 
[44]
. The MPE in total morphine 
clearance ranged between 8% in preterm neonates, 19% in term neonates, and 21% in 
In these equations, Cltot,term and Cltot,preterm represent total morphine clearance in l/h in term 
and preterm patients, respectively, BWi is the bodyweight of the individual paediatric 
patient in kg, and PMA is the postmenstrual age in weeks. According to the maturation 
model, half the standard adult value of morphine clearance is reached at a postmenstrual 
age of 54 weeks. Around the postnatal age of one year, the influence of the maturation 
models becomes negligible, after which the increase in absolute clearance is described 
solely by bodyweight in the allometric equation.
In terms of model evaluation and validation procedures, diagnostics based on 
individual as well as population concentration predictions are reported, although due 
to their layout it is difficult to assess the accuracy of the predictions from these plots. 
No other results on model evaluation and validation were reported. The Anand-model 
was further evaluated by Mahmood using external data [44]. The MPE in total morphine 
clearance ranged between 8% in preterm neonates, 19% in term neonates, and 21% in 
toddlers between one week and two months of age, while the MPE was 1.5% in toddlers 
between two to ten months of age. The MPE in clearance predictions in children between 
the age of 3 to 5 years, which was older than the age-range in internal dataset, was 17%. 
9.4.2.3. Knibbe et al. (2009)
The model by Knibbe et al. (Chapter 3) was also based on data from the 184 term neonates 
and infants of Van Dijk et al. [42]. Additionally data from Simons et al. on 64 preterm and 









































Prediction of Morphine Clearance in the Paediatric Population  |  211
but a scaling factor to adjust morphine clearance in preterm neonates in comparison to 
term neonates was included. There is some ambiguity on which parameter this fraction 
for preterm neonates is applied, as both the standard adult value of morphine clearance 
and the postmenstrual age at which half the allometric adult value of morphine clearance 
is reached, are mentioned. Most probably, the preterm factor was applied to the standard 
value of morphine clearance, indicating that morphine clearance in preterm neonates is 
61% of the clearance in term neonates. This reduction remains constant throughout the 
full age-range described in the model. The equations below show how total paediatric 
morphine clearance is described by the Anand-model:
 7
parameter estimates versus the primary covariate bodyweight revealed that the covariate 
relationships describe the maturational changes in model parameters with bias, which was 
reflected in MPEs for the predictions of total morphine clearance in the external dataset 
of 86% and -27% in term neonates and toddlers respectively. A claimed advantage of the 
application of fixed allometric scaling principles is that it allows for predictions outside 
the studied age-range, however clearance predictions in preterm neonates were found to 
have an MPE of 192%, while clearance predictions in older children have never been 
assessed (Chapter 8).  
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In these equations, Cltot,term and Cltot,preterm represent total morphine clearance in l/h in 
term and preterm patients, respectively, BWi is the bodyweight of the individual 
paediatric patient in kg, and PMA is the postmenstrual age in weeks. According to the 
maturation model, half the standard adult value of morphine clearance is reached at a 
postmenstrual age of 54 weeks. Around the postnatal age of one year, the influence of the 
maturation models becomes negligible, after which the increase in absolute clearance is 
described solely by bodyweight in the allometric equation. 
In terms of model evaluation and validation procedures, diagnostics based on 
individual as well as population concentration predictions are reported, although due to 
their layout it is difficult to assess the accuracy of the predictions from these plots. No 
other results on model evaluation and validation were reported. The Anand-model was 
further evaluated by Mahmood using external data 
[44]
. The MPE in total morphine 
clearance ranged between 8% in preterm neonates, 19% in term neonates, and 21% in 
In these equations, Cltot,term and Cltot,preterm represent total morphine clearance in l/h in term 
and preterm patients, respectively, BWi is the bodyweight of the individual paediatric 
patient in kg, and PMA is the postmenstrual age in weeks. According to the maturation 
model, half the standard adult value of morphine clearance is reached at a postmenstrual 
age of 54 weeks. Around the postnatal age of one year, the influence of the maturation 
models becomes negligible, after which the increase in absolute clearance is described 
solely by bodyweight in the allometric equation.
In terms of model evaluation and validation procedures, diagnostics based on 
individual as well as population concentration predictions are reported, although due 
to their layout it is difficult to assess the accuracy of the predictions from these plots. 
No other results on model evaluation and validation were reported. The Anand-model 
was further evaluated by Mahmood using external data [44]. The MPE in total morphine 
clearance ranged between 8% in preterm neonates, 19% in term neonates, and 21% in 
toddlers between one week and two months of age, while the MPE was 1.5% in toddlers 
between two to ten months of age. The MPE in clearance predictions in children between 
the age of 3 to 5 years, which was older than the age-range in internal dataset, was 17%. 
9.4.2.3. Knibbe et al. (2009)
The model by Knibbe et al. (Chapter 3) was also based on data from the 184 term neonates 
and infants of Van Dijk et al. [42]. Additionally data from Simons et al. on 64 preterm and 
term neonates [45] were added. Both morphine and its main metabolites were included in 
the model.
Model development of the Knibbe-model was based on a comprehensive 
covariate analysis. Bodyweight, bodyweight at birth, body surface area, sex, postnatal 
age, postmenstrual age, serum bilirubin concentration, creatinine clearance, mechanical 
ventilation, surgery versus non-surgery and type of surgery were investigated as 
potential covariates on clearance in equations of various forms. Differences in morphine 
glucuronidation were best described by a bodyweight-based exponential equation 
with an estimated exponent of 1.44. Within this equation the formation clearance of the 
morphine glucuronides was found to be reduced in neonates younger than ten days. 
This discontinuity did not result from stratification of the data, but from the observed 
differences in morphine clearance between young neonates and older patients after 
inclusion of the bodyweight-based covariate relationship. Compared to inclusion of age 
in a continuous relationship or to age cut-points at 3, 7, 14 or 21 days, inclusion of a 
discontinuity at the postnatal age of ten days provided the best mathematical description 
of this observed difference according to predefined statistical criteria. Physiologically a 
rapid but continuous change is however more probable. Clearance through pathways 
other than glucuronidation was found to be not significant and therefore not included in 
the model. The set of equations below shows how total morphine clearance is described 
by the Knibbe-model.
 8
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In these equations Cltot is total morphine clearance in ml/min, ClM3G and ClM6G are the 
formation clearance of M3G and M6G in ml/min with different values for neonates 
younger than 10 days and older patients, and BWi is the bodyweight of the individual 
paediatric patient in kg.  
The model was evaluated using various methods with the learning dataset and 
later also with external datasets (Chapter 4). With a condition number of 293 the model 
was found to be not over-parameterized, which resulted in precise parameter estimates 
causing the bootstrapped parameter values also to be within 10% of the originally 
reported value for all parameters. Plots of individual predicted morphine concentrations 
versus observed concentrations were minimally biased, although the value of diagnostics 
based on individual predictions is limited due to high shrinkage. Population predicted 
concentrations showed limited bias. Simulation-based diagnostics further confirmed that 
the model could accurately predict morphine concentrations based on bodyweight and 
age alone in children under the age of three years that, similar to the patients in the 
learning dataset had undergone major non-cardiac surgery or were mechanically 
In these equations Cltot is total morphine clearance in ml/min, ClM3G and ClM6G are the 
formation clearance of M3G and M6G in ml/min with different values for neonates 
younger than ten days and older patients, and BWi is the bodyweight of the individual 
paediatric patient in kg. 
The model was evaluated using various methods with the learning dataset and 
later also with external datasets (Chapter 4). With a condition number of 293 the model 
was found to be not over-parameterized, which resulted in precise parameter estimates 
causing the bootstrapped parameter values also to be within 10% of the originally 
reported value for all parameters. Plots of individual predicted morphine concentrations 
versus observed concentrations were minimally biased, although the value of diagnostics 
based o  individual predictions is limited due to high shrinkage. P pulation predicted 
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ventilated. Additionally, it was confirmed that covariate relationships describe individual 
parameter values accurately, with MPEs for total morphine clearance in the external 
datasets of 17% for preterm neonates and 30% for term neonates and toddlers (Chapter 
4). The exponential increase in morphine clearance with bodyweight explicitly precludes 
this model from making clearance predictions in children older than three years.
Table II summarizes the details of the pharmacokinetic population models discussed 
above. For comparison, table III lists the absolute clearance values and clearance values 
per kg bodyweight for nine hypothetical patients, predicted by each of these three 
population models. The largest differences in predicted morphine clearance values 
between the models are observed at the extremes of the age-ranges of the models, with a 
difference of almost a factor 2 in the first month of life and around a 30% difference at the 
age of three years. Particularly large differences were found for preterm neonates aged 1 
day to 2 weeks, and term neonates aged 2 weeks.
Table III. Overview of morphine clearance predicted by the three population pharmacokinetic models for 
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9.5 Clearance Estimates Obtained With Physiologically-Based 
Pharmacokinetic Modeling
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9.5.1. Physiologically-Based Pharmacokinetic Modeling
In physiologically-based pharmacokinetic models, an exhaustive set of mathematical 
equations mechanistically describe and quantify the interaction between a drug molecule 
with specific physicochemical properties and the underlying physiological system. 
Additionally, interactions within the physiological system are described and quantified 
as well. These equations and the constants within these equations thereby aggregate 
compound-specific information with anatomical measurements and in vitro or in vivo 
physiological information. So while population modeling yields models for a specific 
drug in a specified population, physiologically-based models are more generalizable and 
non-specific for particular drugs. 
Physiologically-based pharmacokinetic models require a wider variety of 
information compared to population modeling. Some of this information may be 
difficult to obtain, but since a substantial part of this information relates to underlying 
(patho)physiological processes, rather than to specific drugs, this information needs to 
be obtained only once. With the current gaps in our knowledge on human physiology 
and maturation, years of research are still required to properly describe and quantify all 
physiological parameters and interactions. However, the influence of some parameters or 
interactions on the overall drug pharmacokinetics may be negligible and with the major 
physiological determinants of pharmacokinetic processes currently being well described, 
physiologically-based models have already been proven useful to make inferences about 
the changes in pharmacokinetics of drugs that have not yet been studied in a particular 
population [54–56]. The additional research in this area is successively refining these models 
or extending their application to special populations.
The paediatric population can be included into this approach by integrating 
information on maturational changes in the physiological system into the model. 
Maturation of drug clearance is not defined for specific drugs, but for specific elimination 
routes, like glomerular filtration or biotransformation through various phase I and phase 
II enzymes. As morphine is mainly eliminated through hepatic glucuronidation by the 
UGT2B7 isoenzyme [1–3] , information on ontogeny (i.e. expression and function) of this 
enzyme system is required, as well as maturational changes in liver size, hepatic blood 
flow and perfusion, plasma protein binding, and active hepatic transport mechanisms. As 
maturation profiles in physiologically-based pharmacokinetic models are established for 
all the underlying physiological changes, the developmental changes in pharmacokinetic 
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the determination of pharmacokinetic parameters for drugs with specific properties in 
individuals for which certain key demographics (e.g. bodyweight and age) are known, 
which may be helpful in the development of first-in-child doses. However, the net 
maturation profile of pharmacokinetic parameters in a population as a whole cannot be 
directly derived. This complicates the establishment of evidence-based dosing guidelines 
from physiologically-based pharmacokinetic models. 
5.2. Morphine Clearance Determined With Physiologically-Based 
Pharmacokinetic Modeling
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
9.5.2.1. Edginton et al. (2006)
The publication by Edginton et al. [56] is the only retrieved publication that compares overall 
in vivo morphine clearance predictions by a physiologically-based pharmacokinetic 
model to observed in vivo morphine clearances in the paediatric population. In the 
Edginton-model, hepatic UGT2B7 ontogeny profiles were derived from literature values 
of in vivo clearance as well as from in vitro determinations of enzyme activity for morphine 
and lorazepam. First, in vitro determinations of paediatric UGT2B7 enzyme activity 
were expressed as percentage of adult activity. This information was subsequently 
combined with maturational changes in the underlying physiological processes and 
in vivo adult morphine clearance values, to obtain model predicted in vivo paediatric 
clearance parameters. The in vivo maturation profile of morphine glucuronidation over 
the entire paediatric age-range was obtained by determining mean morphine clearance 
per kilogram of bodyweight at 17 distinct ages and generating a cubic spline of mean 
morphine clearance versus age. Available paediatric in vivo clearance values for morphine 
and lorazepam were used to further adjust the UGT2B7 ontogeny profile to provide the 
best visual fit of in vivo predicted drug clearances to the observed clearances. This yielded 
a bi-phasic maturation profile describing the net influence of underlying physiological 
changes on in vivo morphine clearance expressed per kilogram of bodyweight. 
 Optimization of the in vivo maturation profiles was based on visual improvement 
of how well the predicted profile described in vivo literature data, but this model fit was 
not numerically quantified. Age was selected as descriptor for the UGT2B7 ontogeny 
profile in the Edginton-model, but the ambiguity about how to quantify maturation in 
the first few days of life, especially comparing preterm and term neonates, could not be 
resolved. Therefore this model used one single clearance value for all premature neonates 
irrespective of postnatal or postmenstrual age. Additionally, since the maturation profile 
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age-ranges, the quality of model fit could not be assessed properly. In the manuscript, 
the predictive performances of the enzyme ontogeny models are tested on paediatric 
data from test compounds that are eliminated through multiple elimination pathways. 
However, this is not an ideal method to test the prediction of the clearance profiles of 
individual elimination routes. Alternatively, the UGT2B7 ontogeny profile was later 
used in a full physiologically-based pharmacokinetic model to assess the accuracy of 
morphine concentration predictions [55]. It was found that the predicted morphine 
concentrations were on average within a factor 2.06 from the observed value. However, 
in preterm neonates, a clear trend towards under-prediction of concentrations, and thus 
over-prediction of clearance, was observed.
9.6 Discussion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
Morphine pharmacokinetics has been widely studied in the paediatric population, with 
a relatively large amount of this research being performed in children in the first few 
days to months of life. The majority of traditional pharmacokinetic studies in section 3 
were performed in the younger age-ranges and the three population pharmacokinetic 
models in section 4 only included patients up to the age of three years. This is probably 
not only because most developmental changes occur in the early life-stages, but also 
because these very young patients are encountered most frequently in hospitals settings 
and paediatric intensive care units. Only the physiologically-based pharmacokinetic 
model in section 5 covers the entire paediatric age-range. 
As can be seen in table I, there is a twenty-fold difference in the reported morphine 
clearances by traditional methods in neonates which narrows down to about a three-fold 
difference in older children and adolescents. The predicted clearance values by the three 
population models fall within the range of morphine clearance values obtained with the 
traditional methods. When the three population models are compared, the difference in 
morphine clearance predictions is most prominent in preterm neonates (which were not 
included in the Bouwmeester model) and in patients in the first few months of life, as 
illustrated in table III. The morphine clearance predictions by the Edginton-model are in 
the same range as the other studies as well, but an explicit relationship describing the 
developmental changes in morphine clearance in the paediatric population is lacking 
as the maturation of underlying physiologically processes instead of clearance are 
quantified.
The three paediatric population pharmacokinetic models for morphine discussed 
in section 4, were assessed for the accuracy of both their population concentration 








































218  |  Chapter 9
which accurate concentration predictions were confirmed as bias in individual as well 
as population concentration predicted versus observed concentration plots was found 
to be minimal. Especially the Bouwmeester-model proved to have poor population 
concentration predictions, while the population concentration predictions by the Anand-
model were difficult to assess. With regards to MPEs of the population predictions 
of total morphine clearance, the error of the Bouwmeester model reached up to 85% 
(Chapter 8). For the Anand-model the MPE of total morphine clearance ranged between 
8% and 21% [44], while for the Knibbe-model this ranged between 17% and 30% (Chapter 
8). The MPEs reported for the Anand-model cannot be directly compared to the reported 
MPEs of the Bouwmeester-model and the Knibbe-model, as different external data were 
used as well as different age-ranges of the paediatric subsets and different methods to 
determine individual morphine clearances. These results however suggest the accuracy 
of total morphine clearance predictions by the Anand-model and the Knibbe-model to 
be in a similar range, despite the fact that the Anand-model was based on data from a 
larger number of preterm neonates than the Knibbe-model. This illustrates that model 
performance not only dependents on data density, but also on the quality of that data, 
showing that data should be obtained at time points that are informative for the various 
pharmacokinetic processes. 
Concerning the physiologically-based model by Edginton et al., the method to 
assess the model predictions was not quantitative and the visual tools were not optimal 
[56], making it difficult to assess the morphine clearance predictions by this model. 
However, morphine concentration predictions by this model were on average within a 
factor 2 from the observed value, which could be regarded acceptable for determining 
first-in-child doses or inter-drug scaling of new drugs in the paediatric population.
As biased clearance predictions can be harmful when used for paediatric dose 
adjustments or clinical decision making, we would like to emphasize that proper model 
evaluation and validation for all paediatric population pharmacokinetic models is of 
utmost importance. It should however be noted that most evaluation and validation 
procedure assess the accuracy of model predictions for a population as a whole. As 
mentioned by Mahmood [44], the inter-individual variability in paediatric morphine 
clearance is high, causing the prediction error in individual clearances to be high even 
with the most accurate population model. As a result, clinical monitoring is still important 
in paediatric patients on morphine treatment.
As illustrated in figure 1, population modeling and physiologically-based 
modeling approach the study of a drug’s pharmacokinetics from opposite perspectives, 
and are therefore often referred to as the ‘top-down’ and ‘bottom-up’ approach, 
respectively. Inherent to these different perspectives is a difference in the nature of 
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models require a vast amount of data, which is generalizable but may not always 
prove to significantly influence net pharmacokinetic parameters, while population 
pharmacokinetic models only allow for the quantification of rate limiting processes 
that are not always generalizable and have to be repeated for every new drug studied 
in every new population. Future endeavors in paediatric pharmacology will therefore 
benefit from using the physiological insight and generalizability of physiologically-
based models while restricting the focus to significant and rate limiting processes, as 
is done with population modeling. This will yield hybrid models that meet in-between 
the top-down and bottom-up approach and expedited paediatric model development 
(Chapter 6)[57]. 
Figure 1. Population pharmacokinetic modeling and physiologically-based pharmacokinetic modeling are 
often referred to as ‘top-down’ and ‘bottom-up’ approach respectively. Population modeling derives in vivo 
pharmacokinetic parameters from clinically observed drug concentrations, whereas physiologically-based 
modeling derives this information by aggregating physiochemical information of the drug with anatomical 
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One of the disadvantages of both population modeling and physiologically-
based modeling is that they require specialized software and skilled professionals to 
design studies and perform the analyses. Additionally, with the mathematical equations 
that describe and quantify maturational changes in clearance values in the paediatric 
population becoming more complex, reported clearance values also become more difficult 
to interpret and compare. Particularly, the use of fixed allometric scaling principles in 
combination with age-based maturation functions [30] results in a combined function 
of two highly non-linear relationships for the maturation of morphine clearance in the 
Bouwmeester- and Anand-model. Since the analysis of data generated in population 
pharmacokinetic studies often yield complex covariate relationships, evidence-based 
dosing algorithms also grow increasingly complex. As dosing algorithms should be 
as simple as possible, but not simpler, special attention is required to implement these 
regimens in clinical practice. This may require a closer involvement of the hospital 
pharmacist in patient care to optimize and individualize drug dosing and to avoid 
dosing errors [58]. 
To date, most paediatric pharmacological research has focuses on drug 
pharmacokinetics. This is because clearance is generally believed to be the main driver 
of required dose adjustments in the paediatric population [59]. When pharmacokinetic 
models are used to derive evidence-based paediatric dosing algorithms, it is implicitly 
assumed that the pharmacodynamics remain constant. This assumption is acceptable 
when: 1) pathophysiological processes are similar in adults and children, 2) the exposure-
effect relationship can be assumed independent of age based on the mechanism of action, 
and 3) the clinical endpoints for treatment are the same in both populations [57]. Morphine 
does not meet these criteria as the expression of the mu-opioid receptor may differ 
between age groups, and as the clinical endpoints for pain differ in adults and children. 
This implies that morphine pharmacodynamics needs to be studied as well, to establish 
age appropriate target concentrations. Future paediatric pharmacodynamic studies are 
therefore necessary to derive final dosing algorithms in this population that account for 
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9.7 Conclusion
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Traditional compartmental and non-compartmental analysis approaches, population 
modeling and physiologically-based pharmacokinetic modeling have been applied to 
study morphine clearance and the maturational changes in this parameter in the paediatric 
population. This has lead to a variety of reported values for paediatric morphine clearance 
and functions for the maturation profiles of this parameter. However, absolute predicted 
clearance values obtained with the different methods seem to be in good agreement, 
except in preterm and term born neonates and infants in the first three months of life. The 
predictive value of models is determined by accurate clearance predictions (quantified 
by MPE values) and concentration predictions (assessed in population predicted versus 
observed plots). The Knibbe-model was the only model for which accurate concentration 
predictions on the individual as well as population level were corroborated throughout 
the full age-range of the model and for both morphine and its metabolites. With regards 
to the prediction of total morphine clearance the Anand-model and Knibbe-model have 
similar accuracies, although the Anand-model did not include the pharmacologically-
active metabolites. 
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It is common practice for paediatricians to prescribe drug doses per kilogram bodyweight, 
while scientific evidence supporting these dose prescriptions are often lacking for the 
majority of drugs used in children. As a result the number of paediatric patients receiving 
at least one off-label or unlicensed drug ranges between 80% to 93% in neonatal intensive 
care units, between 36% to 100% in paediatric wards, and between 3.3% to 56% in non-
hospital settings [1]. There are many factors that may contribute to age-related changes in 
drug pharmacokinetics or drug pharmacodynamics [2,3]. It is imperative that these changes 
are taken into account when designing drug dosing algorithms for children, because 
although for most drugs clinical experience will in time lead to consensus-based dosing 
guidelines that reduce fatalities, suboptimal dosing algorithms may lead to unnecessary 
therapy failure or to adverse drug reactions resulting from overdosing. Recently, the need 
for optimizing paediatric drug therapy has been recognized by regulatory agencies as 
well. By introducing new legislation to encourage or compel paediatric pharmacological 
studies (e.g. Pediatric Rule (FDA – 1998), the Best Pharmaceuticals for Children Act 
(FDA – 2002), and the Paediatric Regulation (EMEA – 2007)), these agencies are now key 
players in the process of making paediatric drug dosing safer.
The research in the current thesis focuses on a novel model-based approach 
to develop drug dosing algorithms for the paediatric population by accounting for 
developmental changes in pharmacokinetics. Pharmacokinetic changes are believed 
to be a major cause of age-dependent differences in paediatric dose requirements [4], 
although in daily clinical practice not many clinicians are aware of this, as they are more 
concerned with pharmacodynamic endpoints. Specific focus in this thesis was on uridine 
5’-diphosphate glucuronosyltransferase (UGT) 2B7-mediated drug glucuronidation. 
Studies on developmental changes in pharmacokinetics often start in the adult 
population. Subsequently age-related changes in clearance are studied in different 
paediatric subpopulations with successively decreasing age-ranges, often with a 
limited number of patients per subpopulation. Alternatively, the research in this thesis 
started in children under the age of three years, with the inclusion of preterm and term 
neonates. This approach was chosen because the treatment of patients from this young 
population presents a major challenge. Specifically, these young children may require 
drug treatment, for instance after major surgery to correct major congenital anomalies, 
while numerous and profound physiological changes take place of which the influence 
on drug pharmacology is still largely unknown. Morphine and zidovudine are regularly 
prescribed for children and are both predominantly eliminated through UGT2B7-
mediated glucuronidation [5–7], these two compounds were therefore used as probes in 
the development of a population modeling approach and a semi-physiological modeling 
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This thesis started by discussing methods to study ontogeny of liver enzyme 
systems and reviewing results reported for the UGT enzymes in Section I. Subsequently, 
in Section II the developmental changes in morphine glucuronidation in preterm 
and term neonates up to three-year-old children were quantified using a population 
modeling approach. After corroborating the descriptive and predictive properties of 
this population model in internal and external validation procedures, the morphine 
dosing algorithm derived from this model was prospectively evaluated in terms of 
analgesic efficacy in a clinical trial. In Section III, a novel approach to develop paediatric 
population models used for optimized dosing regimens was explored using zidovudine. 
This novel approach is based on the concept that the pattern of developmental changes in 
clearance can be considered a system-specific property, which can be extrapolated from 
one drug to another, provided that these drugs share a common elimination pathway. 
Application of this concept may lead to a reduction of time and resources needed for 
paediatric model development. So far, this semi-physiological approach has only been 
applied to compounds with similar physicochemical properties. As a first step towards 
a more universal modeling concept, the utility of semi-physiological pharmacokinetic 
models towards the prediction of developmental changes in clearance was investigated 
using a physiologically-based pharmacokinetic model. Finally, Section IV focused 
on the evaluation and validation of paediatric population models. This is important 
since with sparse paediatric datasets there is an increased risk of drawing erroneous 
conclusions which may have far-reaching consequences. Commonly used diagnostic 
tools were found to not always suffice for the evaluation of paediatric models, due to 
specific patient and study characteristics in this population. Therefore, a framework was 
developed for the systematic evaluation of paediatric population models that takes these 
characteristics into account. Additionally, the level of scientific evidence supporting the 
predictive value of different published paediatric pharmacokinetic models for morphine 
was evaluated. 
10.1 Paediatric Morphine Glucuronidation Model for 
Individualized Dosing
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinically relevant inter-individual variability in glucuronidation clearance forms the 
basis of paediatric dose adjustments of UGT2B7 substrates. Therefore in vivo clearance of 
UGT2B7 substrates was selected as an endpoint in the studies of the current thesis. Such 
research is however complicated by a unique set of challenges with regards to ethical, 
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Since children cannot consent, it is unethical to perform studies in healthy 
children. Therefore paediatric studies are typically performed in patients that require 
medical treatment, which may increase the heterogeneity of the patient population due 
to differences in the nature and the severity of illness, while the polypharmacy in most 
of these patients may introduce drug-drug interactions. Practical constraints lay in the 
small blood volume of the paediatric patients especially in the very young, limiting 
the volume and number of blood samples that can be obtained from a single patient. 
Additionally, without an indwelling arterial line, arterial blood sampling for the sole 
purpose of pharmacokinetic studies is not allowed. This implies that blood sampling can 
often not adhere to a stringent design. Likewise drug dosing can often not adhere to a 
stringent design, as drug dosing may be clinically titrated to individual medical needs, 
which is guided by both efficacy and possible side effects.
In neonates, practical constraints with regards to limitations in obtainable 
blood volume can be overcome by advanced and sensitive analysis methods like LC-
MS or electrophoresis that can detect drug concentrations in low-volume samples [8,9]. 
Ethical issues with regards to invasive arterial blood sampling for pharmacokinetic 
measurements can be overcome by using scavenged samples (i.e. samples discarded 
from clinical specimens) [10], by developing methods to determine drug concentrations 
from dried blood spots [11], or by investigating the use of other biological matrices like 
for instance saliva [8]. In Section II, the issues with regards to the analysis of data from a 
heterogeneous population, with sparse observations per patient and irregular dosing and 
sampling times were overcome by using a population modeling approach. This approach 
not only allows for the analysis of sparse, dense and/or unbalanced data, it also allows 
for the identification and quantification of the sources of variability in a population, and 
more importantly for the identification of significant predictors of this variability, known 
as covariates [12]. As was shown for morphine in this thesis, covariate relationships 
describing the relationship between a predictor of variability (e.g. bodyweight) and a 
pharmacokinetic parameter like clearance can directly serve as the basis of drug dosing 
algorithms.
In Chapter 3 a population pharmacokinetic analysis was performed based on 
concentration-time data on morphine, morphine-3-glucuronide (M3G), and morphine-
6-glucuronide (M6G) obtained from 248 patients with sparse sampling per patients 
(on average 4 samples per patient). These samples were obtained from postoperative 
or mechanically ventilated preterm or term neonates to children up to the age of three 
years. The analysis revealed that in this young population the developmental changes 
in the pharmacokinetics of morphine are best described by bodyweight-based covariate 
relationships. Increases in formation and elimination clearances of the morphine 
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an exponent of 1.44. Within this exponential equation the formation of the metabolites 
was found to be reduced by approximately 50% in neonates with a postnatal age of 
less than ten days, which was independent from gestational age. The elimination of 
morphine through other pathways was found to be not statistically significantly different 
from zero throughout the entire population. The distribution volume of morphine and 
its metabolites increased linearly with bodyweight. From these covariate relationships 
it was derived that for children under the age of three years morphine IV maintenance 
doses are best dosed on the basis of μg/kg1.5/h with a 50% dose reduction in neonates 
younger than ten days, while IV loading doses and bolus doses are best dosed linearly 
with bodyweight. Model-based simulations indeed confirmed that similar morphine 
and metabolite concentrations would be obtained throughout this entire population with 
this dosing algorithm.
Although the novel model-derived dosing algorithm for morphine covers a 
relatively large age-range in early life, in which many physiological changes occur, like 
many other paediatric drug dosing guidelines it is limited to a specific age-range, in this 
case to preterm and term neonates up to three-year-old children. Due to the exponential 
increase at the higher extreme of the bodyweight-range, this algorithm cannot be used 
for extrapolations to older children. It would therefore be interesting to expand the 
morphine dataset to older paediatric patients up to adults, enabling quantification of 
the developmental changes in glucuronidation clearance over the entire paediatric age-
range. Recently, a bodyweight-dependent exponential covariate model was developed to 
scale propofol clearance from preterm neonates to adult patients with a single continuous 
covariate relationship [13]. This bodyweight-dependent exponential covariate model 
consists of a bodyweight-based allometric equation in which the exponent decreases 
in a sigmoidal fashion with bodyweight. Interestingly, the developmental changes in 
propofol clearance in early life were found to be best described with an exponent close to 
1.44, namely 1.35.The flexible nature of the bodyweight-dependent exponential covariate 
model, makes the model potentially useful for different elimination pathways like the 
UGT2B7-mediated glucuronidation of morphine. 
A single continuous function to describe developmental changes in drug 
glucuronidation would also yield a single dosing algorithm for the entire paediatric 
population. This would resolve issues concerning drug dosing in patients with 
characteristics close to the extremes of the range for which a specific dosing algorithm 
is defined and dosing errors arising from using an incorrect algorithm for a particular 
patient. For instance, when there are two different algorithms for patients younger than 
three years and for patients of three years and older, two different algorithms may be 
used for dosing in children around their third birthday, each leading to a different dose. 
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old patient using the algorithm for children of three years and older or vice versa. In 
daily practice, dosing errors from miscalculations of highly non-linear algorithms for a 
specific patient at the bedside, may be resolved by a close involvement of the hospital 
pharmacist in clinical practice [14] and the use of dosing tables (Chapter 5) or by the 
development of applications for smartphones or tablets [15,16] and the introduction of 
electronic prescription systems.
In Chapter 3, the descriptive and predictive properties of the developed paediatric 
morphine pharmacokinetic model were evaluated in an internal validation procedure, 
using the data that were used to develop the model. To further corroborate the predictive 
value of this model, extensive evaluation and validation procedures were performed 
in Chapter 4, using independent external data from preterm and term neonates up 
to infants of one year, from four different centers. In these procedures, the model was 
found to accurately predict morphine and metabolite concentrations based on dose, 
bodyweight, and age alone, in a population that, like the internal dataset, consisted of 
ventilated neonates and postoperative patients after major non-cardiac surgery. 
The paediatric pharmacokinetic morphine model developed in Chapter 3 
and dosing guidelines derived from this model should not be applied to other patient 
population until the accuracy of model predictions have been established in this 
population. Literature reports for instance suggest paediatric morphine pharmacokinetics 
to be affected by cardiac surgery [17,18]. These effects should therefore be further analyzed 
and quantified in a population analysis. Similarly, critical illness was found to severely 
reduce the CYP3A4-mediated clearance of midazolam [19], since it has not been established 
whether and how critical illness affects UGT-mediated drug clearance, caution is 
warranted when applying the paediatric morphine pharmacokinetics model and the 
model-derived dosing algorithm for this patient population. In Chapter 4, the model 
was shown to make accurate concentration predictions in neonates on extracorporeal 
membrane oxygenation (ECMO) treatment with continuous venovenous haemofiltration 
(CVVH). This is remarkable as the very invasive ECMO treatment had been shown to 
influence pharmacokinetic parameters of various drugs [20–23]. It is unlikely that ECMO 
does not influence pharmacokinetic parameters for morphine, in fact pharmacokinetic 
changes have been reported to occur for morphine in patients on ECMO treatment [24,25], 
but our results suggest that the various changes may have counteracting influences on 
the morphine and metabolite concentrations. This would imply that the model-derived 
dosing algorithm for morphine may also be advantageous for patients on ECMO 
treatment, which is being prospectively studied [26]. 
With the predictive performance of the paediatric morphine pharmacokinetic 
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morphine dosing algorithm was prospectively evaluated in postoperative patients 
in Chapter 5. According to this algorithm neonates younger than ten days received 
a morphine IV infusion of 2.5 μg/kg1.5/h, while older patients received 5 μg/kg1.5/h. 
Compared to a traditional dosing regimen of 10 μg/kg/h, the model-derived algorithm 
resulted in a 50% to 75% dose reduction in neonates younger than ten days, while children 
older than ten days and bodyweights of more than four kilograms received up to 150% 
of the traditional morphine dose. Based on the percentage of patients needing rescue 
medication, the reduced dose in young neonates proved to be efficacious, whereas in 
older children a relatively high need for rescue medication remained despite the increased 
dose for these patients. In both groups, for the patients that did require rescue medication 
the morphine rescue dose per kilogram bodyweight did however not significantly differ 
statistically. As the model-derived dosing algorithm corrects for age-related differences 
in morphine pharmacokinetics, yielding steady state plasma concentrations of about 10 
ng/ml in all patients, the observed age-related differences in the efficacy of the morphine 
regimen are likely the result of age-related differences in the distribution of morphine 
to its effect site or differences in the morphine pharmacodynamics. It can therefore be 
concluded, that adjusting the morphine dose to differences in the pharmacokinetics 
leads to significant improvements in paediatric morphine therapy as it reduces the risk 
of over-exposing young neonates and exposing older children to inefficacious doses. 
Future studies on the pharmacodynamics of morphine and its pharmacologically active 
metabolites in this patient population may further improve the dosing algorithm, by 
defining age-appropriate target concentrations.
 Morphine and its metabolites exert their pharmacological effect by binding to 
μ-opioid receptors in the brain. To reach this effect site the compounds need to pass 
the blood-brain barrier and diffuse through the brain tissue. Age-related changes in the 
functionality of the blood-brain barrier may cause age-related differences in effect site 
distribution, which may clinically manifest in differences in morphine efficacy. It has been 
demonstrated that multiple processes are involved in the transport of morphine across the 
blood-brain barrier. In addition to passive diffusion, this includes carrier mediated and 
active transport mechanisms. In a number of studies it has been shown that the passive 
diffusion of morphine across the blood-brain barrier is slow and that the capacity for 
active uptake is limited, while active efflux of morphine from the brain via P-glycoprotein 
is considerable [27]. As a result, the morphine concentrations in plasma and at the site 
of action are at best in dynamic equilibrium, which complicates the interpretation of 
plasma concentrations in terms of active therapeutic concentrations. In the developing 
brain the various barrier and transport functions mature at different rates [28], therefore it 
is not possible to describe a single maturation pattern for blood-brain barrier penetration 
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blood-brain barrier distribution cause the age-related differences in the morphine 
exposure-effect relationship observed in Chapter 5. It is in this respect important to note 
that blood-brain barrier functionality may also be compromised in patients with certain 
medical conditions like meningitis [29] or epilepsy / seizures [30]. On the other hand, the 
age-related differences in the response to morphine could be the result of differences in 
the sensitivity of the developing biological system to morphine and its metabolites or 
differences in the sensitivity of the developing physiological system to pain stimuli. This 
could be caused by changes in the organization of the central nervous system and the 
expression and differentiation of opioid receptors in the brain, or by changes in down-
stream signal transduction resulting from opioid receptor activation and the integration 
of this signaling pathway with the pathways that process pain [31].
 Pharmacodynamic studies on analgesics in children are associated with 
several methodological complexities. An important factor is that these studies require 
an age-appropriate endpoint to quantify pain. Measurements of pain and analgesia are 
complicated by the subjective nature of pain perception, therefore the gold standard for 
quantifying pain is self-report by means of a visual analogue scale (VAS) or numeric 
rating scale (NRS). In children between the age of four and twelve years a “faces pain 
scale” may be used [32,33], but in preverbal-verbal children under the age of three to four 
years self-report is not possible. The COMFORT-behaviour scale has been developed 
to assess postoperative pain in preverbal children up to the age of three years and 
this score has been extensively validated for this purpose [34] ,which showed that the 
pain intensity quantified the by behavioral items in COMFORT score are in agreement 
with pain intensity quantified from physiological measurements [35]. In addition to 
the COMFORT-behaviour scale, a wide range of other pain scoring instruments have 
been developed for preverbal patients. Most of these pain assessment scales rely on 
behavioral items, with facial expression, crying, and body movement included in most 
instruments [33,36–38]. So far no methods have been developed for the population modeling 
of a single endpoint (e.g. pain) using different quantification methods for that endpoint 
(e.g. different pain rating scales). This impedes the retrospective analysis of data from 
multiple centers that use different pain scores. To analyze developmental changes in 
the pharmacodynamics of analgesic drugs across the paediatric population, a validated 
biomarker that objectively quantifies pain in patients of all ages, is necessary. Potential 
biomarkers include cardiovascular, hormonal, or other physiological parameters, but 
hitherto no biomarker has been identified that can quantify pain, discriminate between 
pain and stress, anxiety or discomfort, and has an acceptable inter-individual variability 
[39–42]. As an alternative, the use of pain scoring instruments for the different paediatric 
subpopulations that all have the same scale (e.g. a range from 0 to 10) could be explored. 
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and maximum efficacy, to yield an optimal risk/benefit ratio. Neonates, especially 
premature neonates, can experience pain which may have both short-term and long-
term effects that could potentially be reversed by morphine [43–46]. Morphine exposure 
is however also associated with acute respiratory, gastro-intestinal, cardiovascular, 
and neurological side effects as well as the occurrence of tolerance, dependence and 
withdrawal. Additionally, animal and in vitro studies raised concerns about the long-term 
effects of exposure of the developing brain to morphine [46–48], which includes enhanced 
neuronal apoptosis [49–51]. Long-term follow-up studies however suggest the influence of 
any potential changes in the central nervous system of human neonates on behavior and 
performance to be small to negligible [52–54]. Nevertheless, studies are being performed to 
evaluate the efficacy of paracetamol or, in infants and children older than three months, 
non-steroidal anti-inflammatory drugs (NSAIDs) as alternative or adjuvant analgesic 
agents to opioids [55–58]. In addition to this, non-pharmacological interventions may also 
reduce (procedural) pain, distress, and opioid consumption in various clinical settings 
and should always be applied before pharmacological interventions. This may include 
none-nutritive sucking or administration of non-nutritive glucose, sucrose or other sweet 
tasting solutions, kangaroo care, holding, or parental presence, auditory or olfactory 
stimulation, swaddling or facilitated tucking, and reducing environmental stimuli [59–62], 
although except for non-nutritive sucrose administration the evidence supporting these 
non-pharmacological interventions is limited.
Conclusions and Recommendations:
• The maturation of morphine glucuronidation in the first three years of life is 
best described by a bodyweight-based exponential equation with an exponent 
of 1.44 and a 50% reduction in preterm neonates younger than ten days, which is 
independent from gestational age.
• A paediatric dosing algorithm that corrects for differences in morphine 
pharmacokinetics reduces the risk of over-exposing young neonates while also 
reducing suboptimal morphine exposure in older patients. 
• Extension of the current morphine pharmacokinetic study to include older 
children up to adults may yield a single continuous dosing algorithm that covers 
the entire paediatric age-range.
• Studies on morphine pharmacodynamics may further improve the dosing 
algorithm. A large number of validated pain assessment instruments in specific 
paediatric age-ranges are available for these studies, however uniform endpoints 
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• Alternative pharmacological and non-pharmacological methods to effectively treat 
pain while reducing opioid consumption should be considered and investigated 
to optimize the risk/benefit ratio of paediatric pain management.
10.2 Semi-Physiological Covariate Model for Paediatric 
Glucuronidation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
The approach used in section II to develop validated model-derived dosing 
algorithms that correct for developmental changes in the pharmacokinetics for each 
drug in every paediatric age-group, would require much time and resources. It was 
therefore explored to what extent the covariate relationship for UGT2B7-mediated 
glucuronidation of morphine could be regarded as descriptor of developmental changes 
in the underlying physiological system rather than as a specific descriptor of changes 
in the pharmacokinetics of morphine per se, and how this information could be used in 
population model development of other drugs.
In Chapter 6 the paediatric covariate model for morphine glucuronidation was 
directly incorporated into a population pharmacokinetic model for zidovudine, as both 
drugs are predominantly eliminated through the same pathway of UGT2B7-mediated 
glucuronidation. This yielded a model with descriptive and predictive properties that 
were similar to a reference model that was based on a comprehensive covariate analysis 
of the same dataset and that provided the statistically best description of the data 
according to predefined criteria. The proposed modeling approach in which paediatric 
covariate models are extrapolated between drugs that share a common elimination 
pathway combines population modeling with the mechanistic insight of physiologically-
based modeling. This approach was therefore called a semi-physiological modeling 
approach and the covariate model for UGT2B7-mediated glucuronidation clearance 
that was extrapolated from morphine to zidovudine was called a semi-physiological 
developmental glucuronidation model.
The findings in Chapter 6 support our hypothesis that paediatric covariate 
models describe system-specific rather than drug-specific properties. This would 
imply that the context of system-specific properties [63] can be extended to not only 
include static descriptors of the physiological system, but to also include age-related 
developmental changes in the physiological system in the paediatric population. This 
would mean that the developmental profile of clearance of a new drug in children can 
be predicted based on findings on a probe compound that is eliminated through the 
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however require further investigation. This approach has now been successfully applied 
to the glucuronidation of morphine and zidovudine in the current thesis as well as to the 
glomerular filtration of vancomycin and netilmicin [64], thereby supporting this approach 
for two drug eliminating pathways using compounds with similar physicochemical 
properties and extraction ratios. It should be further investigated how well this approach 
performs when extrapolating covariate models between drugs that have very different 
physicochemical properties and/or extraction ratios. Additionally, the applicability of 
this approach should be tested on drugs with non-linear pharmacokinetics or drugs that 
are eliminated through multiple pathways. 
The study described in Chapter 7 explored the physiological and physicochemical basis of 
the semi-physiological developmental glucuronidation model from Chapter 6. This was 
done to investigate whether the applicability of the semi-physiological developmental 
glucuronidation model was limited by specific patient or drug characteristics. For this, the 
influence of system-specific and drug-specific parameters on in vivo drug glucuronidation 
was quantified using physiologically-based modeling. The study illustrated that 
developmental changes in liver volume and UGT2B7 ontogeny, rather than the changes 
in milligram microsomal protein per gram of liver, hepatic blood flow or plasma protein 
binding, are the main drivers of the clinically observed developmental increases in drug 
glucuronidation in the first three years of life. This implies that the pharmacokinetics of 
drugs that are eliminated through UGT2B7-mediated glucuronidation may be affected 
in patients with hepatic dysfunction as a result of for instance virus associated hepatic 
disease. 
Bodyweight, which was identified as the main covariate for the developmental 
changes in morphine clearance in the population model developed in Chapter 3, should 
be regarded as a surrogate descriptor of the sum of all underlying changes in physiology 
instead of being regarded as the driver of the observed changes in glucuronidation 
clearance in mechanistic terms. In children under the age of three years, bodyweight is 
closely correlated with age. The evaluation procedure in Chapter 4 in premature neonates 
and neonates small for gestational age, proved bodyweight to be a better predictor of 
inter-individual variability of morphine glucuronidation than age in these patients. It 
remains to be investigated whether bodyweight is also the best descriptor of this inter-
individual variability in toddlers at the extremes of their age-appropriate weight-range 
(i.e. underweight / malnourished or overweight / obese toddlers).
The study in Chapter 7 also illustrated that, provided that changes in drug-
specific parameters do not influence the uptake of the drug into hepatocytes or the 
interaction of drug molecules with the UGT2B7 isoenzyme, physicochemical drug 
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not the pattern of developmental changes in glucuronidation clearance. This suggests 
that the semi-physiological modeling approach can be applied to all small molecular 
substrates of the UGT2B7 isoenzyme. 
Using currently available in vitro data on UGT2B7 enzyme kinetics, the 
physiologically-based model used in Chapter 7 yielded under-predictions for in vivo 
morphine and zidovudine clearances. This discrepancy may result from inaccuracies in 
the values of the in vitro enzyme kinetic parameters obtained from literature. Another 
factor may be the applied assumption that morphine and zidovudine are solely 
eliminated through UGT2B7-mediated clearance. The developmental profile of in vivo 
drug glucuronidation on the other hand was well predicted by the physiologically-
based model in Chapter 7 in infants and toddlers older than approximately two weeks. 
However, the predictions of developmental changes in glucuronidation clearance in 
term neonates in the first two weeks of life were less accurate. This could be explained 
by the fact that the UGT2B7 ontogeny profile in the physiologically-based model used 
in Chapter 7 increased linearly throughout childhood, while literature reports on in vitro 
studies showed a rapid increase in UGT2B7 expression and function in the first few 
weeks in life, which is also reflected in the clinical observations. Accurate prediction 
of clearance in the first few days of life has proven to be difficult with physiologically-
based models in general and predictions for preterm neonates are often not even possible 
with these models. For this purpose, prenatal and postnatal maturation processes in the 
various physiological parameters need better quantification. To improve the availability 
of liver and kidney samples for this purpose, it would be beneficial to always snap-freeze 
liver and kidney samples of diseased paediatric patients and obtain informed consent for 
such studies.
Physiologically-based models largely depend on reliable in vitro enzyme kinetic 
parameters. As reviewed in Chapter 2, in vitro methods to study ontogeny patterns of 
UGT isoenzymes use various endpoints that represent different parts of the physiological 
system. A number of factors contribute to differences in findings between studies on 
hepatic UGT ontogeny: 
1) Inter-individual variability in UGT enzyme expression and activity is high 
and influenced by numerous (patho)physiological [65,66] and experimental [65–69] 
conditions, while the limited availability of paediatric hepatic donor tissue 
prevents the accurate characterization of developmental changes and associated 
variability. 
2) The diversity of endpoints that can be studied may affect the conclusions on 
hepatic enzyme ontogeny. For instance, mRNA and protein expression for many 
UGT isoenzymes did not correlate well with the in vitro activity of the isoenzymes 
[70], possibly because post-translational modifications and interactions with other 
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3) Measured enzyme activity is never absolute nor generalizable, because the rates 
of biotransformation are non-linearly dependent on substrate concentrations 
and specific for a given enzyme-substrate combination. Additionally, substrate 
specificities of the UGT isoenzymes are broad and they may overlap, meaning 
that one isoform may glucuronidate a wide range of compounds and that one 
compound may be metabolized by multiple isoforms, limiting the availability of 
suitable isoenzyme specific substrates to investigate developmental changes in 
the activity of a single UGT isoenzyme. 
With respect to the UGT2B7 isoenzyme, as reviewed in Chapter 2, mRNA 
expression is undetectable in fetuses at a gestational age of 20 weeks, while UGT2B7 
mRNA expression was found to have reached adult values at a postnatal age of six months 
[70]. For UGT2B7 enzyme expression on the other hand, adult values were reached at a 
postnatal age between seven months and two years according to one study [70], or between 
the ages of 12 and 17 years according to another study [76]. Absolute in vitro activity of 
the UGT2B7 isoenzyme as measured on the basis of the rate of biotransformation of 
epirubicin, showed a small age-dependent increase throughout the total paediatric age-
range, with activity levels being lower than adult values in all age-ranges [76].
Due to the variability in study outcomes, incorporation of in vitro data on enzyme 
kinetics into physiologically-based models is not straightforward. Studies to obtain 
enzyme kinetic parameters can be based on microsomes or hepatocytes, with hepatocytes 
being the preferred experimental system. This is because the current protocols for studies 
in microsomes are optimized to study the activity of cytochrome P450 (CYP) enzymes 
rather than UGT activities [65]. Additionally, in hepatocytes the structural integrity, 
including drug-binding cell compartments, cell membranes and transporters, is still 
intact and co-factors are present at physiological concentrations thereby improving 
determination of physiologically relevant in vivo enzyme kinetic values. 
The proposed semi-physiological modeling approach in Chapter 6 combines concepts 
of physiologically-based pharmacokinetic modeling with population pharmacokinetic 
modeling. Future endeavors to predict developmental changes in drug metabolism 
could greatly benefit from a closer integration of these two approaches. Population 
pharmacokinetic modeling offers the advantage of obtaining the best possible 
description of the developmental changes in clearance based on outcome measures. 
As such, it allows for the quantification of net effects of all underlying physiological 
changes that contribute to the observed changes in clearance. This is usually expressed 
with a limited number of covariate relationships that can be directly used as the basis for 
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provides a detailed and generalizable description and quantification of the functioning of 
the physiological system and the interaction of drug molecules with this system. This can 
be of great benefit to make predictions for new drugs or drugs in new populations. Some 
of the parameters in physiologically-based models can be obtained with great accuracy 
from in vitro studies or physiological measurements, while others are more difficult to 
obtain experimentally. The combination of population modeling and physiologically-
based modeling may allow for the quantification and characterization of developmental 
changes of a limited number of parameters in a physiologically-based model, based on 
outcome measures. 
Conclusions and Recommendations:
• Proof-of-concept studies with a semi-physiological modeling approach for 
UGT2B7-mediated paediatric drug glucuronidation support the hypothesis that 
paediatric covariate models describe developmental changes in the physiological 
system and can be extrapolated between drugs that share a common elimination 
pathway.
• By applying physiologically-based pharmacokinetic modeling concepts, 
liver volume and UGT2B7 ontogeny were identified as the main drivers of 
developmental changes in in vivo UGT2B7-mediated drug glucuronidation in 
children younger than three years. 
• Bodyweight to the power 1.44 should be regarded a surrogate descriptor of 
the sum of all developmental changes in the underlying physiological system 
on drug glucuronidation in children. The descriptive value of this covariate in 
toddlers at the extremes of their age-appropriate bodyweight range needs further 
investigation.
• Physicochemical drug properties only influence the absolute value of in vivo 
glucuronidation clearance, not the maturation pattern. Therefore, the semi-
physiological modeling approach can be used to predict the developmental 
changes in the clearance of other UGT2B7 substrates.
• The proposed semi-physiological paediatric pharmacokinetic modeling 
approach is promising. Future studies to investigate to what extent this approach 
is universally applicable should focus on other elimination pathways, on 
extrapolations between drugs with different physicochemical drug properties, 
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10.3 Paediatric Model Evaluation
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
It has been recognized before that population models are often not adequately evaluated 
and validated, both for the adult and paediatric population [77,78]. Model misspecification 
could have far-reaching consequences when pharmacokinetic models are used as 
the basis for dosing algorithms in children. When paediatric covariate models are 
extrapolated to other compounds in a semi-physiological modeling approach these 
consequences are even perpetuated. During the evaluation and validation of the 
morphine pharmacokinetic model in Chapter 3 and Chapter 4 it was discovered that, 
due to some unique properties of paediatric datasets, the evaluation and validation of 
paediatric models requires special attention.
Chapter 8 identified how paediatric patient and study characteristics influence 
the structure of paediatric datasets. It was also shown how to deal with complexities arising 
from these data characteristics in the evaluation and validation of paediatric population 
models. Specific features of paediatric datasets are: the heterogeneity in developmental 
status of the patients, the high variation in drug dosing and blood sampling, and sparse 
and unbalanced sampling per patient. These features require validation procedures 
to be performed on age-stratified subsets of the data, the use of advanced validation 
methodologies and focus on population predictions rather than individual predictions. 
The framework for the validation of pediatric population pharmacokinetic models 
proposed in Chapter 8 takes these requirements into account. In addition a novel 
validation tool to investigate the accuracy of paediatric covariate relationship across the 
entire range in covariate values was also introduced. This framework is based on six 
diagnostics, which include 1) number of parameters and condition number, 2) numerical 
diagnostics, 3) prediction-based diagnostics, 4) η-shrinkage, 5) advanced simulation-
based diagnostics, 6) diagnostics of individual and population parameter estimates 
versus covariates. These diagnostics per se were not necessarily new, but were sometimes 
slightly adjusted (e.g. stratified) or required a shift in emphasis (e.g. focus on population 
predictions instead of individual predictions). The validation framework was applied to 
two paediatric population models for morphine in children younger than three years, 
which were based on the same dataset. This revealed that the proposed paediatric model 
validation framework can identify model over-parameterization, model instability and 
structural model misspecification leading to poor predictive model performance.
Model misspecification may lead to serious consequences when conclusions 
based on these models are used for clinical decision making. As peer-reviewed 
publications reach a large audience and may be considered to be accurate by this 
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publication without confirming their results with proper model evaluation and validation 
procedures as described in Chapter 8.
Morphine pharmacokinetics has been widely studied in the paediatric population. The 
reported morphine clearance values in children are reviewed in Chapter 9 with specific 
focus on model-based results. Since the results of Chapter 8 raised questions with regards 
to the accuracy of published pharmacokinetic models, special attention was paid to the 
evidence supporting the accuracy and precision of the pharmacokinetic predictions 
obtained with these models. Three population models in children younger than three 
years used different clearance parameterizations and expressions for the quantification 
of developmental changes in clearance. This mainly led to differences in clearance 
predictions in patients in the first few weeks of life. The three population models 
included the model developed in Chapter 3 of this thesis and two other models based on 
fixed allometric scaling principles [79,80]. Of these models, the model from Chapter 3 was 
the only model for which accurate concentration predictions on the individual as well 
as population level were corroborated throughout the full age-range of the model and 
for both morphine and its metabolites. With regards to the prediction of total morphine 
clearance this model had similar accuracies as the model by Anand et al. [80] , although 
the Anand-model did not include the pharmacologically-active metabolites. Moreover, 
serious model misspecification was reported for neonates by the third model (Chapter 
8). No adequate evaluation and validation was performed on the accuracy of morphine 
clearance predictions by a published physiologically-based pharmacokinetic model [81]. 
The results from Chapter 8 and Chapter 9 could suggest that population 
models based on fixed allometric scaling principles [82] generally have poor predictive 
performances. This is however not directly evident from these results, although the 
incorporation of covariates without formally testing them for significance does increase 
the risk of obtaining a model that is not supported by data. Provided that a model is 
supported by results from evaluation and validation procedures, results from paediatric 
population models that are based on fixed allometric scaling principles may be equally 
suitable for clinical decision making as any other properly validated model. For the 
research in the current thesis a comprehensive covariate modeling approach was 
applied rather than a fixed allometric scaling approach. This was based on a wide range 
of theoretical and experimental evidence against the application of allometric scaling 
with a universal fixed exponent of 0.75 in paediatric pharmacokinetics [83–90]. More 
recent publications on the development of population models with strongly correlated 
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The findings on developmental changes in drug glucuronidation in children obtained in 
the current thesis may appear to be very different from previous findings, but they are 
not. Morphine pharmacokinetics has been widely studied in the paediatric population 
using traditional methods for the analysis of in vivo data, which was reviewed amongst 
others in Chapter 2 and Chapter 9. In line with our findings, in vivo pharmacokinetic 
studies of morphine and its metabolites in literature also showed that preterm 
neonates with a gestational age as young as 24 weeks already metabolize morphine by 
glucuronidation [93]. In most published studies morphine clearance is parameterized 
per kilogram bodyweight and investigated in age-strata with a limited range. The thus 
reported morphine clearance values cover a wide range [18,94–100], with different studies 
reporting clearance to remain either constant [93,101,102] or to change with postconceptual 
age [103–106], postnatal age [17,107–111], or bodyweight [103,104,112]. However, figure 5 of Chapter 4 
illustrates how the highly non-linear covariate relationship for morphine glucuronidation 
clearance developed in the current thesis accurately describes the trend observed in 
reported morphine clearances over the entire age-range from preterm neonates to three 
year old children. Although the pharmacokinetics of zidovudine has been studied less 
extensively in children than morphine, literature findings on this drug are also in line 
with the findings on developmental changes in glucuronidation in the current thesis. 
Zidovudine clearance was shown to increase rapidly in the first two weeks of life. The 
subsequent increase in zidovudine clearance was reported to be slower, with studies 
reporting adult values to be reached within two months [113,114], while others reported a 
two year period of slower increase to be followed by an even slower increase to reach 
adult values in late adolescence [115]. 
Compared to the traditional methods, population model-based analysis 
approaches to study drug pharmacokinetics offer several advantages as discussed in 
Chapter 9. With population modeling each individual is regarded as constituent of the 
overall population. By analyzing the population as a whole, fewer samples per individual 
are required and the precision of findings may be improved as it is possible to simultaneous 
analyze data from multiple studies with different study designs, as long as detailed 
records are available on the exact time of drug dosing and blood sampling. Moreover, 
inter-individual variability can be distinguished from other sources of variability like 
intra-individual variability, measurement error and model misspecification. Descriptors 
that can explain (part of) the inter-individual variability can be identified and quantified 
in continuous relationships, without the need for stratification of the population based on 
age. One of the biggest advantages of the covariate relationships in population models is 
that they quantify the net changes in pharmacokinetic parameters that can directly serve 
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In conclusion, the approach described in Section II of this thesis should be the basis for 
the development of evidence-based paediatric dosing algorithms for off-patent drugs 
that are already regularly prescribed for children. This approach entails 1) population 
pharmacokinetic and/or pharmacodynamic model development which can be based on 
data from various (existing) sources, 2) internal and external model validation according 
to the framework developed in Chapter 8 to assess the predictive performance of the 
population model, and 3) a prospective clinical trial as proof-of-principle to confirm the 
efficacy and safety profile of the model-derived dosing algorithm. Although the broader 
applicability and generalizability of the semi-physiological modeling concepts proposed 
in Section III need further investigation, our initial results are promising and show that 
semi-physiological modeling could limit the time and resources needed for paediatric 
population model development. This approach could also be expanded to derive first-
in-child doses in the drug development process, based on in vitro and adult information 
on the elimination pathways of a new chemical entity.
Conclusion and recommendations:
• Proper model evaluation and validation based on appropriate tools should be a 
standard requirement for the publication of all population models.
• Patient and study characteristics in the paediatric population differ from the adult 
population and require special considerations in model evaluation and validation 
procedures that are taken into account in the framework developed in Chapter 8.
• Only when a model is proven to be supported by clinical data can it be considered 
to provide an accurate reflection of clinical reality, therefore only validated 
(covariate) models should be used for clinical decision making, for deriving 
dosing algorithms or for application in a semi-physiological modeling approach. 
• A theory-based modeling approach rather than a data-driven approach may 
lead to models that are not supported by clinical evidence which may limit the 
predictive value of these models. 
• Population pharmacokinetic modeling is ideally suitable for quantifying net 
developmental changes in drug clearance. The model-based approach described 
in Section II of this thesis should be the basis for the development of evidence-
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I. Achtergrond en Doel van het Onderzoek
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Voor de meeste geneesmiddelen zijn geen wetenschappelijk onderbouwde 
doseervoorschriften voor kinderen beschikbaar, dat geldt in het bijzonder voor 
pasgeborenen (neonaten) en jonge kinderen. Als gevolg hiervan komen zowel 
onderdosering als overdosering vaak voor. De voornaamste oorzaak hiervan is dat 
vaak niet is onderzocht welke factoren bij kinderen bepalend zijn voor de variatie in de 
werking van geneesmiddelen. 
De intensiteit en duur van de werking van geneesmiddelen wordt bepaald 
door twee processen, te weten de farmacokinetiek (het verloop van de concentratie van 
het geneesmiddel in het lichaam in de tijd) en de farmacodynamiek (de verandering 
in het biologische systeem die een geneesmiddel bij een bepaalde concentratie te weeg 
brengt). Beide kunnen in kinderen veranderen met de leeftijd. Factoren die bij kinderen 
de farmacokinetiek van een geneesmiddel, en daarmee de blootstelling, beïnvloeden 
zijn: i) de grootte en groei van het lichaam en ii) de veranderingen in de processen die 
bepalend zijn voor de opname en de verdeling van stoffen in het lichaam en de eliminatie 
uit het lichaam. Deze veranderingen kunnen het gevolg zijn van veranderingen in a) 
de expressie en functie van enzymen en transporteiwitten, b) het hartminuutvolume 
en de doorbloeding van organen, c) de pH van het bloed en d) de concentratie 
van geneesmiddelbindende plasma-eiwitten en andere componenten in het bloed. 
Bovendien veranderen ook de relatieve grootte van de organen, de verhouding tussen 
water en vetweefsel en de verhouding tussen tussen intra- en extracellulair water. Naast 
de veranderingen in farmacokinetiek kunnen veranderingen in de expressie en functie 
van receptoren of andere‘targeteiwitten’ leiden tot een veranderde farmacodynamiek 
bij kinderen in vergelijking met volwassenen en tussen kinderen van verschillende 
leeftijden. 
Wanneer er geen rekening wordt gehouden met leeftijdsafhankelijke verschillen 
in de farmacokinetiek en farmacodynamiek van geneesmiddelen kan dit leiden tot 
het falen van de behandeling of tot bijwerkingen met soms zelfs fatale afloop. Het is 
daarom van groot belang dat er onderzoek plaatsvindt naar de factoren die bij kinderen 
de farmacokinetiek en de farmacodynamiek van geneesmiddelen kunnen beïnvloeden. 
Recente wet- en regelgeving in Europa en de Verenigde Staten is er op gericht om 
geneesmiddelonderzoek in kinderen te bevorderen. Dat heeft ertoe geleid dat onderzoek 
in kinderen verplicht is voor nieuwe, nog op de markt te brengen geneesmiddelen. Er 
zijn vooralsnog geen wetten die betrekking hebben op onderzoek voor geneesmiddelen 
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Het doel van het onderzoek in dit proefschrift was om nieuwe methodes te ontwikkelen 
die gebruikt kunnen worden voor het vaststellen van wetenschappelijk onderbouwde 
doseervoorschriften voor geneesmiddelen in kinderen. De gebruikte methoden zijn 
gebaseerd op zogenaamde “populatie” analyses. Bij deze analyses worden wiskundige 
en statistische modellen gebruikt om farmacokinetische en farmacodynamische 
processen te beschrijven op basis van waargenomen geneesmiddelconcentraties of 
geneesmiddeleffecten. Daarnaast wordt ook de variabiliteit in de verschillende processen 
tussen individuen geanalyseerd. Hierdoor is het mogelijk om patiëntkarakteristieken 
te identificeren op basis waarvan de variabiliteit in de verschillende processen tussen 
individuen kan worden voorspeld. Deze voorspellende patiëntkarakteristieken 
worden covariaten genoemd. Covariaten vormen de basis voor geïndividualiseerde 
doseervoorschriften, of te wel doseervoorschriften die op de individuele patiënt zijn 
toegesneden. 
Het onderzoek in dit proefcshrift  is vooral gericht op kinderen jonger dan drie jaar, 
omdat de grootste en belangrijkste veranderingen plaatsvinden in de eerste levensjaren. 
Omdat wordt aangenomen dat leeftijdsafhankelijke verschillen in geneesmiddeleffecten 
bij kinderen voornamelijk het gevolg zijn van veranderingen in de farmacokinetiek, 
is het onderzoek in dit proefschrift hierop gericht. De belangrijkste farmacokinetische 
parameter in dit verband is de klaring. Dit is de parameter die beschrijft hoe snel een 
geneesmiddel uit het lichaam wordt geëlimineerd. Bij chronische toediening wordt 
bij een gegeven doseringsschema de hoogte van de gemiddelde plasmaconcentratie 
uitsluitend bepaald door de klaring. Geneesmiddelen kunnen geklaard worden door 
onveranderde uitscheiding in de nieren of door metabolisme in de lever. Bij metabolisme 
worden geneesmiddelen door enzymen omgezet in metabolieten die gemakkelijker 
door de nieren kunnen worden uitgescheiden dan het geneesmiddel zelf. Het onderzoek 
in dit proefschrift richt zich op de klaring van geneesmiddelen via metabolisme door 
het enzym uridine 5’-diphosphate glucuronosyltransferase (UGT) 2B7. Afbraak van 
geneesmiddelmoleculen door dit type enzym wordt glucuronidering genoemd. 
Morfine en zidovudine zijn twee geneesmiddelen die regelmatig aan kinderen worden 
voorgeschreven en beiden worden voornamelijk via glucuronidering door het UGT2B7 
enzym geklaard. Deze twee geneesmiddelen zijn daarom gebruikt als modelstoffen om 
de rijping (het patroon waarmee de snelheid van geneesmiddelmetabolisme zich in 
kinderen ontwikkelt) van deze klaringsroute in kinderen te bepalen.
In Hoofdstuk 2 wordt een overzicht gegeven van beschikbare in vitro en in vivo methodes 
om de rijping van enzymen in de lever te bestuderen. Hierbij worden ook de resultaten 
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De rijping van enzymen kan op verschillende niveaus onderzocht worden, 
waarbij telkens specifieke onderdelen van het biologische systeem worden uitgelicht. 
Hierbij moet gedacht worden aan i) mRNA transcriptie, ii) expressie van enzymen, iii) de 
activiteit van enzymen in vitro en iv) in vivo klaring. Deze verschillende onderdelen van 
het biologische systeem worden op verschillende manieren door de overige processen 
in dat biologische systeem beïnvloed. Daarnaast bestaan er vaak meerdere technieken 
om het biologische systeem op één specifiek niveau te bestuderen. Afhankelijk van de 
gebruikte techniek en het niveau van het biologische systeem dat wordt bestudeerd, 
kunnen de conclusies met betrekking tot enzym rijping dus verschillen. 
Op basis van literatuurgegevens kon worden vastgesteld dat de rijping van de 
verschillende UGT enzymen erg varieert. Over het algemeen kan expressie en activiteit 
van deze enzymen al worden waargenomen in foetussen na een draagtijd van 20 weken 
en vindt er een snelle toename in expressie en activiteit plaats in de eerste weken na 
de geboorte. De gerapporteerde leeftijd waarop de rijping van de verschillende UGT 
enzymen is voltooid verschilt tussen 6 maanden en 18 jaar. 
Van alle technieken die beschikbaar zijn om rijping van UGT enzymen te 
bestuderen is de klaring via glucuronidering in de mens de meest relevante parameter 
voor het vaststellen van het doseervoorschrift. Daarom is er in dit proefschrift voor 
gekozen om klaring via glucuronidering te gebruiken als eindpunt in de studies.
II. Morfine Glucuronidering in Kinderen.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In Sectie II van dit proefschrift wordt het onderzoek naar de glucuronidering van 
morfine in kinderen jonger dan drie jaar beschreven. Het doel van dit onderzoek was 
om een wetenschappelijk onderbouwd doseervoorschrift voor dit geneesmiddel in deze 
kinderen te ontwikkelen. Bij het klinisch geneesmiddelonderzoek dat daarvoor nodig is, 
spelen specifieke ethische, wettelijke en praktische factoren een rol. 
 Omdat (jonge) kinderen zelf niet kunnen instemmen met deelname aan 
studies, is het onethisch geneesmiddelstudies uit te voeren in gezonde kinderen. Om 
die reden is geneesmiddelonderzoek in gezonde kinderen wettelijk niet toegestaan. 
Geneesmiddelstudies vinden daarom alleen plaats in kinderen die een middel als 
onderdeel van hun medische behandeling voorgeschreven krijgen. Dit vergroot de 
variabiliteit tussen de patiënten die worden onderzocht, omdat de ernst van de ziekte 
en het aantal en soort van de overige voorgeschreven geneesmiddelen sterk kunnen 
verschillen. Praktische beperkingen vinden hun oorzaak in het kleine bloedvolume van 
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worden afgenomen voor de bepaling van geneesmiddelconcentraties. Daarnaast mogen 
kinderen niet worden blootgesteld aan de stress van bloedafname wanneer dit alleen 
voor onderzoeksdoeleinden wordt gedaan. Bloedmonsters kunnen daarom alleen 
verkregen worden van patiënten die een permanente arterielijn hebben. Wanneer er geen 
permanente arterielijn aanwezig is, mogen er alleen bloedmonsters worden afgenomen 
op tijdstippen dat er bloed wordt verzameld voor behandeldoeleinden. Hierdoor kan 
het tijdstip van bloedmonsters afname niet altijd vooraf in het studieprotocol worden 
vastgelegd. Ook de hoogte en het tijdstip van dosering kan vaak niet vooraf worden 
vastgesteld, omdat dit door de behandelend arts wordt voorgeschreven op basis van 
de individuele behoefte van een patiënt. Voor de analyse van data met grote variatie in 
patiëntkarakteristieken, in het tijdstip en de hoogte van de dosering en in het tijdstip en 
de frequentie van de bloedmonsterafname, is de  populatie analyse die in dit proefschrift 
is toegepast uitermate geschikt.
Het onderzoek dat wordt beschreven in Hoofdstuk 3 heeft betrekking op de 
farmacokinetiek van morfine, inclusief de twee belangrijkste metabolieten morfine-3-
glucuronide (M3G) en morfine-6-glucuronide (M6G), in kinderen jonger dan drie jaar. Dit 
onderzoek is uitgevoerd op basis van een populatie analyse van de bloedconcentraties 
in 248 patiënten. Per patiënt waren gemiddeld 4 bloedconcentraties beschikbaar. Deze 
patiënten kregen morfine toegediend voor pijnbestrijding na een zware operatie (met 
uitzondering van hartoperaties) of tijdens mechanische beademing. Op basis van 
deze analyse kon worden vastgesteld, dat lichaamsgewicht de meeste voorspellende 
covariaat is om de verandering in morfine klaring ten gevolge van groei en ontwikkeling 
in deze jonge kinderen te beschrijven. De verandering in morfine klaring werd het beste 
beschreven met een exponentiële functie op basis van lichaamsgewicht met een exponent 
van ongeveer 1.5. Daarnaast bleek dat de snelheid van glucuronidering van morfine 
ongeveer 50% lager is in neonaten die jonger zijn dan tien dagen, ongeacht de draagtijd.
De voorspellende waarde van het ontwikkelde model is uitvoerig getest door 
te bepalen of het model de morfine, M3G en M6G concentraties die gebruikt zijn voor 
de ontwikkeling van het model ook inderdaad accuraat kan voorspellen. Een goede 
voorspelling van de concentraties van de twee metabolieten is daarbij net zo belangrijk 
als een goede voorspelling van de morfine concentraties, omdat beide metabolieten 
bijdragen aan de (bij)werkingen van morfine. In deze analyse zijn de voorspellingen 
van de concentraties gedaan op basis van het lichaamsgewicht en leeftijd van de patiënt, 
het tijdstip van toediening en het tijdstip van de concentratiebepaling. De voorspelde 
concentraties zijn vervolgens vergeleken met de gemeten concentraties. Hieruit bleek dat 
de voorspellingen van de concentraties van morfine en de twee metabolieten tijdens en 
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De evenwichtsconcentraties van geneesmiddelen in het bloed zijn bij continue 
infusies uitsluitend afhankelijk van de klaring van het geneesmiddel. Op basis van het 
ontwikkelde model kon daarom worden vastgesteld dat continue morfine infusies het 
best gedoseerd kunnen worden in microgram per kilogram tot de macht 1.5 per uur (μg/
kg1.5/uur), in plaats van in de meer gebruikelijke dosering in microgram per kilogram per 
uur (μg/kg/uur), en dat de dosering in neonaten jonger dan tien dagen met 50% moet 
worden gehalveerd. Simulaties met het model lieten inderdaad zien dat de variabiliteit 
in concentraties van morfine, M3G en M6G in pasgeborenen tot peuters van drie jaar met 
dit nieuwe doseringsregime lager is dan de variabiliteit in de concentraties die voorspeld 
worden bij dosering volgens het traditionele doseringsschema.
 
Voordat het bovengenoemde doseervoorschrift in de praktijk kon worden getest, is in 
Hoofdstuk 4 bestudeerd of het model ook accurate concentratievoorspellingen kan 
doen voor externe data. Hiermee worden data bedoeld die afkomstig zijn van patiënten 
die geen onderdeel vormden van de dataset waarmee het model is ontwikkeld. Voor 
deze analyses waren morfine en metaboliet concentraties beschikbaar van 90 patiënten 
uit vier verschillende studies die waren uitgevoerd in vier verschillende ziekenhuizen. 
Deze studies waren uitgevoerd in neonaten tot peuters van één jaar oud die een zware 
operatie hadden ondergaan (met uitzondering van hartoperaties) of die mechanisch 
beademd werden. Met behulp van verschillende methodes is vastgesteld dat de morfine 
en metaboliet concentraties in deze externe patiënten met behulp van het model kunnen 
worden voorspeld op basis van het lichaamsgewicht, de leeftijd en de morfine dosering. 
Bovendien zijn de waarden van de klaringen via glucuronidering van morfine die door 
het model worden voorspeld vergeleken met literatuurwaardes. Ondanks de grote 
spreiding in de gerapporteerde waardes voor deze jonge populatie, bleek het model de 
trend in de resultaten van verschillende studies goed te beschrijven. 
 
Nadat was vastgesteld dat het model goede voorspellingen voor de concentraties van 
morfine en de metabolieten oplevert, is in Hoofdstuk 5 de effectiviteit van het nieuwe 
doseervoorschrift voor morfine geëvalueerd in de klinische praktijk. In een studie in 
neonaten tot peuters van één jaar die een morfine infusie kregen voor pijnbestrijding 
na een zware operatie (met uitzondering van hartoperaties), kregen neonaten jonger 
dan tien dagen een morfine infusie van 2.5 μg/kg1.5/uur terwijl oudere kinderen een 
infusie kregen van 5 μg/kg1.5/uur. Ten opzichte van traditioneel gebruikte morfine 
infusiesnelheid van 10 μg/kg/uur, betekende dit een dosisvermindering van 50% tot 
75% voor neonaten jonger dan tien dagen, en een dosis verhoging tot 150% in oudere 
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De effectiviteit van de nieuwe dosering is geëvalueerd op basis van een analyse 
van de zogenaamde ‘rescue doses’. Dit zijn extra morfine doses die worden toegediend 
wanneer de pijnbestrijding onvoldoende is op basis van objectieve methodes voor het 
vaststellen van pijn in deze jonge patiënten. In de neonaten jonger dan tien dagen had 
maar 27% van de patiënten rescue doses nodig, ten opzichte van 90% in de oudere 
patiënten. Ook het aantal rescue doses en de gemiddelde rescue dosis was beduidend 
lager in neonaten jonger dan tien dagen ten opzichte van de oudere kinderen. Deze 
resultaten tonen aan dat de gereduceerde dosis in jonge neonaten nog steeds voldoende 
effectief is, terwijl de verhoogde dosering in oudere patiënten nog niet hoog genoeg is. 
Ten opzichte van de traditioneel gebruikte morfine doseringen, leidt het nieuwe morfine 
doseervoorschrift dus tot een verbetering van de behandeling, omdat het de blootstelling 
aan te hoge doses in jonge neonaten vermindert, terwijl het ook, weliswaar in minder 
mate, de blootstelling aan ineffectieve doses in oudere patiënten tot één jaar vermindert. 
Waar mogelijk waren er in deze studie ook bloedmonsters afgenomen om de 
concentraties van morfine, M3G en M6G te bepalen. Deze concentraties zijn vergeleken 
met de voorspellingen van het populatie model uit Hoofdstuk 3, om vast te stellen of 
de voorspellingen van dit model ook accuraat zijn bij doseringen volgens het nieuwe 
doseervoorschrift. Dit bleek het geval te zijn. Dit bevestigt dat het ontwikkelde 
doseervoorschrift corrigeert voor verschillen in de klaring van morfine in deze 
patiëntengroep. Er kan worden aangenomen dat doseervoorschriften die corrigeren voor 
verschillen in klaring voldoende zijn wanneer de farmacodynamiek van het geneesmiddel 
gelijk is in kinderen van alle leeftijden. Dit is niet waarschijnlijk voor morfine. Morfine 
werkt door binding aan specifieke opiaat receptoren in de hersenen. Het transport van 
morfine van het bloed naar deze receptoren in hersenen en de expressie en functie van 
deze receptoren in de hersenen zijn mogelijk beide onderhevig aan leeftijdsverschillen. 
Deze verschillen verklaren mogelijk het verschil in effectiviteit van het nieuwe morfine 
doseervoorschrift in oudere en jongere kinderen in deze studie. In vervolg onderzoek 
kan een populatie analyse van de farmacodynamiek van morfine in deze jonge kinderen 
gebruikt worden om voor elke leeftijdsgroep te bepalen welke concentratie tot het 
gewenste effect leidt. Simulaties met het huidige farmacokinetische model kunnen dan 
worden gebruikt om vast te stellen welke dosering tot de gewenste concentraties zal 
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III. Semi-Fysiologisch Model voor de Glucuronidering van 
Geneesmiddelen in Kinderen.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
De methode die in Sectie II van de dit proefschrift is gebruikt voor het vaststellen 
van wetenschappelijk onderbouwde doseervoorschriften voor morfine in kinderen, 
is tijdrovend en intensief. Het is onmogelijk om een soortgelijke analyse uit te voeren 
voor elk geneesmiddel en in elke leeftijdsgroep. In Sectie III is daarom gezocht naar 
een algemene methode voor de ontwikkeling van populatie modellen voor kinderen, 
die gebruikt kunnen worden voor het vaststellen van wetenschappelijk onderbouwde 
doseervoorschriften. De ontwikkelde methode is gebaseerd op de hypothese dat het 
rijpingspatroon van geneesmiddelklaring door metaboliserende enzymen een systeem-
specifieke eigenschap is. Dit betekent dat het rijpingspatroon van toepassing is op 
alle geneesmiddelen die via een specifiek enzym worden geëlimineerd. Met andere 
woorden, als voor één geneesmiddel de covariaatrelatie voor de rijping van de klaring is 
vastgesteld, kan deze relatie ook worden gebruikt om de leeftijdsafhankelijke verandering 
in klaring van andere geneesmiddelen die via hetzelfde enzym worden gemetaboliseerd 
te voorspellen. De absolute waarde van de klaring kan daarbij wel verschillend zijn, 
omdat dit een geneesmiddel-specifieke eigenschap is.
 De modellen die in deze sectie beschreven worden, worden semi-fysiologische 
modellen genoemd, omdat ze zijn afgeleid van fysiologische modellen. Fysiologische 
modellen zijn mechanistische modellen. Deze modellen gaan niet, zoals populatie 
modellen, uit van gemeten concentraties, maar zijn gebaseerd op een beschrijving en 
kwantificering van alle onderliggende biologische processen die bepalend zijn voor 
het verloop van de concentratie van een geneesmiddel in het lichaam (de absorptie, de 
verdeling, het metabolisme en de eliminatie) en de interacties tussen geneesmiddelen en 
het biologische systeem. Een fundamentele eigenschap van fysiologische modellen is het 
strikte onderscheid tussen systeem-specifieke eigenschappen (b.v. doorbloeding van het 
lever, concentratie van plasma-eiwitten, expressie en functie van enzymen en transport-
eiwitten) en geneesmiddel-specifieke eigenschappen (b.v. lipofiliciteit, en affiniteit voor 
bindingseiwitten, enzymen en transporters). Deze modellen worden in de praktijk 
onder meer toegepast om de absolute waarden van de klaring van nieuwe stoffen in 
de mens te voorspellen op basis van pre-klinische gegevens. In de semi-fysiologische 
modellen in dit proefschrift, combineren eerder opgedane kennis van het biologische 
system met een populatie analyse. Zo wordt de covariaatrelatie die het rijpingspatroon 
voor het metabolisme van een bepaald geneesmiddel beschrijft, rechtstreeks gebruikt 
om de veranderingen in klaring van een nieuw geneesmiddel dat via hetzelfde enzym 
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basis van gemeten concentraties gebruikt om de absolute waarde van de klaring (een 
geneesmiddel-specifieke eigenschap) vast te stellen.
In Hoofdstuk 6 is onderzocht of covariaatrelaties voor de rijping van specifieke 
klaringsroutes in kinderen uitwisselbaar zijn tussen geneesmiddelen die via hetzelfde 
enzym worden gemetaboliseerd. In deze studie zijn twee populatie modellen voor 
een dataset met concentraties van zidovudine en zidovudine-glucuronide met elkaar 
vergeleken. De data waren verkregen in een studie met gezonde kinderen tussen nul 
en vijf maanden, waarin werd onderzocht of zidovudine een geschikt middel is om de 
overdracht van het Hiv-virus tussen moeder en kind te voorkomen. 
Zidovudine wordt, net als morfine, voornamelijk geklaard via metabolisme door 
het UGT2B7 enzym. In het eerste model is daarom de covariaatrelatie voor de rijping van 
de activiteit van UGT2B7 die in Hoofdstuk 3 is gevonden voor de glucuronidering van 
morfine, onveranderd toegepast op de glucuronidering van zidovudine. Vervolgens is 
de absolute waarde van de klaring voor de glucuronidering van zidovudine bepaald 
op basis van de zidovudine en zidovudine-glucuronide concentraties. Dit model is het 
semi-fysiologische model. Om vast te kunnen stellen hoe goed de beschrijvende en 
voorspellende waarde van het semi-fysiologische model is, is er tevens een referentie 
model ontwikkeld dat statistisch gezien de beste beschrijving van de zidovudine data 
geeft. In dit referentie model is een populatie analyse gebruikt om zowel de absolute 
glucuronideringsklaring van zidovudine vast te stellen, als de covariaatrelatie die het 
patroon van de leeftijdsafhankelijke verandering in de klaring beschrijft in deze groep 
kinderen. 
 De covariaatrelatie voor de glucuronidering van zidovudine die in het referentie 
model is gevonden verschilde van de relatie die in Hoofdsuk 3 is gevonden voor de 
glucuronidering van morfine. Dit komt waarschijnlijk omdat het leeftijdsverschil van de 
patiënten in de zidovudine dataset een stuk kleiner is (voldragen neonaten tot peuters 
van vijf maanden) dan het leeftijdsverschil van de patiënten in de morfine dataset (te 
vroeg geboren (onvoldragen) en voldragen neonaten tot kleuters van drie jaar). Ondanks 
dit verschil waren de beschrijvingen van zowel individuele zidovudine klaringen als 
individuele zidovudine en zidovudine-glucuronide concentraties door beide modellen 
vergelijkbaar. Bovendien waren voor beide modellen ook de voorspelde concentraties 
die werden verkregen op basis van informatie over de leeftijd, het gewicht en de dosis 
vergelijkbaar. Deze resultaten ondersteunen de hypothese dat covariaatrelaties voor de 
klaring van geneesmiddelen in kinderen systeem-specifieke eigenschappen zijn, die 
uitwisselbaar zijn tussen stoffen die via hetzelfde enzym worden gemetaboliseerd. 
Door het gebruik van eerder opgedane kennis over de ontwikkeling van 
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sneller ontwikkeld worden dan het referentie model. Dit toont aan dat deze methode de 
ontwikkeling van populatie farmacokinetische modellen voor kinderen, en daarmee de 
ontwikkeling van wetenschappelijk onderbouwde doseervoorschriften, kan bevorderen.
In Hoofdstuk 6 is voor het eerst aangetoond dat covariaatrelaties in een kinderpopulatie 
uitgewisseld kunnen worden tussen twee geneesmiddelen die via dezelfde route uit het 
lichaam worden geklaard. Omdat morfine en zidovudine echter veel op elkaar lijken 
met betrekking tot hun moleculaire eigenschappen, zal verder onderzocht moeten 
worden of het semi-fysiologische model voor glucuronidering ook gebruikt kan worden 
voor twee stoffen die weliswaar door hetzelfde enzym worden gemetaboliseerd, maar 
verder erg verschillen in hun moleculaire eigenschappen. Daarnaast is het model voor 
de glucuronidering van morfine gebaseerd op data van postoperatieve kinderen en 
kinderen aan de mechanische beademing, terwijl de zidovudine data verkregen zijn 
in gezonde kinderen. Het is belangrijk om te weten welke onderliggende biologische 
veranderingen verantwoordelijk zijn voor de verandering in klaring in kinderen, om 
vast te stellen of patiëntkarakteristieken het gebruik van het semi-fysiologische model 
voor glucuronidering in een bepaalde patiëntenpopulatie kunnen beperken. 
Het onderzoek dat betrekking heeft op de invloed van zowel verschillende 
eigenschappen van het geneesmiddel als eigenschappen van het biologische systeem op 
het rijpingspatroon van UGT2B7 metabolisme wordt beschreven in Hoofdstuk 7. In dit 
onderzoek is gebruik gemaakt van simulaties met een fysiologisch model. Bij simulaties 
wordt de werkelijkheid nagebootst met behulp van modellen van die werkelijkheid. 
Er zijn verschillende scenario’s gesimuleerd, waarin de waardes van geneesmiddel-
specifieke parameters zoals moleculair gewicht, logP en pKa, en biologische systeem-
specifieke parameters zoals lever volume, milligram eiwit per gram lever, plasma-eiwit 
binding, doorbloeding van de lever en UGT expressie en activiteit, één voor één zijn 
veranderd. Door te bepalen wat de invloed van deze veranderingen is op de voorspelde 
glucuronidering in kinderen, kon worden vastgesteld of en hoe de glucuronidering door 
de individuele parameters wordt beïnvloed. 
Deze theoretische studie liet zien dat logP en pKa de absolute waarde van de 
klaring door glucuronidering kunnen beïnvloeden. Deze moleculaire eigenschappen 
van het geneesmiddel hadden echter geen invloed op het patroon waarmee de 
glucuronidering zich in kinderen ontwikkelt. Dit betekent dat de covariaatrelatie die 
deze ontwikkeling beschrijft, voor alle substraten hetzelfde zou zijn, wat suggereert 
dat geneesmiddeleigenschappen het gebruik van het semi-fysiologische model 
voor glucuronidering niet beperken. Deze bevindingen zijn echter gebaseerd op de 
aanname dat de geneesmiddeleigenschappen geen invloed hebben op de opname van 
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het UGT2B7 enzym. Daarnaast zal verder onderzocht moeten worden of het semi-
fysiologische model voor glucuronidering gebruikt kan worden voor geneesmiddelen 
met een lever extractie-ratio die anders is dan de extractie-ratio voor morfine en 
zidovudine en voor geneesmiddelen met verzadigbare glucuronidering. 
Met betrekking tot the systeem-specifieke eigenschappen toonde deze 
theoretische studie aan dat veranderingen in het volume van de lever en in de expressie 
en activiteit van de UGT2B7 enzymen in de eerste drie levensjaren voor het grootste 
deel verantwoordelijke zijn voor de waargenomen veranderingen in glucuronidering 
door UGT2B7. Dit suggereert dat glucuronideringsnelheid in patiënten met insufficiënte 
leverfunctie mogelijk is afgenomen, wat zou kunnen betekenen dat de semi-fysiologische 
functie voor glucuronidering niet gebruikt kan worden in een patiëntenpopulatie met 
lever insufficiënties. Dit zal echter nog verder onderzocht moeten worden.
IV. Evaluatie van Farmacokinetische Modellen voor Kinderen
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Een belangrijke eigenschap van de populatiebenadring voor de analyse van 
farmacokinetische data is dat het kan worden toegepast wanneer er een beperkt aantal 
waarnemingen per individu beschikbaar is. Vooral in zeer jonge kinderen komt dat vaak 
voor. Echter, hoe beperkter de data, hoe groter de kans op mis-gespecificeerde of ‘onjuiste’ 
modellen. Wanneer zulke ‘onjuiste’ modellen worden gebruikt als basis voor klinische 
beslissingen (bijvoorbeeld voor het bepalen van doseringen) kan dit grote gevolgen 
hebben. Uitgebreide evaluatie en validatie van een model, waarbij wordt vastgesteld 
of een model juiste voorspellingen geeft, is daarom heel belangrijk. In Hoofdstuk 3 en 
Hoofdstuk 4 is gebleken dat het evalueren en valideren van populatie farmacokinetische 
modellen voor kinderen op sommige punten aanpassingen vereist ten opzichte van de 
evaluatie en validatie van populatie farmacokinetische modellen voor volwassenen.
 In Hoofdstuk 8 zijn patiënt- en studiekarakteristieken geïdentificeerd die de 
eigenschappen van farmacokinetische datasets van kinderen beïnvloeden. Omdat 
(jonge) kinderen zich snel ontwikkelen, is de variatie in de ontwikkelingsstadia tussen 
patiënten bijvoorbeeld vaak groot. Daarnaast is, zoals eerder genoemd, de variabiliteit in 
geneesmiddeldosering en bloedmonster afname vaak groot omdat deze sterk beïnvloed 
worden door de conditie van de patiënt, en is het aantal bloedmonsters per patiënt vaak 
beperkt. Als gevolg van deze factoren zijn er voor de evaluatie en validatie van populatie 
modellen in kinderen vaak aanpassingen nodig van al bestaande validatietechnieken. 
Een belangrijk punt is bijvoorbeeld om vast te stellen of het model de data in alle 
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alleen in zijn geheel te bekijken, maar de dataset ook op te splitsen in verschillende 
leeftijdscategorieën. Daarnaast zijn soms geavanceerde evaluatie technieken nodig ter 
vervanging van meer traditionele technieken. Een zogenaamde “normalized prediction 
distribution error” (NPDE) analyse is bijvoorbeeld een meer geschikte evaluatie methode 
op basis van simulaties, dan de meer traditionele visual predictive check (VPC), omdat 
het flexibeler kan omgaan met grote variabiliteit in dosering en afname schema en 
in covariaatdistributies. Tot slot is in Hoofdstuk 8 ook een nieuwe evaluatie techniek 
gepresenteerd om vast te stellen of een gevonden covariaatrelatie de patronen in de 
variabiliteit in parameterwaardes tussen individuen goed beschrijft.
Het onderzoek dat is beschreven in Hoofdstuk 8 heeft betrekking op de 
ontwikkeling van een theoretisch raamwerk voor de systematische evaluatie en validatie 
van populatiemodellen in kinderen. Dit raamwerk omvat zes verschillende onderdelen. 
Het raamwerk werd toegepast in de evaluatie van twee verschillende populatie 
farmacokinetische modellen voor morfine in kinderen. Deze twee modellen zijn op 
verschillende manieren ontwikkeld. Het eerste model is gebaseerd op het model dat 
is beschreven in Hoofdstuk 3, wat tot stand is gekomen op basis van een uitvoerige 
covariaat analyse. Het tweede model is gebaseerd op specifieke theoretische aannames 
met betrekking tot de samenhang tussen lichaamsgewicht en klaring. Omdat voor de 
ontwikkeling van beide modellen gebruik was gemaakt van exact dezelfde dataset, was 
een directe vergelijking tussen de twee modellen mogelijk. De resultaten van de analyse 
laten zien dat het ontwikkelde evaluatie en validatie raamwerk in staat is om problemen 
met de beschrijvende en voorspellende waarde van populatie modellen voor kinderen 
te identificeren. Daarnaast kan het ook gebruikt worden om vast te stellen waardoor 
gebrekkige beschrijvingen en voorspellingen van deze modellen worden veroorzaakt.
De farmacokinetiek en klaring van morfine in kinderen zijn uitgebreid bestudeerd in 
de literatuur. In Hoofdstuk 9 worden de verschillende analysemethodes die hiervoor 
gebruikt zijn beschreven en zijn de voor- en nadelen van elke methode in kaart 
gebracht. Daarnaast zijn de gerapporteerde klaringswaardes met elkaar vergeleken en 
is de voorspellende waarde van gepubliceerde modellen (zowel populatie modellen als 
fysiologische modellen) geëvalueerd. 
 In de afgelopen twintig jaar zijn twintig studies naar de klaring van morfine in 
kinderen gerapporteerd waarin gebruik werd gemaakt van traditionele farmacokinetische 
analyse technieken. Deze studies zijn veelal beschrijvend en gebaseerd op waarnemingen 
in een klein aantal kinderen. De gerapporteerde waarden voor de klaring van morfine 
lopen ver uiteen, waarschijnlijk doordat de metingen met traditionele technieken minder 
nauwkeurig zijn en het aantal patiënten in de studies vaak klein is. Daarnaast is een 
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lichaamsgewicht en dat de leeftijdsafhankelijke veranderingen alleen maar beschreven 
kunnen worden door kinderen in leeftijdscategorieën in te delen en een gemiddelde 
klaring per groep te berekenen. Het patroon van leeftijdsafhankelijke verschillen in 
klaring hangt daarmee af van de meestal willekeurig gekozen leeftijdscategorieën.
 De beschrijving van leeftijdsafhankelijke verschillen in klaring in populatie 
modellen en fysiologische modellen is niet afhankelijk van een indeling van de patiënten 
in leeftijdsgroepen. Daarnaast kunnen met deze technieken data van verschillende studies 
gecombineerd worden, wat de nauwkeurigheid van de bevindingen kan vergroten. Voor 
morfine zijn drie populatie farmacokinetische modellen beschreven in de literatuur, 
waarbij verschillende technieken voor de covariaatanalyse zijn gebruikt. Alle drie de 
modellen zijn voor kinderen die jonger zijn dan drie jaar waarbij in twee modellen ook de 
farmacokinetiek in onvoldragen neonaten wordt beschreven. De verschillende functies 
voor de verandering van morfineklaring in deze patiëntengroep in deze modellen, 
leveren ongeveer gelijke klaringswaardes op, behalve in neonaten die jonger zijn dan één 
maand en dan vooral in onvoldragen neonaten. Voor één fysiologisch model is gekeken 
naar de voorspellingen van morfine klaringen in kinderen en ook deze voorspellingen 
waren in dezelfde grootte orde dan de overige gerapporteerde klaringswaardes. Helaas 
is het vooralsnog niet mogelijk om met fysiologische modellen voorspellingen te doen in 
te vroeg geboren neonaten.
 Met betrekking tot de validatie van de populatie modellen en het fysiologische 
model, kon worden vastgesteld dat niet voor alle modellen voldoende is bewezen dat ze 
de werkelijkheid accuraat kunnen beschrijven en voorspellen. Voor één populatiemodel 
is zelfs bewezen dat het model een te hoge morfineklaring in neonaten voorspelt. 
Wanneer dit model zou worden gebruikt voor het bepalen van morfine doseringen, zou 
dat kunnen leiden tot ernstige overdosering.
V. Conclusie
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
In de eerste paar levensjaren vindt er een groot aantal veranderingen plaats in het 
lichaam van een kind. Deze veranderingen kunnen de blootstelling aan en werking 
van geneesmiddelen beïnvloeden. Dit proefschrift beschrijft hoe wetenschappelijk 
onderbouwde doseervoorschriften voor geneesmiddelen in kinderen kunnen worden 
ontwikkeld waarbij rekening wordt gehouden met veranderingen in farmacokinetische 
processen in deze populatie. Deze aanpak omvat de volgende stappen: 
1) Ontwikkeling van populatie farmacokinetische modellen in kinderen. Deze 
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zoals beschreven in Hoofdstuk 3, of door middel van een semi-fysiologische 
aanpak zoals beschreven in Hoofdstuk 6, hoewel de bredere toepasbaarheid van 
de semi-fysiologische methode nog verder onderzocht dient te worden.
2) Evaluatie en validatie van het ontwikkelde model met behulp van het 
raamwerk dat in Hoofddstuk 8 is ontwikkeld. De evaluatie en validatie dienen 
plaats te vinden op basis van zowel interne data (data die gebruikt zijn voor de 
ontwikkeling van het model), als externe data (data die niet gebruikt zijn voor 
de ontwikkeling van het model of van externe bronnen afkomstig zijn).
3) Een prospectieve klinische studie om de veiligheid en effectiviteit van het 
doseerregime dat van het populatiemodel is afgeleid, vast te stellen, zoals voor 
morfine is gedaan in Hoofdstuk 5.
Voor morfine heeft deze aanpak een onderbouwd doseervoorschrift opgeleverd 
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